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Abstract 
Computational Protein Design with Multiple Functional and Structural Constraints 
by 
Elisabeth L. Humphris 
 
In this work, a series of computational tools to predict protein sequences 
compatible with a given three-dimensional protein structure and a set of structural or 
functional constraints are presented. First, a “multi-constraint” protocol to design protein 
sequences optimized for multiple criteria is presented. For a number of multi-specific 
signaling and structural proteins, interface sequences are computationally designed to 
bind multiple interaction partners and design predictions are compared to naturally 
occurring amino acid sequences.  In many cases, the multi-constraint design algorithm 
successfully “added up” diverse sequence preferences seen among several characterized 
binding partners, resulting in the prediction of highly native-like interface sequences. 
Multi-constraint designed sequences were also found to have overall weaker predicted 
binding scores than sequences designed to bind only a single interaction partner, 
suggesting that multi-specificity may come at a cost of affinity.  This section concludes 
by discussing two distinct mechanisms for maintaining multi-specific binding, and 
providing examples of how the design protocol presented here might be used to rationally 
design proteins with multiple functional roles.  
A method to predict sets of amino acids tolerated at protein-protein interfaces is 
presented next. By incorporating a flexible backbone move, termed “backrub”, 
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computational predictions of amino acid tolerances at a model interface, human growth 
hormone with its receptor, are found to closely mimic sequences observed in an 
experimental phage display dataset. The importance of incorporating backbone flexibility 
when predicting amino acid tolerance to substitution is discussed and an automated 
method to computationally predicting sequence libraries to enable challenging protein 
engineering problems is given.  
Finally, a protocol for predicting single amino acid substitutions tolerated for a 
protein of great biological relevance, HIV-1 protease is presented.  In this work multiple 
constraints present on the HIV-1 protease fold and function are integrated and a reduced 
set of amino acid mutations (able to be reached by a single mutation at the nucleotide 
level) was considered. Despite the simplifications inherent in the model, ~80% of amino 
acid substitutions that occurred in clinical HIV-1 protease sequences were predicted as 
tolerated.  This work further demonstrates that use of a single, fixed backbone as a 
structural template for design results in overall poorer predictive performance than 
designing on an ensemble of either crystallographically determined or computationally 
generated backbone structures.  
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Chapter 1  
Introduction 
This thesis is organized as follows.  Chapter 1 gives a brief introduction to 
proteins, focusing on the relationship between sequence, structure, and function (Section 
1.1).   An overview of computational protein design, which attempts to predict novel 
protein sequences compatible with a given protein fold and/or function, follows.  Notable 
computational design successes are highlighted, and possible reasons for computational 
design to fail to predict folded, functional sequences are discussed in detail (Section 1.2).  
Two computational tools used throughout this thesis are introduced: the protein sequence 
design program, RosettaDesign and the “backrub” protocol for computationally 
generating ensembles of protein backbones (Section 1.3), and an overall outline of the 
work presented in this thesis is given (Section 1.4).    
Chapters 2 and 3 describe the development and testing of two new algorithms that 
seek to improve upon traditional computational design methodologies.  Chapter 4 
demonstrates how the novel methodologies introduced in Chapter 2 and 3 can be used to 
predicting sequence mutations tolerated by a highly biologically relevant protein, HIV-1 
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protease.  Finally, Chapter 5 addresses possible future research directions for the 
computational protein design methodologies introduced in this work.   
 
1.1. Introduction for the Non-Scientist: The sequence-structure-
function paradigm 
Proteins are a type of biological molecule, present in all organisms from bacteria 
to mankind, responsible for an overwhelming number of important biological functions.  
Some types of proteins, called enzymes, have evolved to catalyze or speed up chemical 
reactions, breaking down large molecules or building up larger molecules out of smaller 
components.  Other proteins play a structural or mechanical role by binding together to 
form your hair, fingernails, or cartilage or by providing the contractile force of your 
muscles.  A large number of proteins function by specifically recognizing and binding 
other partners.  For example, the hemoglobin in your blood specifically binds and 
transports oxygen, proteins in your immune system recognize and bind foreign particles, 
and a number of proteins are responsible for binding to DNA.  The specific recognition 
and binding of proteins to other molecules or each other can be responsible for setting in 
motion complex biological signaling cascades, such as an allergy attack or the 
duplication of an entire cell.   
At the simplest level, each protein can be thought of as a linear sequence of 
“beads” on a string.  Each bead represents one of 20 chemically diverse “building 
blocks”, called amino acids, and the total number of beads can vary from ~50 to several 
thousand.  Every amino acid has been assigned a unique single letter (for instance, A for 
alanine) and thus every protein can be described by writing out an ordered amino acid 
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sequence of single letters.  Some proteins have special modifications to amino acids 
within their sequence, but in most cases the incredible diversity of biological functions 
observed among naturally occurring proteins is due only to variations in their precise 
sequence and total number of amino acids.   
Most proteins, however, do not perform their biological function as a random coil 
or a linear chain of amino acids.  Chemical properties of amino acids in the linear amino 
acid sequence interact with each other, forming secondary structures such as flat sheets, 
three dimensional helices, or relatively unstructured loops.  These secondary structures in 
turn often interact with each other and form a complex three-dimensional shape that 
brings amino acids far apart in the linear sequence close together in space.  The shape 
that the “string” traces in three-dimensional space is often referred to as the protein 
backbone while the amino acids, or beads, on the backbone are called side-chains.  It is 
the three dimensional structure of proteins that mediates all the diverse functional roles 
described above.  For example, cavities or binding surfaces may be created during the 
folding process through which proteins can interact with chemical substrates, small 
molecules, or each other.   
The relationship between linear amino acid sequence, formation of three-
dimensional structure, and biological function is an area currently undergoing intense 
research.  Computation offers great promise to advance understanding of the sequence-
structure-function relationship.  Even for a relatively small protein of 100 amino acids, 
the total number of possible linear amino acid sequences available is astronomically large 
at (20)100 or  ~10130.  Determining which of these linear combinations of amino acids will 
adopt a stable, well-folded structure and then experimentally characterizing the resulting 
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folded three-dimensional coordinates and biological function of such an astronomical 
number of sequences would be an impossible task.    
Computational optimization and search tools offer great promise to efficiently 
search sequence space and suggest novel folded and functional protein sequence variants.  
Computation also offers an ideal platform to test our current understanding of the 
physical forces mediating short- and long- range interactions between amino acids.  If 
accurate models of the physical forces responsible for protein structure and function can 
be developed, computational tools should be able to make direct predictions of how 
changes at the amino acid sequence level affect the formation of three-dimensional 
structure or result in altered biological function.    
 
1.2. Computational Protein Design: Current Strategies and Novel 
Approaches 
In 1961, Anfinsen proposed that the linear amino acid sequences of proteins 
contain all the information necessary to specify the three dimensional structure of a 
protein.  Today, almost 50 years later, the problem of protein folding, or using 
computation to reliably and accurately predict the precise three dimensional coordinates 
of a folded, functional protein from knowledge of only its amino acid sequence, remains 
a formidable computational task.  A related, but independent field is that of 
computational protein design.  Here, one begins with a known three-dimensional 
structure of a single protein, or a protein-protein complex, and amino acid sequences 
compatible with the given starting structure are predicted.  Protein design has made great 
progress in dissecting the relationship between altering amino acid sequence and 
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modifying protein structure and function.  Starting from known three-dimensional 
coordinates, protein design has been able to predict non-native amino acid sequences able 
to stably adopt the starting fold, and in many cases the sequences are also able to take on 
altered biological function.  Before discussing some of the successes and future 
challenges of protein design in detail, I first give a basic introduction to some general 
computational principles.   
1.2.1. Principles of Computational Design  
Successful protein design typically requires at least three components: a set of 
starting three-dimensional backbone coordinates, a scoring or energy function which 
indicates the suitability of each linear amino acid sequence under consideration to adopt 
the starting three-dimensional structure, and an optimization algorithm to efficiently 
focus computational time on evaluating those sequences, from among the astoundingly 
large set of theoretically possible sequences, most likely to score favorably.  I will discuss 
each component in order.   
Experimentally, several methods have been developed to visualize the three 
dimensional structures of proteins, the most common of which determine approximate 
atomic coordinates of proteins either in solution (using nuclear magnetic resonance, or 
NMR) or in a crystallized state (using X-rays).  There has been exponential growth in the 
number of protein structures experimentally determined each year since the first protein 
structure was solved in 1958, and today there are over 60,000 structures (about half of 
which are independently determined coordinates of the same protein sequence) deposited 
in the Protein Data Bank (PDB).  However, the techniques to experimentally determine 
protein structures are often difficult and time-consuming, and there are no experimentally 
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determined structures for many naturally occurring protein sequences.  For sequences for 
which experimental structures do exist, the “fuzziness” (or the structure resolution) of the 
structural picture from which the three-dimension coordinates are determined can vary.  
The performance of most protein design tools is often best when high-resolution 
structures whose coordinates have been most accurately determined are used. 
 Once a three-dimensional structure has been selected, one can computationally 
remove the identity of any starting side-chains, leaving the atomic coordinates of the 
backbone fixed.   The starting backbone coordinates provide a fixed template onto which 
differing side-chains sequences can be computationally modeled and scored.  However, 
for any single sequence under consideration, the side-chains can be modeled onto the 
backbone in any number of possible configurations or orientations.  To simplify the 
possible number of side-chain conformations, protein design tools often consider only a 
small number of discrete side-chain orientations, where each unique orientation is 
referred to as a rotamer.  Standardized libraries of rotamers for all 20 amino acids have 
been developed to represent the most common side-chain conformations observed in high 
resolution crystallographic structures.   
At each point during a computational design simulation, a unique set of rotamers 
is selected and scored.  (It is the task of the computational search algorithm to ensure 
rotamers that are likely to be a good fit for the backbone conformation under 
consideration are ultimately selected for scoring).  A variety of scoring functions have 
been developed, most of which include terms that model physical interactions and forces 
among the side-chains and backbone atoms, such as attraction and repulsion caused by 
sterics, electrostatics, solvation, and hydrogen bonding.  Often statistical scoring terms 
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are included to measure whether designed sequences mimic properties that have been 
commonly observed among experimentally determined structures but as of yet can not be 
adequately modeled by physical interaction terms.  Other statistical terms that have been 
parameterized to increase performance may also be included to aid in the scoring 
function being able to correctly discriminate sequences compatible with a given three-
dimensional structure from those that are not. Specific examples and details of statistical 
terms found in the RosettaDesign scoring function are given in Section 1.3.1.  In order to 
increase the speed with which all the terms of the scoring function can be evaluation for 
each rotameric conformation of side-chains, most scoring functions are limited to 
including only terms which are pair-wise additive.  It should be noted that in the field of 
computational protein design, scoring functions are often constructed such that sequences 
with lower (e.g. more negative) scores represent better compatibility for the selected 
backbone.  Details of the scoring function of the computational design program, 
RosettaDesign (which was used for all computational work in this thesis) can be found in 
Section 1.3.1.    
In Section 1.1, the number of possible sequences for a relatively small, 100-amino 
acid protein, was calculated to be ~10130.  While the last decade has seen significant 
advances in the speed of performing computational calculations, sampling and scoring 
this number of sequences (each of which likely has many distinct possible sets of side-
chain conformations), is not yet possible.  Computational protein design tools thus often 
employ any one of a number of optimization protocols, including Monte Carlo simulated 
annealing, dead-end elimination, and genetic algorithms, to bias sampling of side-chain 
conformations towards configurations that score better and better with respect to the 
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starting fixed backbone conformation.  In some cases, such as dead end elimination, the 
search algorithm is guaranteed to output the optimal, or lowest energy, sequence for the 
given scoring function and starting backbone.  Deterministic search algorithms, however, 
tend to be limited by the size of the design task, such that efficiently redesigning an entire 
protein sequence may be unfeasible.  Other search algorithms, such as the Monte Carlo 
simulated annealing protocol used by RosettaDesign, are not deterministic and thus not 
guaranteed to find the optimum possible conformation.  Instead, at the end of the design 
run, the output sequence is a “best guess” at the optimal, or lowest scoring rotameric 
conformation, possible for the given backbone.  In these cases, design simulations may be 
performed multiple times, with the lowest result seen among all runs taken to be the 
design output.  
In some instances, one may perform protein design for some sequence positions 
and not others.  This might occur, for example, when designing a protein binding surface 
or interface.  Here, one might choose to allow the computational design tools to sample 
all possible 20 amino acids only at side-chains whose location on the backbone are 
located within a protein or small molecule binding site.  In this case, backbone sites 
allowed to change their amino acid identities are then referred to design positions. To 
reduce the possibility of physical clashes between sites whose amino acid identities are 
changing and other sites where amino acid identities remain fixed, side-chain 
conformation at sites neighboring design positions are often allowed to change rotameric 
state.  These surrounding positions are then referred to as having been repacked.   
  9 
1.2.2. Successes in Computational Design  
 Protein design methodologies have generally focused on choosing an amino acid 
sequence optimal for a specific criterion, such as protein stability, interaction energy with 
a single binding partner, or introduction of catalytic activity into a protein scaffold.  Early 
protein redesign attempts focused on computationally predicting amino acid sequences 
compatible with protein cores [3] [4].  The first successful redesign of a complete protein 
was that of a small zinc protein motif [5] and this landmark success was followed by the 
design of two novel protein folds [6, 7].  These studies demonstrate that computational 
design search tools and scoring functions have advanced such that prediction of amino 
acid sequences compatible with adopting a given three-dimensional fold is now possible 
in many cases.  
More recently, there has been significant interest in use of computational tools to 
design protein sequences with altered functionality.  A large number of proteins function 
through specifically binding and recognizing to each other, and specific protein-protein 
interactions are known to modulate numerous cellular signaling pathways.  
Computational design tools able to create novel protein-protein interactions, or interfere 
with existing protein interactions involved in cellular pathways, offer exciting promise 
for advancing the creation of biological pharmaceuticals or developing basic science 
tools for understanding and dissecting complex protein interaction networks.   
In general the same physical principles and forces involved in protein folding are 
also dominant at protein-protein or protein-ligand interfaces.  However, deciphering the 
general principles unpinning the specificity and recognition in binding may pose some 
unique challenges.  The distribution of amino acids in protein interfaces is often 
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significantly more polar than what is observed in well-packed protein cores.  Thus, 
successful redesign of protein interfaces may, in some instances, require more accurate 
models of solvation, including the treatment of buried water molecules, electrostatics and 
hydrogen bonding than needed in the design of protein stability.  Additionally, protein 
binding may be accompanied by conformational changes, which can range from subtle 
re-arrangements of side chain locations to larger scale movements of loops, helices, or 
domains.  Despite these unique challenges, scoring functions used for predicting 
sequences stable for a given three-dimensional conformation have been successfully 
applied to the redesign of protein-protein and protein-ligand interfaces ([8-11], for a 
review see [12]).  Additionally, several groups have attempted to engineer catalytic 
activity into otherwise non-catalytic protein folds [13, 14], While the catalytic activity of 
the resulting designed enzymes are still several orders of magnitude less efficient than 
natural enzymes, these successes indicate that computational tools are advancing such 
that computer aided design of proteins with sophisticated functionality is now becoming a 
real possibility.   
Despite the computational design accomplishments described above, the rate of 
success in using computation to design folded, functional proteins with desired functions 
remains low.  This suggests that computational tools may still be far from successfully 
being able to model all the complex pressures under which naturally occurring sequences 
have evolved.   In the next few sections, several topics that will likely play a large role in 
the future success of protein design are discussed, including incorporation of multiple 
functional constraints into protein design, tools to model and incorporate protein 
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backbone flexibility, and the creation of computational design libraries and tolerance 
profiles.  These topics will be re-visited in greater detail in Chapters 2 and 3.   
1.2.3. Designing protein sequences to satisfy multiple functional roles  
The field of computational protein design initially began by studying whether one 
could design, or optimize, a protein sequences for a single fold or function.  The 
examples of protein design given above are primarily examples of single-state, positive 
design.  In single-state design, each sequence under consideration is evaluated only with 
respect to its suitability for fulfilling a single desired property, such as taking on a 
specific backbone fold, binding a single partner, or catalyzing a single reaction.   Whether 
the same sequences might be able to adopt another backbone fold, bind additional 
partners, or catalyze multiple reactions is not explicitly considered.   
However some design tasks, especially those involving the specificity of binding 
in protein interfaces, may necessitate multi-state computational design methodologies 
directly able to evaluate the ability of sequences to fulfill multiple properties. A multi-
state design protocol, which included explicitly designing against unwanted functional 
states, was also shown by Havranek and Harbury to be necessary for the specific design 
of homo- or hetero-dimeric coiled-coil interfaces [15].  Further, Bolon and coworkers 
found that when traditional single-state positive design was used to create a stable hetero-
dimeric protein-protein interface, the alternate homo-dimeric state (which had been 
ignored during the design process) was almost as stable as the designed hetero-dimeric 
state [16].  In contrast, when a multi-state negative design approach was used, in which 
both homo-dimeric and hetero-dimeric stability was evaluated for each sequence, the 
resulting designed sequence assembled almost exclusively into the hetero-dimeric state.  
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Chapter 2 of this thesis builds on these initial multi-state design successes that 
designed against an unwanted function by presenting a multi-state positive design 
methodology to predict protein sequences able to fulfill multiple functional roles. 
Naturally occurring protein sequences can, in some cases, adjust and adapt their 
backbone conformations in response to binding, and further, may be responsible for using 
overlapping interface surfaces to specifically interact with distinct differing binding 
partners at varying times in cellular signaling pathways. While numerous studies have 
examined the role particular amino acids may play in ensuring fold stability or binding 
towards a single partner, less is known about how naturally occurring amino acid 
sequences have been optimized in order to ensure the correct balance and interplay of 
multiple properties.  The algorithm presented in Chapter 2 is presented as one solution 
towards incorporating diverse and multiple functional roles into the computational design 
of protein sequences.   
1.2.4. Limitations of Fixed Backbone Design and Methods to Incorporate 
Conformational Plasticity and Backbone Flexibility 
The use of fixed backbone templates, along with libraries of distinct side chain 
rotameric conformations, has significantly reduced the number of possible 
conformational states associated with any sequence that must be computationally 
evaluated and scored.  However, naturally occurring protein backbones are often found to 
adjust their backbone conformation in response to sequence changes [17, 18].  These 
backbone motions can result in alleviating steric clashes between side-chains that might 
otherwise be predicted to occur without any backbone movement.  Current fixed 
backbone design methodologies may thus be most likely to provide successful sequence 
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predictions only in cases where the designed sequence undergoes very little to no 
backbone adjustments with respect to the starting backbone template.  Thus, as it is likely 
that current fixed backbone methodologies under-predict tolerance to certain sequence 
changes, the incorporation of backbone flexibility into the protein design process is an 
area undergoing intense research. 
Early incorporations of backbone flexibility relied upon parameterizations of 
regular secondary structures [19, 20] or random torsional moves [21].  Other groups have 
sought to incorporate short backbone fragments, obtained from datasets of solved 
crystallographic structures, with small compensatory torsional moves into protein design 
[22, 23].  It was with an iterative protocol of incorporating backbone flexibility via 
fragment insertion and rounds of side-chain design, a novel protein fold, called Top7, was 
designed [24].  Despite this astounding success of incorporating backbone flexibility into 
the design of a new protein topology, current flexible backbone methodologies have 
several limitations.  Fragment insertions or small torsional moves can be rejected as 
incompatible with the starting backbone far more often than they are accepted, and 
designed backbones can score far worse than the native starting backbone, making 
discrimination of favorable backbone templates from unfavorable ones more difficult [21, 
25].  
In Chapter 3, a protocol for using pre-generating ensembles of “near-native” 
backbones (with root mean squared deviations from the starting fixed backbone structure 
of typically less than 0.5 Angstroms) in protein design is presented.  This protocol 
independently models sequences of amino acids onto a set of backbone conformations, 
each of which are a subtle variation of the same fixed backbone, and uses information 
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gathered from the entire conformational ensemble to determine suitable amino acid 
substitutions.  In Chapter 4, this protocol is modified slightly such that for each sequence 
change under consideration, the single, most favorable backbone conformation from 
among the ensemble of conformational variants is chosen. 
1.2.5. Using protein design to predict tolerated sequence space and 
computationally design libraries 
Arbitrary protein sequences are rarely functional, as they often fail to take on 
well-defined three-dimensional structures.  In contrast, naturally occurring protein 
sequences (often referred to as native sequences) can carry out specific functions that are 
dependent on both their three-dimensional fold and precise amino acid sequence.  
Changing only a single amino acid within a native sequence (called a point mutation) can 
result in a wide range of functional and/or structural effects.  Some sequence changes can 
be thought of as “neutral”, if they leave the three-dimensional structure and function of a 
protein virtually unchanged.  Other sequence changes however may result in more drastic 
effects.  These can range from inducing subtle changes in the three-dimensional fold, 
altering the biological function of the original protein such that it takes on new 
functionality, or even completely destabilizing the formation of any well-folded, stable 
three-dimensional structure. Protein design may offer unique insights into discriminating 
sets of point mutations and amino acid sequence changes the are forbidden (e.g. those 
causing the protein fold to become unstable) from other sequence changes that may 
enable the protein to develop new functionality or fold stability.  Thus, rather than 
outputting a single sequence predicted to be optimal for a single design task, 
computational protein design could also be used more broadly to predict amino acid 
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tolerances at each position in a protein sequence.  This would allow the astronomically 
large theoretical sequence space for a given protein fold to be narrowed down to a more 
manageable number of sequences, that could then be experimentally screened as 
combinatorial sequence libraries and tested for novel functionality.  Further, use of 
computationally designed sequence libraries could help overcome some of the limitations 
in design scoring functions, search methodologies, and fixed backbone approximations 
discussed above.    
Computational design libraries have shown some success when used by several 
groups to enhance protein folds for added stability and then screen for altered 
functionality [26, 27].  In Chapter 3, I present a protocol to predict computational design 
libraries for protein sequences under multiple constraints, using RosettaDesign.  This 
methodology would allow one to directly design libraries enhanced in both fold stability 
and novel functionality.  Further, I present a method to incorporate backbone flexibility, 
via use of ensemble design, into the computational prediction of design libraries. Current 
protein design tools are still far from being able to create designer protein sequences at 
will.  Hopefully, the approach presented in Chapter 3 of combining backbone flexibility 
with experimental screens of computational libraries designed to satisfy multiple criteria 
will prove useful in enhancing the overall success rate in the design and engineering of 
protein sequences.     
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1.3. Introduction to RosettaDesign and the “Backrub” Protocol for 
Generation Backbone Ensembles 
All computational protein design experiments described within this work use 
RosettaDesign, which has previously been shown to successfully predict binding energy 
hotspots in protein-protein complexes and has been used to reengineer specificity in 
protein interfaces [11, 28].  The most general features of the RosettaDesign program, 
including the sampling methodology and the scoring function, are described in this 
section.  As needed, specific modifications to the standard RosettaDesign protocols of 
sequence sampling and scoring will occur in the Chapters that follow.   
 
1.3.1.  RosettaDesign Scoring and Sampling   
The RosettaDesign scoring function is described in detail in [7].  It is dominated 
by attractive and repulsive Lennard-Jones packing interactions, an orientation-dependent 
hydrogen term [29], and an implicit solvation model, based on that proposed by 
Lazaradis-Karplus [30]. Several statistical terms, derived from probabilities of certain 
features occurring among experimentally determined high-resolution crystallographic 
structures, are also included.  These include backbone dependent terms which account for 
the suitability of a given amino acid type, or a specific conformation of a given amino 
acid type, for a given set of backbone phi/psi angles (Ramachandran torsional preferences 
and rotamer self energies).  Also included is a statistical pair term, which encodes the 
statistical likelihood that two amino acid types are found a certain physical distance from 
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each other.  Unfolded, reference state energy terms are also included for each amino acid 
type.  
A per-residue energy (ERES), consisting of the sum of all scoring terms described 
above, is calculated for every position among a fixed protein backbone or protein-protein 
complex, and the sum of all per-residue energies over all protein chains is referred to as 
the complex or folding score.  In order to facilitate quick estimates of binding energies at 
protein-protein interfaces, an interface score was approximated by summing all the pair-
wise terms of the RosettaDesign scoring function between all sites i and j, where i and j  
are on differing protein chains.  
A published rotamer library [5] was used for generating the rotameric side-chain 
conformations of each amino acid residue type, and this library was often further 
expanded by including the native amino acid PDB conformation as well as additional 
rotamers around the !1 and !2 angles.  Standard RosettaDesign samples rotamers on a 
fixed backbone using a Monte-Carlo simulated annealing optimization protocol.  
 
1.3.2. Structure Preparation for RosettaDesign 
Structural templates for all RoesttaDesign calculations described in this work 
were taken directly from the protein data bank (PDB) and, unless otherwise noted, were 
chosen to have a resolution of 2.5 Angstroms or better.  Prior to performing any 
calculations, each structure was initially prepared by removing all water molecules, 
heteroatoms, and hydrogen atoms.  Hydrogen atoms were then computationally re-
introduced as previously described [29].  An initial round of side-chain minimization was 
performed using the RosettaDesign scoring function and keeping all amino acid identities 
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and backbone coordinates fixed.  After this initial minimization, positions were selected 
for design and repacking (as described in each Chapter) and all backbone and side chain 
positions not designated as either to be designed or repacked were kept fixed for all 
subsequent steps.  
 
1.3.3. Backrub protocol for computationally generating structural ensembles  
Chapters 3 and 4 describe research projects that rely on a computational protocol for 
generating small adjustments in fixed protein backbone conformations, termed 
“backrub”.  The backrub move was first presented by Richardson and Richardson [31]to 
describe subtle variations in backbone conformations observed in high-resolution 
crystallographic structures.  These backbone adjustments were often coupled with the 
presence of alternative side-chain conformations.  A generalized version of the backrub 
move, as described in [31], was implemented into RosettaDesign by Colin Smith [32, 
33].  This protocol for computationally introducing backbone flexibility proved 
invaluable throughout my thesis work as providing a means to model backbone 
conformations close in three-dimensional space to a starting PDB protein structure or 
protein-protein complex of interest. Detailed descriptions of the backrub protocol can be 
found within the methods sections of Chapters 2 and 3.   However, a brief description of 
how an ensemble of backbones was computationally generated from a single starting 
crystallographic structure (containing either a single protein backbone or a protein-
protein complex) using the backrub move is given here.  
Prior to beginning simulations to computationally introduce flexibility, each 
residue within the starting PDB structure can be designated to either remain fixed or be 
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designated as allowed to take part in a backrub “move”.  This allows for generation of 
flexibility focused around a particular structural section of a starting structure.  Residues 
ending or beginning a stretch of consecutive residues selected to undergo movement are 
always fixed in this protocol, and thus selecting every residue of a protein to be 
“backrubbed” will nevertheless result in the first and last amino acids retaining their 
original conformation.  In this thesis, ensembles of backbones with variable 
conformations were generated from the same starting PDB structure by allowing all 
residues to take part in the backrub move and then performing 100 or more independent 
Monte Carlo simulations.  Each simulation consisted of randomly selecting two residues 
that were separated by 1 to 10 intervening residues, rotating the protein backbone 
segment between the two C" atoms of the selected residues by 0 to 40 degrees, and 
optimizing the positions of the C# and H" atoms branching off the pivot C" atoms 
(according to the CHARMM bond angle potential as described in [33]).  This process of 
selecting and rotating atoms was repeated 10,000 times per Monte Carlo run, and 
throughout the simulations side chain rotamer moves were interleaved with backbone 
“backrub” moves.    
For the protocols described in this thesis, the lowest energy conformation 
observed during each of 100 or more Monte Carlo simulations was saved and referred to 
as a backbone “ensemble member”.  In some cases (as described in Chapter 4), additional 
conformational variability was introduced by also saving the last conformation sampled, 
regardless of its score, during each Monte Carlo simulation or by increasing the Monte 
Carlo temperature, so that more variable conformations were sampled and accepted.  
Root mean squared deviations (RMSD) between the lowest energy backbone 
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conformations generated independently from a single crystal structure by performing the 
backrub move at low Monte Carlo temperatures (KT=0.6) were usually small, and on the 
order of 0.3 – 0.4 Angstroms.  In contrast, ensembles generated at higher Monte Carlo 
temperatures (KT=1.2) or including the last conformation sampled rather than only 
considering the lowest energy conformations, displayed greater conformational 
variability, and could have average RMSD values of up to 0.6 Angstroms.   
 
1.4. Outline of Thesis  
In Chapter 2, I present a computational algorithm designed to optimize protein 
sequences for multiple functional criteria.  The algorithm itself is general in nature and its 
implementation allows for incorporation of any constraint able to be quantified using an 
objective function into the optimization procedure.  After describing the algorithm in 
detail, I examine its performance in predicting protein interface sequences able to bind to 
multiple protein partners.   Development and testing of such an algorithm could be a 
crucial first step towards fulfilling the goal of successfully rationally designing novel 
proteins able to be expressed and function correctly in a cellular environment and in the 
context of many possible interaction partners.  Finally, I suggest some possible insights 
into the mechanisms nature might have used to tune protein surfaces to recognize 
multiple correct partner proteins by comparing computationally predicted amino acid 
sequences to solutions found in nature.  
In Chapter 3, I present a modified version of RosettaDesign able to not just 
predict the optimal amino acid sequence for a given set of functional constraints, but also 
able to output a profile of expected amino acid tolerances for each protein design site.  I 
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examine the ability of this modified RosettaDesign tool to predict amino acid sequence 
tolerance profiles at the interface of a well-studied protein-protein interaction, human 
growth hormone (hGH) with its receptor (hGHR).  Incorporation of backbone flexibility 
(via the “backrub” move) is shown to be critical for correct discrimination of sequence 
positions displaying high mutational robustness from those displaying high sensitivity to 
mutation.  It is hoped that the computational prediction of amino acid tolerance profiles, 
such as those presented in Chapter 3, might prove useful for computationally predicting 
design libraries that could be experimentally screened for novel proteins variants with 
new functionality. 
In Chapter 4, I combine the multi-constraint design principles tested in Chapter 2 
with the ideas of predicting sequence tolerance developed in Chapter 3 in order to make 
predictions of the total set of single amino acid sequence mutations, reachable by a single 
mutation at the DNA nucleotide level, tolerated by the biologically important protein, 
HIV-1 protease.  Correct functioning of HIV protease is critical to viral infectivity, and 
this function is itself constrained by the need of HIV protease to maintain a protein 
sequence that can stably fold and dimerize, as well as cleave at least 10 endogenous 
substrates.  By computationally including each of these functional constraints into the 
protein design process, I show that computation can, in many cases, predict which sites in 
the HIV protease sequence are most mutatable as well as which specific amino acid 
mutations are most likely to occur in both a neutral (i.e. “drug” free) as well as a selective 
(i.e. after protease inhibitor treatment) setting.  It is hoped that this protocol may be 
further developed for use as a general tool to preemptively predict mutations likely to 
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occur in protein sequences in response to complex sets of evolutionary (or drug-induced) 
pressures. 
Chapter 5 describes how the tools presented in Chapters 2 – 4 could be modified 
and expanded for future use in computational protein design and prediction.   
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Chapter 2  
Designing Sequences to Satisfy 
Multiple Functional Constraints 
 
This chapter describes a “multi-constraint” protein design protocol to predict 
sequences optimized for multiple criteria.  We use this protocol to examine how naturally 
occurring proteins are able to maintain specific sets of interactions by characterizing the 
mechanism and extent to which the interface sequences of 20 multi-specific proteins may 
be constrained by binding to multiple partners. We find that multi-specific binding can be 
accommodated by at least 2 distinct patterns.  In the simplest case all partners share key 
interactions, and sequences optimized for binding to either single or multiple partners 
recover only a subset of native amino acid residues as optimal. More interestingly, for 
signaling interfaces functioning as network “hubs” we identify a different,  “multi-
faceted” mode, where each binding partner prefers its own subset of wild-type residues 
within the promiscuous binding site. Our calculations suggest that these interfaces might 
have been substantially optimized for multi-specificity. The two strategies make distinct 
predictions for interface evolution and design. Shared interfaces may be better small 
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molecule targets, whereas multi-faceted interactions may be more “designable” for 
altered specificity patterns. While this work has focused on examining multiple protein 
interactions, the computational methodology we present can easily be generalized for 
examining how naturally occurring protein sequences have been selected to satisfy a 
variety of positive and negative constraints, such as taking on multiple, distinct backbone 
conformations.  Finally, we hope that our multi-specific design protocol will provide 
useful in the future for rationally designing proteins to have desired patterns of altered 
specificity or fulfill multiple functional roles.  
 
2.1. Introduction    
Interactions in protein networks may place constraints on protein interface 
sequences to maintain correct and avoid unwanted interactions.  Proteins have evolved to 
operate within the context of crowded cellular milieus and complex functional networks 
[34]. It is not well understood how and to what extent protein sequences and structures 
are optimized for multiple and likely interdependent properties such as stability and 
efficiency of folding, low propensity for aggregation, and functional characteristics. 
Protein-protein interaction networks may impose particular pressures on amino acid 
residues in protein interfaces if each protein needs to maintain correct and avoid 
unwanted interactions. Not only specificity of interactions but also a defined level of 
promiscuity may be required, as it is known that many proteins use regions of 
overlapping interface residues to bind several partners at different points in time [35].  
Protein design predictions offer great promise to help dissect the structural 
determinants of the interplay between promiscuity and specificity, as well as to create 
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new molecules that interfere with defined cellular protein-protein interactions with high 
fidelity and selectivity [36]. Yet in at least some cases sequences completely redesigned 
on a known protein fold often differ substantially from naturally occurring sequences [5] 
and the properties of designed proteins can be unusual. Top7, a computationally designed 
protein with a fold not previously seen in nature [7], has a complex folding landscape 
strikingly different from that of evolved small, single domain proteins [37]. Thus, if we 
wish to rationally design new proteins that can be expressed and function correctly in a 
cellular environment and in the context of many possible interaction partners, it is likely 
that we will need modeling procedures that are able to consider a variety of requirements 
defining optimal protein “fitness”.  
Here we focus on the multiple constraints interaction networks may impose on 
protein interfaces, both to characterize the evolutionary and biophysical principles 
shaping these networks, and to develop computational design methods to reengineer 
them. Previous studies have suggested the importance of negative selection to maintain 
specificity for a single binding partner [38]. Havranek & Harbury developed a negative 
design strategy selecting against unwanted partners to predict highly specific coiled-coil 
interfaces [10]. We extend the idea of incorporating additional selection constraints into 
computational protein design by examining the inverse problem:  how are multiple 
positive criteria, such as the binding of different partners, accommodated at multi-
specific (e.g. promiscuous) protein interfaces?  
We perform two computational experiments on 20 multi-specific proteins: First, 
we optimize each multi-specific interface sequence to maintain interactions with all 
known structurally characterized partners (multi-constraint protocol). Second, we predict 
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interface sequences optimal for interacting with each partner individually (single-
constraint protocol). We hypothesize that, to the extent that a multi-constraint protocol is 
a good approximation of pressures acting on promiscuous interfaces, predicted sequences 
should be more “native-like” when all characterized binding partners are included in the 
optimization procedure than if only the interaction with a single binding partner is 
considered. Further, if multiple pressures are playing a role for sequence choices, we can 
compare the differences in interface sequences selected by each partner alone (single 
constraint) and all partners considered together (multi-constraint). This comparison 
should highlight which amino acids are compromises among the various outcomes 
favored by each binding partner individually.   
We show that, overall, inclusion of multiple binding partners during optimization 
returns sequences closer to those found in native promiscuous interfaces. We find native 
interface residues predicted to be “hotspots” for each partner remain optimal in the 
context of optimization for single or multiple partners, while other positions may or may 
not undergo compromises in order to maintain binding of all partners. These trends 
resulted in the classification of two broad groups of multi-specific interfaces. In the first 
group, the number of native residues recovered as optimal was similar for optimizations 
performed over single or multiple partners. Here key interactions within the interface 
appeared to be shared, and there was little evidence of compromise in binding 
preferences among all partners. In contrast, a second group of multi-specific proteins, 
including signaling “hubs” such as the GTPases, ubiquitin and actin, appeared to have 
optimized large fractions of their interfaces for binding multiple partners. In these cases, 
each partner appears to pick and choose subsets of the interface to make key interactions 
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with, and integrating differences in the binding preferences over all partners often 
resulted in the native residues being the “optimal compromise” for maintaining binding 
of all partners.  
Our method thus both predicts interface sites responsible for multi-specificity and 
provides an estimate of the magnitude of pressure exerted on sites by each interaction 
partner. The method we present here can be used as a predictive tool to study how 
naturally occurring amino acid sequences might have been constrained by any number of 
positive or negative criteria - including the ability to adopt two different conformations 
[39] - or as a protein design tool to rationally redesign variants of native proteins to have 
a desired set of properties matching user-defined constraints.  
 
2.2. Rationale: Test for optimization and compromise by applying 
multi- and single-constraint design to promiscuous protein 
interfaces  
 
We set out to address two main questions (Figure 2.1). First, how optimized are 
native multi-specific interface sequences for binding multiple partners?   It is known that 
the free energy of binding a single interacting partner is generally not evenly distributed 
among the native interface residues, but rather some positions are energetically more 
important than others [40]. Further, phage display experiments have revealed that 
substantial sequence plasticity may be tolerated at protein interfaces without significantly 
destabilizing, and often improving, binding of a single partner [41-43].  
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Figure 2.1 Multi-State Design Methodology and Flow Chart 
(A) Computational strategy for determining the degree of optimization and predicted cost of multi-
specificity.  (B) Flowchart illustrating the methodology for generating a dataset of multi-specific proteins 
and computational protocol for predicting sequences optimal for each binding interaction alone (single-
constraint) as well as sequences predicted to satisfying binding in the context of all structurally 
characterized partners (multi-constraint). 
 Thus, only a subset of a protein sequence may need to be constrained to native in 
order for a single criterion to be satisfied, while other sequence positions may be less 
optimized and tolerate a wider set of amino acid types. We hypothesize that the presence 
of multiple constraints (e.g. multiple binding partners) might substantially restrict 
interface sequence space such that only native or near native amino acid residues would 
be tolerated at most sites in multi-specific interfaces. If this is true, sequences that have 
been computationally designed to optimize binding with all known interaction partners 
should be more “native-like” than sequences designed to bind each partner 
independently. Thus, for each promiscuous protein we examine, we compare the 
sequence predicted to be optimal by our multi-constraint protocol to the wild-type 
sequence in order to provide an estimate of how extensively each interface is optimized 
for multi-specificity (Test for Optimization, Figure 2.1). Importantly, differences between 
predicted and wild type sequences could highlight that evolved sequences are not 
necessarily optimized for maximal affinity but that other pressures are at play.  
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Secondly, we ask if each binding partner prefers similar interactions throughout 
the binding site, or if some partners must make energetic compromises in order for multi-
specificity to be maintained. In order to address this question, we compare sequences 
computationally designed to bind only one partner at a time (without consideration of the 
other characterized partners) with the sequence selected as optimal for interacting with all 
partners (Estimate Cost, Figure 2.1). We reasoned that for a given interface position, if an 
identical amino acid is chosen when each partner is optimized separately as is selected 
when all partners are included in the optimization process, key interactions at that site 
might be highly shared among all partners. In contrast, some single-constraint 
optimizations might choose an amino acid type different from the one selected in the 
multi-constraint protocol. For such positions, we can use our scoring function to estimate 
the degree of compromise occurring between differing preferences seen among the 
interaction partners.  
We imagined two extreme case scenarios:  If all binding partners of a given 
promiscuous protein prefer similar interface sequences (“shared” scenario), single and 
multi-constraint optimizations are expected to give similar results and comparable 
agreement with wild-type sequences (termed “native sequence recovery”). If only a core 
set of shared residues is sufficient for binding to all partners, the total native sequence 
recovery over the entire interface could be low as the exact amino acid identity of 
peripheral residues may be less important. Alternatively, each residue in a multi-specific 
interface could be optimal for only one or few partners (“multi-faceted” scenario). In this 
case, designed sequences from single constraint simulations would be expected to 
resemble the wild-type sequence only for certain positions, and these positions could be 
  30 
different for each partner. The multi-constraint simulations should act to integrate 
preferences across all partners and would be expected to generate sequences that are 
more native-like than those resulting from optimization for any single binding partner 
alone. For this scenario, there could be significant tradeoff between the preferences of 
differing partners, and amino acid residues within this type of interface could be 
compromises with respect to the amino acid type preferred by some or all partners. 
However, for each interface position we hypothesize that there should be an “optimal 
compromise” that satisfies the constraints imposed by all partners to maintain multi-
specific binding.  
 
2.3. Computational strategy 
Our computational protocol to test for optimization and compromise in multi-
specific interfaces outlined above is illustrated schematically in Figure 2.1B. To 
determine whether the shared or multi-faceted strategies are used in naturally occurring 
promiscuous interfaces, we first compiled a data set of protein complexes from the PDB 
(Section 2.4.1). Each promiscuous protein along with all its structurally characterized 
binding partners is listed in Figure 2.2. In total, we examined 65 PDB complexes, each of 
which included one of 20 multi-specific proteins. While this analysis is inherently limited 
by the set of promiscuous proteins characterized in the PDB and ignores much known 
information on biological interactions, it has the advantage that we can rely on high-
resolution structural information for each of the complexes, and hence are more likely to 
obtain reliable predictions from protein design methods. Our dataset of 20 promiscuous 
proteins is nevertheless quite broad and includes all SCOP [44] folds (except membrane 
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proteins) as well as representatives from diverse functional families such as signaling 
proteins (GTPases, CheY), structural proteins (actin), ubiquitin, and several enzymes 
(Figure 2.2). Further, in order to estimate the connectivity or number of putative protein-
protein interactions for each promiscuous protein in our dataset, we performed a BLAST 
search against sequences within the database of interacting proteins (DIP, http://dip.doe-
mbi.ucla.edu/, [45]). Protein-protein interaction graphs for homologs to the multi-specific 
proteins in our set (leftmost column of Figure 2.2; e-value <1*10-9, Section 2.4.5) suggest 
at least half of the proteins we analyze can be classified as “hubs” (1st shell nodes > 5; 
2ndshell nodes > 15) and many of these proteins are involved in cellular signaling 
processes.  
As we wished to examine promiscuous interface positions believed to be under 
multiple constraints, only interface positions that had an atom within 4 Å of 2 or more 
separate binding partners were considered in our analysis. On average, each characterized 
binding partner contacted 15 (± 4.5) residues in this overlapping set (Figure 2.2). Any 
conformational changes occurring between the different complexes were taken into 
account implicitly by using the backbone conformations directly from each complex PDB 
structure. 
Sequence optimizations used a genetic algorithm [10] and fitness for binding was 
evaluated using inter-molecular scores (Section 2.4.3). Single constraint optimizations 
minimized the binding score for interaction with a single partner while multiple 
constraint optimizations minimized the sum of the calculated binding scores over all 
partners (Section 2.4.3).  
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Figure 2.2 Dataset of Multi-Specific Proteins 
PDB codes and descriptions of multi-specific proteins and their 65 crystallized interaction partners are 
given. For each binding partner, the total number of residues it contacts (within 4 Angstroms) on its multi-
specific binding protein as well as the number of these residues which are also utilized by at least one other 
characterized binding partner are given in the ‘‘Total’’ and ‘‘Shared’’ columns. Fold classes are as assigned 
using SCOP [20]. Protein–protein interaction maps of sequence homologs to the promiscuous proteins in 
our dataset (see Section 2.4.5) are as taken directly from the Database of Interacting Proteins [21], 
http://dip.doe-mbi.ucla.edu/, see Supplementary Table A.1). Root nodes are colored red and the number of 
first (orange) and second (yellow) shell nodes for each map is given on the far left. Edges are color-coded 
based on the reliability of data used to infer interactions, with green lines indicating data verified by one or 
more computational methods and red lines depicting unverified high-throughput screens. The width of lines 
in interaction graphs reflects the number of independent experiments verifying each predicted interaction. 
2.4. Methods 
2.4.1. Generation of a dataset of multi-specific proteins.  
Each domain of every protein-protein interface listed in PIBASE (http://alto. 
compbio.ucsf.edu/pibase/introduction.html [46]) was classified using the standard SCOP 
domain definition. SCOP domains were clustered at 90% sequence identity. Clusters 
containing only intra-protein domain interactions (only one chain in the PDB file) were 
removed, and clusters with duplicates were merged, leaving 168 clusters. Additional 
filtering via PDB header descriptions to remove multi-subunit, viral coat, and 
immunoglobulins/MHC proteins resulted in approximately 50 clusters. All clusters 
containing multiple structures of the same promiscuous protein interacting with differing 
binding partners using an overlapping binding site (by visual inspection) were selected 
for the dataset of multi-specific proteins. Lower resolution structures of redundant 
protein-protein complexes were discarded, as well as all structures (except 1FXT) 
determined by NMR. PDB codes of the resulting 20 clusters are given in Figure 2.2. 
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2.4.2. Energy function and preparation of structures.   
All simulations were performed using the RosettaDesign methodology as outlined 
in [7] and described below. The RosettaDesign scoring function is dominated by 
attractive and repulsive Lennard-Jones interactions, an orientation-dependent hydrogen 
bonding term [29], and an implicit solvation model [30]. Side chains from a rotamer 
library including the native amino acid PDB conformation with additional rotamers 
around the !1 and !2 angles [5] were sampled on a fixed backbone using a Monte-Carlo 
simulated annealing optimization protocol.  
All water molecules, heteroatoms, and hydrogens present in the original PDB 
were removed, and hydrogen atoms were added as previously described [29]. An initial 
round of side-chain Monte-Carlo minimization was then performed using the 
RosettaDesign scoring function, keeping all amino acid identities and backbone 
coordinates fixed, while selecting for the optimal rotamer at each side chain position from 
the rotamer set as described above. After this initial minimization, all backbone and side 
chain positions not determined to be in the shared interface were kept fixed for all 
subsequent steps.  
 
2.4.3. Single and Multi-State Optimization Protocol 
Amino acid positions on each promiscuous protein were considered for single and 
multi-constraint design simulations only if any atom of 2 or more known binding partners 
was located within 4Å of any atom of the side chain of interest. For promiscuous proteins 
with 5 or more characterized binding partners, only interface positions with an atom 
within 4 Å of 3 or more partners were considered. Each single or multi-constraint 
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optimization allowed all amino acids (except cysteine) to be substituted at each position 
examined. Positions for which the native residue was a cysteine were disregarded. For all 
simulations a genetic algorithm was used to generate and propagate putative sequences 
based on inter-molecular scores, and optimal rotamers for each sequence were chosen 
separately with consideration of both inter- and intra-molecular interactions by simulated 
annealing Metropolis Monte Carlo for each fixed backbone as taken from the PDB. This 
ensured that in the multi-constraint protocol rotameric conformations could differ among 
binding partners even as identical interface amino acids were scored for each. 
Simulations were started with an initial random population of 2000 sequences, 
and the genetic algorithm was allowed to propagate for 100-200 generations. For single-
constraint simulations, fitness was defined to be the inter-molecular score for a single 
complex while for multi-constraint simulations the fitness was a linear sum of the inter-
molecular scores of a given amino acid sequence calculated across all characterized 
binding partners.  
FITNESS  =  $ wi*(Complex score) 
For all calculations the weights (wi) were set uniformly to 1. For single-constraint 
simulations the sequence that scored optimal with respect to a single complex 
independently was advanced to the next generation while the multi-constraint protocol 
advanced the sequence for which the fitness as defined above was minimized. The best 
(lowest) scoring sequence from each generation was automatically retained and uniform 
crossover was used to generate the remaining sequences of the population for the 
following generation. Random mutation of any given interface sequence was allowed for 
each generation with a probability of 20% at any given interface position. Simulations 
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converged (dependent on the size of the shared interface) on average within 50-130 
generations (see Figure 2.3A and Figure 2.3B).  
 
2.4.4. Per-residue Energetic Analysis. 
Over the 20 multi-specific proteins in our dataset, 338 interface residues met the 
criteria for design. Consideration of each interface position in the context of the 65 
characterized binding partners resulted in 1199 individual interactions. For each 
individual interaction, a per-residue inter-chain score was calculated by summing, for any 
given residue on chain i, pair-wise contributions to the score from all residues on chain j% 
i. An interface residue was classified as a hotspot for all binding partners for which the 
per-residue inter-chain score of the original native amino acid in the wild-type complex 
was calculated to be less than –2 (see pink shading, Supplementary Figure A.4).  
Estimates in predicted per-residue improvements (Figure 2.6) in binding affinity 
were made by calculating, for each binding partner, the difference in per-residue score of 
the amino acid chosen by single or multi-constraint simulations (Figure 2.6A and Figure 
2.6B, respectively) from native. Positions for which the per-residue score for the native 
amino acid, as well as the amino acid chosen in single- and multi-constraint simulations 
was zero were eliminated from the analysis. These 214 positions represented cases where 
one binding partner did not interact with an interface residue in contact with other 
partners in our dataset (see grey shading, Supplementary Figure A.4) 
Estimates of per-residue constraint (Figure 2.7) were made by calculating, for 
each binding partner, the difference in per-residue scores for the amino acid type/rotamer 
chosen in the single-constraint optimization from the respective score for the amino acid 
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type/rotamer selected by the multi-constraint protocol. The largest magnitude of 
difference seen among all partners was the constraint value assigned. For simulations that 
did not recover the native amino acid type, constraint scores between sequences selected 
using single and multi-constraint optimization were also calculated and assigned to the 
native amino acid type.  
 
2.4.5. Generation of protein-protein network graphs.  
The complete sequence, as taken from the pdb files, of each promiscuous protein 
within our dataset was searched against all sequences contained within the Database of 
Interacting Proteins (http://dip.doe-mbi.ucla.edu/ [45]). Hits were considered as 
significant if they had an e-value of less than 1*e-9. Protein-protein interaction graphs 
(Figure 2.2) were shown for sequences predicted to be homologous to Saccharomyces 
cerevisiae whenever possible. The DIP identification number, organism, e-value, and 
assigned DIP protein name for interaction graph shown in Figure 2.2 are as given in 
Supplementary Table A.1.  
 
2.4.6. Multiple Sequence Conservation of Ras. 
A multiple sequence alignment (MSA) and evolutionary rates for Ras were 
calculated using the automated web-server http://consurf-hssp.tau.ac.il for the Consurf-
HSSP database [47] using the PDB ID code 1WQ1. Evolutionary conservation scores (1-
10, 10 most conserved) were 9 and 8 for 32Y and 67M respectively. 90% (186/206) of 
sequences within the MSA for the native position 32Y contained either a Y or H while 
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89% (184/206) of sequences at the native position 67M contained (H, I, L, M, Q, V). 
Multi-constraint simulations selected 32H and 67H as optimal, respectively.  
 
2.5. An example case study: Ran GTPase shows multi-faceted 
binding 
Before discussing results over the entire dataset (complete data for all 
promiscuous proteins in our set are available as Supplementary Figure A.4), we consider 
as a representative example the promiscuous protein Ran with 5 of its structurally 
characterized interaction partners (Figure 2.3). One multi-constraint and five single-
constraint optimizations were performed for the Ran set. The trajectories of the five 
independent single-constraint optimizations monotonously decrease in score at each 
generation, and in each case the converged final sequence is predicted to have a binding 
score better than wild type (Figure 2.3A, squares at final generation). Additionally, the 
sequences selected as optimal in each single constraint simulation differed significantly 
from native (22-39% native sequence recovery, plus signs in Figure 2.3C).  
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Figure 2.3 Simulation Trajectories and Designed Sequences for the Multi-Specific Protein Ran 
Trajectories of single-constraint and multi-constraint optimizations are shown in (A) and (B). PDB codes of 
complexes used to model the five different Ran binding partners are given in the legend. For reference, the 
score of the native amino acid sequence for each binding partner is marked on the y-axis (squares, final 
generation). Scores among partners are correlated for multi-constraint simulations (arrows). Optimal 
interface sequences taken from the endpoint of the trajectories in (A) and (B) are shown in (C). The first 
row in the table contains the interface residue PDB numbering, the second row lists the native sequence 
(red), and the following rows list sequences predicted to be optimal in each simulation: multi- constraint 
(second sequence), single-constraint (third through seventh sequences). Plus signs in the table denote that 
the wild-type amino acid residue type was recovered as optimal. The number and percent of interface 
residues recovered as identical to native is shown for each simulation in the rightmost column. Grey 
shading denotes interface positions not within 4 Angstroms of the shaded interaction partner (see Section 
2.4.3).  
In contrast, the trajectories of the multi-constraint simulation show correlated 
changes in binding scores as each sampled sequence is evaluated separately in the context 
of the 5 complexes (Figure 2.3B). Cases where the simulation makes tradeoffs that are 
more favorable to some partners and less favorable for others can be clearly seen (arrows 
in Figure 2.3A). Here, the sum of scores over all complexes decreases with time and the 
final converged sequence ranks closer to the native score than the sequences selected by 
the single partner optimizations (compare endpoints of trajectories of Figure 2.3A and 
Figure 2.3B with squares). Most notably, the amino acid sequence selected as optimal by 
the multi-constraint protocol is quite similar to the evolved wild-type sequence (67% 
identical to wild type, plus signs in Figure 2.3C).  
In the Ran example, the high native sequence recovery seen in the multi-
constraint optimization indicates that a significant fraction of wild type residues in this 
promiscuous interface is optimized for multi-specificity by “adding up” information from 
single partner optimizations (Figure 2.3C). This is consistent with the multi-faceted 
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scenario described above. Further, the multi-constraint trajectories illustrate that there 
may be tradeoffs in preferences among the binding partners (Figure 2.3B, arrows), and 
comparison of sequences selected by the single and multi-constraint simulations suggest 
interface positions where the wild-type residue may represent a compromise to allow 
promiscuity. 
The top row of Figure 2.4 (panels A-F) shows such instance where several single-
constraint optimizations select residues differing from native, yet the multi-constraint 
optimization integrates the single partner preferences to recover the wild type glycine 
(single constraint models shown for Figure 2.3C, 1st box, residue 74). The design 
simulations predict three of Ran’s binding partners (1A2K.pdb, 1IBR.pdb, 1K5D. Figure 
2.4A,C-D) prefer side-chains larger that the wild-type glycine that have additional side-
chain hydrogen bonding capability. However tight steric constraints for binding the 
remaining two partners (1I2M.pdb and 1WA5.pdb, Figure 2.4B,E) necessitate glycine to 
be the “optimal” compromise for this interface position. Similar instances of compromise 
at interface positions that are under substantial steric constraint with a subset of the 
interaction partners are a common pattern in our dataset; many of these cases involve 
wild-type glycine residues.  
 
Figure 2.4 Single and Multi Constraint Structural Models for Two Ran Interface Sites 
Computational models of interface regions around residues predicted to be optimal for binding each partner 
of Ran are shown (orange, 1A2K.pdb, yellow, 1I2M.pdb; green, 1IBR.pdb, purple, 1K5D.pdb; blue, 
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1WA5.pdb). Single-constraint predictions for residue 74 (A–E) (wild-type glycine) indicate compromise 
among the preferences of the five partners. Three partners (A,C,D), when optimized alone, prefer a residue 
with greater hydrogen bonding capabilities than the wild-type glycine. Steric constraints imposed by the 
remaining two partners (B,E) forced selection of the wild-type glycine by the multi-constraint protocol. 
Multi- constraint predictions for residue 76 are shown in panels F–J. The wild- type arginine is also chosen 
in all single-constraint predictions where it mediates an inter-chain hydrogen-bonding network (F,G,H,J). 
Single- constraint selection of leucine at position 76 for 1K5D.pdb is not shown. 
 
In contrast to the compromised scenario described above, the bottom row of 
Figure 2.4 (panels F-J, structural multi-constraint models shown for Figure 2.3C, 2nd 
box, residue 76) depict a Ran interface residue that our simulations predict to be highly 
shared among all partners. Here the wild type residue, arginine, is correctly recovered by 
every single constraint simulation where it mediates an inter-chain hydrogen bonding 
network. This is the case for all partners except one (Figure 2.4I). Here the inter-chain 
interactions are formed largely by the aliphatic part of the arginine side chain, and design 
simulations favor a leucine residue. Hence for this interface position, where the multiple-
constraint simulation also correctly selects the wild type arginine, there is little indication 
that recovery of this native amino acid is the result of compromises among the interaction 
partners. Interestingly, the Ran interaction partners depicted in Figure 2.4F and Figure 
2.4G form very similar hydrogen bonding interactions with the wild-type arginine, 
although the partner proteins comprise different fold classes. This behavior of physio-
chemically similar interactions formed by structurally distinct interfaces has been 
observed previously [48, 49]. 
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2.6. Sequences selected by multi-constraint simulations can be 
substantially more native-like that single constraint sequences  
We next investigated whether the trend of optimization for promiscuity using the 
multi-faceted scenario we observed for Ran was common in our dataset. In total, 65 
separate single constraint optimizations and 20 multi-constraint optimizations were 
performed (Figure 2.2). Figure 2.5A shows that, over our entire dataset, sequences 
predicted as optimal by the multi-constraint protocol are more native-like than the 
sequences selected in the corresponding single-constraint runs (compare distance from 
red squares of black diamonds versus grey circles). There was only one instance (elastase 
in complex with inhibitors, promiscuous protein set #9) where the single-constraint 
optimization for binding one of the partners out-performed the multi-constraint protocol 
in native amino acid recovery.    
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Figure 2.5 Comparison of Single- and Multi-State Sequence Recovery and Binding Scores 
(A) The number of residues recovered as identical to native are plotted for each promiscuous protein (see 
Figure 2). For reference, the size of the shared interface is shown for each protein in red. For roughly half 
the dataset, (group II, pink shading), sequence recovery from the multi-constraint simulations (black) 
significantly out-performed the average single-constraint recovery (grey). The remaining proteins (group I, 
blue shading) showed similar native recovery regardless of whether sequences were optimized with respect 
to one or all characterized partners. Error bars represent the best and worst native sequence recovery in a 
single-constraint optimization. (B) Calculated binding scores of native (red), single-constraint (grey), and 
multi-constraint (black) sequences for each of the 65 complexes examined in this study (see Figure 2.2). 
Sequences selected by single- and multi-constraint optimizations often show a favorable decrease in 
binding score relative to native sequences for group I proteins (blue shading), while multi-constraint 
binding scores were close to native for group II proteins (pink shading). 
Upon closer look at the pattern of interface residues recovered as native in each 
case, there seem to be two broad groups of multi-specific interfaces represented in the 
dataset. About half of the proteins comprised group I (blue shading, Figure 2.5A), for 
which the improvement in native sequence recovery in multi-constraint optimizations 
over single-constraint optimizations was small and total native amino acid recovery was 
low, regardless of interface size. As described for the shared scenario above, the low 
native sequence recovery could be due to all interaction partners binding via a few key 
residues, with the residues peripheral to these free to vary in sequence. This behavior is 
likely for several group I proteins including elastase, ovomucoid inhibitor and the SH3 
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domain complexes. These proteins bind their targets within a narrow groove or cavity and 
in addition a considerable fraction of interactions may be mediated through backbone 
contacts [50]. Low native sequence recovery in group I could also be influenced by 
inclusion of cross-species interactions (enzyme-inhibitor complexes and interleukin 6 
receptor binding to mammalian and viral interleukin) as well as lack of sufficient 
constraints to fully specify the wild type sequence (see discussion below).  
 In contrast, for the other half of the proteins in our dataset (group II), sequence 
optimization over all characterized binding partners resulted in significant improvements 
in native sequence recovery compared with optimizations for binding to a single partner 
(pink shading, Figure 2.5A). Here, as described for the multi-faceted scenario above, the 
multi-constraint optimization procedure was able to “add up” differing amino acid 
preferences among partners. The resulting high recovery of native amino acids indicates 
that binding interfaces for proteins in this group are optimized for multi-specificity. 
Additionally, as compared with group I, group II proteins tended to use larger and flatter 
interfaces to mediate binding, were more likely to show high connectivity in protein-
protein interactions networks, and bound interaction partners with a greater number of 
different fold types (Figure 2.2). Although generalizations of our conclusions are 
necessarily limited by the restricted size of our dataset of 20 proteins, a “multi-faceted” 
recognition pattern spread over a large interface may be a common strategy used by 
highly connected signaling hubs to bind diverse partners.  
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2.7. Binding scores of sequences selected by multiple constraint 
simulations are closer to native than those of single constraint 
sequences for group II interfaces 
We have shown that for about half the multi-specific proteins in our dataset 
(group II) the multi-constraint designed sequences were substantially more native-like 
than single-constraint sequences (Figure 2.5A). According to our rationale outlined 
above, this suggested a significant level of optimization for multi-specificity in these 
interfaces. However, not all interface positions were predicted to be native-like, and 
native sequence recovery over the whole interface in multi-constraint simulations varied 
between 40 and 71% in this group.  
Non-native amino acids could be chosen by our optimization protocol because 
they are predicted to be more favorable than the wild type residue or, alternatively, 
because a number of different amino acid types are allowed at a certain position without 
substantial energetic differences. To test whether the non-native interface residues 
selected by the design simulations were predicted to lead to significant interface 
stabilization, we compared the binding scores of sequences selected by the single- and 
multi-constraint protocols to the scores of the wild-type sequences. For both group I and 
group II, optimization for a single binding partner always resulted in a favorable decrease 
in predicted interface binding score (Figure 2.5B, grey line) relative to the wild type 
amino acid sequence (Figure 2.5B, red line). The binding score patterns for multi-
constraint optimizations (Figure 2.5B, black line) however differed among the two 
groups: multi-constraint binding scores were often similar to single constraint scores for 
group I proteins (compare black and grey lines, blue shaded box) while for group II 
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proteins multi-constraint binding scores were much closer to those calculated for the wild 
type sequences (compare black and red lines, pink shaded box).  
The division of our data set into two groups suggested by the native sequence 
recovery results (Figure 2.5A) were thus mirrored in the predicted binding score patterns 
for wild type and designed sequences (Figure 2.5B). Our simulations suggest that for 
group I proteins, where sequences and binding scores for single- and multi-constraint 
optimizations were similar, there might be non-native amino acids which could improve 
the promiscuous compromise and at the same time strengthen each interaction with each 
binding partner alone. In contrast, non-native amino acids selected for group II proteins 
in multi-constraint simulations are predicted to offer little improvement over the binding 
scores of the original wild type sequences; this confirms our notion of high levels of 
optimization for multi-specificity in this group. Interestingly, while our simulations 
sought solely to maximize binding affinity for each partner, and did not explicitly 
consider either the relative binding affinities among partners or that naturally occurring 
interfaces often need to be transient, incorporation of multiple constraints alone was often 
sufficient for our simulations to predict sequences with binding scores near or identical to 
that calculated for native sequences.  
  
2.8. For all multi-specific interfaces, energetically important residues 
are generally optimized for binding  
We next investigated, on a per-residue basis, at which interface positions our 
optimization protocols predicted native residues to be suboptimal. Experimental analysis 
of residues critical for maintaining binding with respect to a single interaction partner 
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have shown that often only a subset of the interface is comprised of key hotspot residues 
optimized for binding [40, 41] and that other non-hotspot positions may show a high 
degree of plasticity [43]. We thus wished to examine how often native residues were 
being recovered as optimal by our single and multi-constraint simulations at positions 
calculated to be energetically important “hotspots”.  
For each binding partner we calculated the per-residue score of the native residue 
at every interface position, and labeled sites with a native per-residue score of less than -2 
as a predicted “hotspot”. Next we calculated for each position the difference in score 
between the residue selected by each of our protocols and the score of the native residue 
(Test for optimization, Figure 2.1). We reasoned that small score differences (<1 score 
units; scores are parameterized to approximate kcal/mol [28]) should reflect that a given 
optimization protocol recovered the native (or energetically similar to native) residue 
during optimization and large score differences (>1 score units) should indicate the extent 
to which a non-native residue is predicted to improve binding affinity over native.  
 
 
Figure 2.6 Distribution of Optimization in Promiscuous Interfaces  
Predicted per-residue binding score improvements (relative to native) for sequences selected in single-
constraint (A) and multi-constraint (B) simulations. Coloring indicates the magnitude of predicted 
improvement over native. Darker-colored bars (compromise value 1–1.5, orange; more than 1.5, red) 
indicate positions for which the simulation predicts a non-native residue to bind stronger than native. 
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Lighter-colored bars (compromise value 0–0.5, wheat; 0.5–1, yellow) indicate simulations recovered the 
native (or near-native) residue type. Whether optimization was in the context of single or multiple partners, 
positions calculated to be hotspots (see Section 2.4.4) consistently returned the native amino acid as 
optimal (244/303 and 272/303, for single- and multi-constraint simulations, respectively). In contrast, 
roughly half of non-hotspot interface positions were predicted as suboptimal for binding when each partner 
was considered separately (350/682), but only a quarter (167/682) were estimated to still be suboptimal in 
the context of binding multiple partners. Overall, the total number of interface sites for which 
improvements in binding scores could be found was significantly less for multi-constraint optimizations. 
Scores for the same residue position with differing binding partners are included in all plots. 
 
At hotspot positions, whether optimizations were performed with respect to single 
or multiple partners, native (or energetically equivalent) residues were recovered for each 
partner with high fidelity (Figure 2.6A and Figure 2.6B, wheat bars, 244/303 and 272/303 
for single- and multi-constraint optimizations, respectively). This inability to predict non-
native residues scoring better than native at hotspot positions was seen for proteins in 
both group I and group II (Supplementary Figure A.1). In contrast, at non-hotspot 
positions, the native residue was predicted to be suboptimal (yellow, orange, red bars) 
with respect to binding a single partner in approximately half of all instances (Figure 
2.6A, “all other residues”, 350/682). This is in agreement with experimental phage 
display data showing the native residue to often be suboptimal for binding at non-hotspot 
positions [43]. When considered in the context of binding multiple partners however, 
these same non-hotspot sites often are now predicted to be suboptimal in only 14% of all 
instances (Figure 2.6B, “all other residues”, yellow, orange, red bars 167/682). Thus we 
find that the need to maintain multi-specificity is imposing constraints primarily on non-
hotspot residues, resulting in native residues being recovered more often at such sites as 
they become the “optimal compromise” for binding of multiple partners. This trend for 
increased recovery of native residues at non-hotspot positions during multi-constraint 
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simulations was much stronger for proteins in group II than in group I (Supplementary 
Figure A.1).  
 
2.9. Distributions of shared and compromised interactions in 
promiscuous interfaces 
Finally, we wished to estimate the extent of compromise each multi-specific 
protein in our dataset made in order to maintain binding to all its partners compared to the 
“ideal” interaction it could have if one a single partner was considered (see Section 2.2 
and Figure 2.1A, Estimate of Cost). For each site within an interface, each partner was 
assigned a “compromise value” (ranging from 0-2). Compromise values were defined as 
the per-residue difference in score of the amino acid selected when each partner was 
optimized alone (single-constraint) and the residue selected at the same site when all 
partners were included in the optimization protocol (multi-constraint). The interface site 
itself was then assigned the largest compromise value seen among all binding partners.  
For each position in the interface, this number should provide a rough estimate of 
the maximal amount of tradeoff paid by any partner due to the necessity of other partners 
binding via the same site (see Section 2.4.4 and Figure 2.1A). Small compromise values 
(0-1 score units) should indicate that all binding partners prefer the same (or similar) 
residue type as optimal, regardless of the presence or absence of other binding partners. 
Larger values (>1 score units) suggest that for at least one partner, a non-native amino 
acid is predicted to make more favorable interactions than the wild type, but may not be 
tolerated when preferences of all additional binding partners are considered.  
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Figure 2.7A shows, over our entire dataset, the percentage of sites within each 
protein interface calculated to have a compromise score between 0 and 0.5. These 
positions are predicted as essentially shared, in that no partner considered would have to 
give up potential gain so that other partners could fulfill their optimal interactions. While 
we observed a continuum ranging from interfaces calculated to have few completely 
shared interactions (all GTPases, Actin, Ubiquitin) to those for which the majority of 
interactions were shared (inhibitor complexes, SH3 domain), this analysis largely 
confirmed our earlier grouping of the multi-specific proteins within our dataset (Figure 
2.7A, pink and blue symbols). A few group I proteins showed levels of compromise 
similar to that seen in group II. Interestingly, at least 2 of these proteins, Importin Beta 
(set #2) and CheY (set #4), were also calculated to be protein interaction “hubs” in our 
earlier analysis (Figure 2.2). These proteins may thus also employ a “multi-faceted” 
binding strategy, and the low native sequence recovery seen with the multi-constraint 
protocol is likely due to our computational prediction being under-determined (since we 
lack of structural information for a more complete set of binding partners). Likewise, we 
note that among the group II proteins, for IGG1-FC (set #15) many interactions were 
predicted as shared by all binding partners, a result that is consistent with an earlier 
structural analysis of these proteins by Delano et al. [48].  
To illustrate the three-dimensional distribution of predicted compromises in 
multi-specific interfaces, we generated color-coded mappings of compromise scores. 
Representative maps for three promiscuous protein interfaces calculated to display high 
(Figure 2.7B, Ran), medium (Figure 2.7C, CheY), and low (Figure 2.7D, Ovomucoid 
Inhibitor) overall compromise are shown in Figure 2.7 (maps for the entire dataset are 
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given in Supplementary Figure A.2). Throughout our dataset, higher compromise scores 
often occurred along the periphery of a binding site, while highly shared residues tended 
to be more centrally located. While further analysis is needed, this could indicate strong, 
shared interactions with core hotspots may be necessary for each partner to bind, but that 
it is along the rim of the overlapping interface site where compromises among the 
binding partners have to be integrated in order to maintain multi-specificity. This is 
reminiscent of the idea that hotspot residues necessary for binding often occur in 
interface cores sequestered from solvent, whereas other non-hotspot parts of the interface, 
possibly around the rim, account for recognition [40]. 
 
 
 
Figure 2.7 Distribution of Constraint Scores in Promiscuous Interfaces  
Tradeoff at each interface position in our dataset was estimated by the per-residue difference in scores of 
amino acids chosen when each partner was optimized alone as compared with when all binding partners 
were considered in the optimization procedure. The percentage of interface sites displaying the lowest level 
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(0–0.5) of ‘‘tradeoff value’’ (see Section 2.4.4) is shown for all 20 proteins in our dataset (A). Such 
positions are predicted as highly shared, in that no partner considered had to ‘‘give up’’ potential gain so 
that other partners could fulfill their optimal interactions. Blue and pink shading denotes whether each 
protein was assigned to group I or II. Right-hand panels show color-coded mappings of constraint scores 
onto three promiscuous protein interfaces calculated to display high (B) (Ran set #11), medium (C) (CheY 
set #4), and low (D) (Ovomucoid Inhibitor set #3) compromise. Compromise values are colored as follows: 
0–0.5, wheat; 0.5–1 yellow; 1–1.5 orange; >1.5 red. 
2.10. Experimental verification of a non-native residue predicted 
optimal for multi-specific binding  
Our energetic analysis suggests that many positions within naturally occurring 
multi-specific interfaces have been optimized for binding to multiple partners, while 
some native amino acids are predicted to be sub-optimal in the context of single or even 
multiple partners. Over the entire dataset, our multi-constraint protocol recovered the 
native interface residue as optimal for just under half (161/338) of all interface residues 
examined. Ultimately, experimental data are needed to verify whether choices of non-
native amino acids by our multi-constraint optimization protocol are incorrect or 
underspecified predictions by our energy function, or whether the predicted choice would 
indeed strengthen binding for all partners.  
In general experimental data validating binding affinities of sequences predicted 
by our single and multi-constraint simulations with all interaction partners were not 
available. However, we did observe one notable case where we could compare one of our 
predictions of an improved interface to direct experimental data. This occurred in the 
third domain of turkey ovomucoid inhibitor (set #3) at the key P1 position at which the 
inhibitor (or natural substrate) residue extends into a deep binding pocket. The predicted 
per-residue binding score at this site suggested that the wild-type residue was a hotspot 
crucial for maintaining binding with all partners, yet our multi-constraint protocol 
predicted a non-native amino acid residue to be significantly preferred over native by all 
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partners. As discussed above, prediction of a native “hotspot” residue to be suboptimal 
was an infrequent occurrence throughout our dataset (see Figure 2.6, “hotspots”, yellow, 
red, orange bars).  
Binding affinities for ovomucoid inhibitor mutants containing all 20 amino acids 
at the P1 position have been experimentally characterized for 6 different serine proteases 
[51]. This allowed us to compare the experimental preferences at the P1 position for the 
two serine protease complexes in our dataset (Chymotrypsin and SGPB, see Figure 2.2) 
with the computational predictions. The residue chosen at this site by the multi-constraint 
protocol, a phenylalanine, was ranked experimentally as the 3rd and 4th most favorable 
residue for Chymotrypsin and SGPB, respectively. There was no amino acid choice more 
favorable in common for both proteins and the native lysine residue was ranked 11th and 
8th, respectively. We note that while our multi-constraint protocol correctly selected the 
optimal choice for binding the 2 characterized binding partners in our dataset, other 
amino acid types may be optimal for selectively binding different combinations of the 6 
serine proteases studied. Interestingly, the P1 residue of ovomucoid inhibitor is known to 
vary significantly in nature, with 8 differing amino acid types occurring at this position in 
the 153 avian species analyzed [51].  
2.11. Discussion 
 Our study uses a protein design method that can in principle be applied to 
computationally select amino acid sequences under any set of positive and negative 
constraints that can be defined by a fitness function. Here we have made comparisons 
between single- and multi-constraint predicted and naturally occurring sequences to 
quantify optimization and compromise in multi-specific interfaces. 
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Our analysis indicates that first, the protocol presented here is able to detect 
optimization for multi-specificity in promiscuous interfaces, as sequences and binding 
scores from multi-constraint simulations are closer to native than those obtained in 
single-constraint optimizations. Secondly, we identify two distinct mechanisms of 
achieving multi-specificity: (1) shared or low compromise interfaces where a small 
subset of interface residues have been optimized such that all binding partners utilize this 
set as hotspots and (2) multi-faceted or intermediate compromise interfaces where a far 
larger percentage of the interface has been optimized for multi-specific binding and each 
partner picks and chooses a subset of interface residue interaction with which to make 
key interactions.  
Signaling proteins with large, flat interfaces fall clearly within the “multi-faceted” 
group II while enzymes, motif recognition domains, and receptors with smaller, narrower 
binding interfaces are often found within the shared group I. We speculate that the 
“multi-faceted” mode might have an evolutionary advantage for signaling interfaces, as 
here the chance that single mutations will deleteriously affect all binding interactions is 
reduced. On the other hand, a single mutation may substantially alter the pattern of 
interaction partners by now favoring certain interactions over others. In this way, multi-
faceted interfaces may be more “evolvable” for new sets of interactions.  
It is interesting to note that the ability to a priori predict binding sites from 
surface sequence conservation or surface cavity size has been shown to be easiest for 
proteins similar to those classified as “shared binding” by our methodology [47]. This is 
consistent with our observations, as in these cases there should be shared evolutionary 
pressure for conservation of key surface residues by all partners. In contrast, for proteins 
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predicted to display some degree of compromise among the differing binding preferences 
of their multiple partners, evolutionary pressures could differ depending on which subset 
of binding partners is most strongly selected for over time. Further, allowing each partner 
to pick and choose its own subset of interface amino acids for key interactions, as in the 
multi-faceted case, could necessitate large, easily accessible (i.e. flat) binding surfaces 
with a certain degree of conformational flexibility; this mechanism could hence partly 
explain why flat surfaces and conformational variability are frequently seen in multi-
specific signaling proteins such as G-proteins [52].  
We hypothesize that there should be significant differences in the ease with which 
binding specificities among partners could be rationally modified and/or small molecule 
inhibitors could be designed for proteins exhibiting the two modes of multi-specificity 
described here. The patterns of varying amino acid preferences among different binding 
partners revealed by comparing the single- and multi-constraint protocols suggest 
mutations at specific interface positions that could rationally change the specificity or 
promiscuity seen among binding partners. However, these same factors might make drug 
or small molecule design towards “multi-faceted” interfaces more difficult. For the group 
II interfaces in our set, the different partners display varying interface residue preferences 
(Figure 2.3C) and there may be a substantial number of constrained residues in each 
binding interface (Figure 2.7). Hence, proteins using this mode of interaction may have 
fairly distributed hot spots that are difficult to interfere with by a small molecule targeted 
to a single region.  
A caveat of our study is that the generalizations may be somewhat limited 
because of the restricted size of our dataset of high-resolution structures. Further, the 
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results presented here are necessarily dependent on the quality of the scoring function 
used for optimizations. However, improvement in native recovery seen in multi-
constraint simulations could not be directly due to energy function biases, as the same 
scoring function was used for all simulations. The ability of the Rosetta scoring function 
to predict energetically important residues has been analyzed previously [28]. We note 
that amino acid types for which our simulations consistently select the native residue as 
the best (optimal) choice for binding multiple partners include tryptophan, tyrosine, and 
arginine (Supplementary Figure A.3; the predicted amino acid frequencies for W, Y and 
R closely match the native distribution), amino acid types which have previously been 
shown to be energetically important in binding interfaces [40, 53, 54]. Interestingly, 
where allowed by steric constraints (for example at the interface periphery), we observed 
an increased selection in our simulations of larger amino acids such as tryptophan, 
arginine, and histidine, and against smaller amino acids such as alanine, threonine, and 
valine (Supplementary Figure A.3 and Supplementary Figure A.4). While this could be 
due to approximations in our scoring function, an alternative explanation could be that 
these non-native sequences would, at least in some cases, truly bind more strongly. An 
overrepresentation of large hydrophobic residues may have been selected against in 
nature to maintain protein solubility in the absence of binding partners. In addition, while 
our computational protocol optimizes binding score, naturally occurring transient 
interfaces may not necessarily have evolved for strong binding. The complexes between 
small GTPases and their exchange factors (GEFs) may be examples of interactions that 
need to be transient to fulfill their cellular function: in the case of the ARF1-Sec7 
interaction, the fungal metabolite Brefeldin A inhibits signaling by stabilizing the 
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complex [55]. It may also be a general trend that multi-specificity must come at a cost of 
affinity [16]. Additional constraints not explicitly considered in our current protocol, such 
as selection at the level of on- or off-rates for complex formation could also account for 
differences in native and computationally selected sequences.  
Lastly, we note that while the analysis presented here has focused on the ability of 
our simulations to identify the wild type amino acid, strict conservation of a single native 
amino acid over evolutionary time is rare, and the tolerance for substitution to differing 
amino acid types can vary between sites in an interface [47]. For example, for the multi-
specific protein Ras we found two instances (Supplementary Figure A.4-12, positions 
32Y and 67M) where we predicted the interface positions to be energetically important 
but failed to correctly recover the native amino acid. In both cases, the non-native amino 
acids selected by our multi-constraint simulations were among the evolutionarily 
tolerated set seen in a multiple sequence alignment (data not shown, generated as 
described in Section 2.4.6). A clear extension of our method is thus to not only predict 
optimal but a set of tolerated amino acid sequences for a given set of constraints (ELH 
and TK, unpublished data). 
While we have applied the multi-constraint design protocol described in this work 
to examine whether and how promiscuous proteins are optimized for binding multiple 
partners, the methodology presented here is general and can be extended to analyze how 
any number of enumerable constraints (both positive and negative) affects sequence 
selection. A logical related analysis would be to characterize the sequence determinants 
of conformational flexibility where the input constraints would be stability for two or 
more different conformations. Further, the multi-constraint protocol introduced here is 
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not only predictive of naturally occurring amino acid sequences, but also allows for 
rational redesign of proteins with altered binding properties which could be instrumental 
towards understand the role of specificity in protein interaction networks as well as in the 
engineering of biosensors and new cellular pathways. 
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Chapter 3  
Prediction of sequence diversity at a 
protein-protein interface using 
flexible backbone protein design 
 
This chapter describes a method that uses flexible backbone move, inspired by 
coupled side chain-backbone motions observed in high-resolution protein crystal 
structures, to predict sets of amino acids tolerated at each interface position within the 
binding site of human Growth Hormone (hGH) with its receptor (hGHR).  We compare 
our computational predictions to an experimental phage display dataset quantitatively 
mapping the sequence space of the hGH-hGHR interface and show that computationally 
predicted sequences to be enriched in functional members.  Although the modeled 
structural changes are subtle, our results on predicting sequence plasticity suggest that 
backrub sampling may capture a sizable fraction of localized conformational changes that 
occur in natural proteins. The described method has implications for predicting sequence 
libraries to enable challenging protein engineering problems.  
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3.1. Introduction 
Sequences of naturally occurring proteins show a remarkable robustness 
(neutrality) to mutations within a sizable “tolerated” sequence space, where many diverse 
sequence solutions are compatible with a given fold [56, 57]. This initial robustness [58] 
may help evolve new function [59], as sequence positions able to accommodate different 
amino acid residue types may be exploited to alter protein functionality. There is thus 
considerable interest in computational models describing the tolerated sequence space for 
a given protein fold and/or function, both to advance fundamental understanding of 
structure-function relationships [60, 61] and to engineer proteins with new properties 
[62]. 
Computational protein design methods which seek to identify low-energy 
sequences compatible with a target structure or interaction [5, 36, 60, 63], should in 
principle be able to capture at least some of the tolerated sequence variation of proteins. 
Accordingly, several methods have been developed to estimate the sequence space 
compatible with a given protein fold [25, 63, 64], but there are a number of theoretical 
challenges in evaluating the performance of any such method. Previous approaches have 
compared computational sequence predictions to multiple sequence alignments of protein 
families [56, 64-68]. However, evolved sequences have likely not sampled all tolerated 
amino acid combinations [43]. In addition, it is often difficult to determine whether given 
sequence positions have been under additional functional constraints not directly 
accounted for by design methodologies. 
The ability to estimate tolerated sequence space also has practical implications for 
the engineering of proteins with new folds and functions. Despite several examples of 
  61 
computational design successes, a re-occurring problem has been whether functional 
sequences can reliably be identified as top predictions. A promising approach to help 
overcome this problem and increase the success rate of design is therefore to combine 
computational predictions of the sequence space tolerated by a given fold and/or function 
with experimental library selection methods [69, 70]. This combined strategy can be used 
to significantly reduce the sequence space to be searched through experimentally. A key 
study showed that a library of sequences computationally designed to be more stable was 
also enriched in functional proteins [70]. This work suggests that computational 
methodologies can successfully sample within the sequence space available to folded 
proteins, but did not consider an explicit measure of the extent to which the full sequence 
space consistent with fold stability and function can be predicted computationally. 
Here we aim to more directly assess the accuracy of computational methods for 
predicting the tolerated sequence space of folded and functional proteins. We make use of 
a recent study that screened phage display libraries to quantitatively map the sequence 
space of human growth hormone (hGH) able to bind human growth hormone receptor 
(hGHR) [43]. This dataset has several important properties: First, the diversity of 
sequences selected by phage display at this interface is considerable, making it a non-
trivial test case for capturing tolerated sequence space. Second, the experimental 
pressures assayed, to fold and bind the receptor, can be directly mimicked 
computationally, without complications of other pressures acting on the sequences of 
evolved proteins. Third, the extensive phage display screening data can be compared to 
design predictions to assess the extent to which a hypothetical computational library is 
enriched in functional members. 
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It has previously been shown that protein design methods that neglect 
conformational adjustments, especially in cases where the input backbone design 
template is kept rigid, may restrict modeled sequence diversity. In contrast, models 
allowing for conformational diversity may broaden the sequence diversity accessible by 
protein design [64, 71, 72]. Therefore, we chose to compare computational predictions 
made using standard fixed-backbone simulations to those made using a model of 
conformational flexibility (termed “backrub”) inspired by coupled side chain-backbone 
motions observed in high-resolution crystal structures [32, 33]. 
We find good qualitative agreement between the tolerated sequence space 
observed experimentally at the hGH-hGHR interface [43] and our predictions and show 
improvements of the flexible over the fixed backbone protocol. Based on these results, 
we suggest a flexible backbone computational protocol to design protein libraries 
enriched in functional members. Such a computational strategy of incorporating 
conformational flexibility and library design may broaden the use of computational 
methods for difficult engineering tasks such as constructing proteins with new functions. 
 
3.2. Computational strategy for estimating the tolerated sequence 
space at protein-protein interfaces 
We set out to develop a computational model for predicting tolerance to amino 
acid substitutions at protein-protein interfaces. Our overall computational strategy is 
illustrated in Figure 3.1 and outlined below. We reasoned that we needed, at a minimum: 
(1) a method to model local conformational changes (structural plasticity) that may result 
from sequence changes and binding interactions, (2) an efficient way to search sequence 
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space together with an easily computable folding and binding score for each sequence 
sampled, and (3) a measure to select the set of amino acid residues predicted to be 
tolerated at each interface position and compatible with the protein-protein interaction. 
We term these sets of amino acid residues a “tolerance profile” for each interface 
position. To test our computational strategy, we compare the computationally generated 
tolerance profiles to experimentally determined profiles [43] for each of the 35 positions 
in the ~1300A2 hGH-hGHR site I interface (Figure 3.2A). 
 
Figure 3.1 Schematic of the Computational Strategy for Predicting Interface Tolerance Profiles 
Amino acid profiles were generated independently or each member of the ensemble by selecting for each 
backbone sequence predicted to have Rosetta ‘binding’’ (across-chain) and ‘‘folding’’ (within-chain) 
scores within a threshold score value of that of native hGH-hGHR interface sequence (checkmarks). 
Tolerance profiles over all members of the ensemble were combined and sets of allowed (X.75>1%) and 
preferred (X.75 >10%) amino acid residues were calculated for each interface position (see black dotted 
lines and arrows).  Note that this protocol assumes independence of interface positions. 
As a model for structural plasticity (requirement 1), we mimicked “backrub” 
motions inspired by coupled side chain-backbone motions observed in high-resolution 
crystal structures [32]. Briefly, each backrub move consists of selection of two residues 
(separated by 1 to 10 intervening residues) followed by a rigid rotation around the axis 
defined by the two C" atoms of the selected residues. We generated an ensemble of 100 
near-native backbones for both chains in the hGH-hGHR complex (Figure 3.2B; see 
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Section 3.3.3). As intuitively expected, the largest changes in C" RMSD in the 
computationally generated hGH-hGHR ensemble occurred in loops connecting secondary 
elements. Average per-residue B-factors calculated for the computationally generated 
ensemble qualitatively reproduced experimental values for both hGH (Figure 3.2C) and 
hGHR (Figure 3.2D) (see also Supplementary Figure B.1). 
 
Figure 3.2 Overview of the hGH-hGHR interface and the Computationally Generated Backrub 
Ensemble 
(A) Close-up of the 35 residues in the interface of human growth hormone (hGH, blue) with its receptor 
(hGHR, yellow).  (B) Superposition of the 100 computationally generated backbones in the backbone 
ensemble.  Comparison of hGH (C) and hGHR (D) B-factors in the crystallographic structure 1A22.pdb 
(red) and the hGH-hGHR backrub ensemble (black).  Note that, due to our backrub procedure holding 
chain end-point residues rigid, ensemble B-factors have not been calculated for residues within five 
consecutive positions of a chain break or endpoint.  Also note the differences in scales between the 
crystallographic and calculated ensemble B factors. 
For sequence sampling and scoring (requirement 2) we chose to use the program 
Rosetta for protein design [68]. As a simplification, we performed design simulations on 
each backbone in the ensemble independently (Figure 3.1). Amino acid residue choices 
for the 35 hGH interface positions were sampled on ensemble members by performing 
several smaller independent simulations, each of which selected 5-6 hGH interface 
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positions to be targeted simultaneously for “design” and allowed to sample any of the 20 
naturally occurring residues except cysteine (Section 3.3.5). This procedure directly 
mimicked the experimental phage display setup described in [43], and allowed our 
protocol to more efficiently search the large number of possible sequence combinations 
possible at the hGH-hGHR interface. 
During each simulation, initially random interface sequences were scored by the 
Rosetta all-atom scoring function, which has been shown to predict the changes in 
stability upon point mutations in proteins and protein interfaces with reasonable accuracy 
[28].  Sequences with favorable binding (across hGH-hGHR interface) and folding 
(within the hGH fold) scores were then propagated using a previously published genetic 
algorithm (Section 3.3.5, [10] and [73]). Sequences sampled at any point during a 
simulation with both hGH-hGHR binding and hGH folding scores within a threshold 
value (a tunable parameter set to 1% of the score of the starting wild type sequence for all 
data shown) were saved and the frequency of appearance of each amino acid residue type 
in the selected sequences was recorded for every interface position (Figure 3.1). Profiles 
generated in this way for each backbone in the ensemble were then combined in box-plot 
format to visualize amino acid tolerances shared by many backbones (“flexible 
backbone” protocol) and compared with box-plots of 100 independent simulations on the 
fixed, crystallographic hGH-hGHR backbone (“fixed backbone” protocol). Note that the 
procedure described here assumes independence of the interface positions but can be 
extended to compute co-variation in designed sequences. 
To address requirement 3, we defined measures to quantify which amino acid 
residues were predicted to be allowed at each interface site and which interface sites were 
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predicted to be most tolerant (“plastic”) to amino acid substitution overall. We reasoned 
that subtle conformational changes in the hGH fold or at the hGH-hGHR interface might 
result in tolerance to certain amino acid types, and that the motions could vary depending 
on the interface position and the amino acid substitution being considered. Thus we 
hypothesized that some subsets of pre-generated ensemble members might be more or 
less appropriate for different interface positions and/or amino acid residue substitutions. 
To allow for this variability, we ordered the frequency with which each backbone 
member in the ensemble accepted a particular amino acid substitution at each interface 
position and selected the top 25% of all predictions for each site (this is represented by 
the X.75 value; see box-plots in Figure 3.1 and Section 3.3.6 for details). Following this 
logic, we classified an amino acid residue type to be “allowed” by the flexible backbone 
protocol at a given interface position if it computationally appeared at a frequency of > 
1% for each of the top 25% of ensemble backbone members “best suited” for the 
substitution considered  (X.75>1%; see Section 3.3.6 and Figure 3.1). Similarly, an amino 
acid residue type was considered “allowed” by the fixed backbone protocol when it 
appeared with a frequency > 1% on 100 independent design simulations on the 
crystallographic backbone. Amino acid types at each interface position for which the X.75 
value was !10% were considered to be “preferred” (see Section 3.3.6 and dotted lines 
and arrows in Figure 3.1). 
Using these measures, we first show that both the flexible and fixed backbone 
protocols can successfully explore the tolerated sequence space at the model hGH-hGHR 
interface (Table 3.1 and Figure 3.3A). Second, we show that the flexible backbone 
protocol is better able to discriminate interface sites that experimentally showed near-
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equal tolerance to substitution with many amino acid residues (“plastic” positions) from 
more “restricted” positions where fewer amino acid residues accounted for the majority 
of the sequences selected by phage display (Table 3.1). Third, for these restricted 
positions, we show that the flexible backbone protocol displays stronger qualitative 
(Figure 3.3B-C) and quantitative (Figure 3.4B-F; Table 3.1) agreement between 
computationally predicted and experimentally observed sequence tolerance profiles. 
Further, we provide structural examples and suggest possible explanations for how 
modeled backbone conformations might have resulted in improved predictions of 
tolerated sequences at several positions in the hGH-hGHR interface (Figure 3.5; 
Supplementary Figure B.2). Finally, we show that a hypothetical design library 
constructed by using our flexible backbone protocol would be enriched over a naïve 
library (consisting of residue types chemically similar to native, see Section 3.3.9) for 
generating folded hGH sequences that bind hGHR (Table 3.2/ Figure 3.6). 
3.3. Methods 
3.3.1. Source of experimental tolerance profiles.  
Experimental data on comprehensive sequence mapping of the interface of human 
growth hormone (hGH) with its receptor (hGHR) were taken as published [43]. In order 
to be able to quantitatively screen sequence combinations of 20 amino acids, the 35 tested 
interface positions were experimentally screened in groups of 5-6 residues by using 6 
separate display phage libraries each consisting of approximately 1010 unique members. 
The six residue groups, chosen in [43] to maximize the distance between individual 
interface positions as well as include no more than one known hot spot residue position 
per group, were as follows: 
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(1) 14M, 28Y, 47N, 61P, 171D, 179I 
(2) 18H, 42Y, 62S, 65E, 164Y, 175T 
(3) 21H, 29N, 45L, 60T, 67T, 178R 
(4) 22Q, 43S, 66E, 167R, 176F, 183R 
(5) 26D, 44F, 48P, 64R, 168K, 174E 
(6) 25F, 41K, 46Q, 63N, 172K 
 
3.3.2. Preparation of structures.  
Starting atomic coordinates for all simulations were taken from PDB structure 
1A22 (1:1 hGH-hGHR complex), which was stripped of all water molecules and 
prepared for design by an initial round of side chain minimization and optimization of 
hydrogens as previously described [73]. 
 
3.3.3. Generation of backbone ensembles.  
All calculations were performed with the Rosetta full-atom scoring function, 
which is dominated by attractive and repulsive Lennard-Jones interactions, an 
orientation-dependent hydrogen bonding term [29], and an implicit solvation model [30]. 
In order to take into account sequence diversity which might require small backbone 
adjustments, an ensemble of “near-native” backbone conformations was generated from 
the minimized hGH-hGHR complex crystal structure by taking the lowest energy 
structures from 100 independent Monte Carlo runs using a new flexible backbone 
procedure termed “backrub” [32, 33]. A backrub move consists of rotating a peptide 
segment up to 40 degrees around an axis defined by the C" atoms of two residues 
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separated by 1 to 10 intervening residues and subsequently optimizing the positions of 
the C# and H" atoms (branching off the pivot C" atoms) according to the CHARMM bond 
angle potential as described in [33]. Backrub simulations were performed over all 
positions in both chains of the hGH-hGHR complex by repeatedly choosing random 
backrub beginning and end points and a rotation angle for a total of 10,000 moves, 
interleaved with side chain rotamer moves in the backrub regions. The resulting 
conformations of the 100-member ensemble had an RMSD to the native structure 
1A22.pdb less than 0.4 Å. 
 
3.3.4. Calculation of ensemble B-factors.  
Average B-factors (the root mean square fluctuation, RMSF) for each C" atom in 
the 100-member hGH-hGHR ensemble was calculated using Gromacs v3.3.2 and the 
function g_rmsf. 
 
3.3.5. Generation of tolerance profiles.  
Tolerance profiles for all 35 experimentally scanned positions of the hGH–hGHR 
interface were estimated from computational design simulations implemented in the 
program Rosetta. As described above, we performed designs on 6 independent groups 
(with a theoretical maximum of 106-107 sequence combinations per run), each of which 
allowed 5-6 interface positions (“designed positions”) to vary among 19 amino acids 
(cysteine was excluded from all designs). During each design run, a genetic algorithm 
[73] was used to propagate an initially random population of 2000 sequences for five 
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generations for 100 independent simulations, scanning a total of 106 sequences. Runs 
with up to 30 generations gave essentially identical results (see Section B.1.1). This 
convergence is most likely explained by the fact that the experimentally screened groups 
were selected to contain positions spatially separated in the interface, reducing potential 
co-variation. 
For each sequence selected by the genetic algorithm (including the native), Monte 
Carlo simulated annealing was used to minimize the Rosetta full energy function over the 
entire protein complex and find optimal rotameric conformations (chosen from the 
Dunbrack rotamer library [74] expanded around the chi1 and chi2 angles) of the selected 
sequence. All residues with a side-chain atom within 4Å of a designed residue were 
allowed to change their rotameric conformation (“repacked positions”) while all other 
backbone and side-chain positions not considered for design or repacking were kept 
fixed. After optimized rotameric conformations were determined, each sequence was 
scored over the entire hGH-hGHR complex. The inter-chain score across the interface 
(all pair-wise scores i,j where atom i is found on hGH and atom j on hGHR) was used as 
an estimate for binding. The “binding” score was then subtracted from the complex score 
and the result was used as an estimate for “folding” (here the assumption is made that the 
score of hGHR for which the sequence is not changing is approximately constant). 
Sequence combinations with an inter-chain hGH-hGHR score within 1% of the “binding” 
score calculated for the native (starting) sequence and with an intra-chain hGH score 
within 1% of the “folding” score calculated for the native sequence were saved. 
On average 150-5,000 sequences, dependent on the particular backbone used as 
well as the group of designed interface positions, passed both the binding and folding 
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thresholds and were used for inclusion in the computational tolerance profiles. Profiles 
from all “near-native” backbones were combined into a final computational prediction of 
tolerance at each interface position by plotting the median (as well as the 1st and 3rd 
quartile) frequency of occurrence of each amino acid residue (excluding cysteine) 
observed in each of the independent backbone runs. In order to estimate the variation in 
sequences selected in different runs on the same backbone, profiles for 100 independent 
simulations on the crystallographic backbone were also computed. 
  
3.3.6. Selection of allowed and preferred amino acid types.  
For all computational predictions, selection of allowed and preferred amino acid 
residue types were made using the third quartile (X.75) value from the box-plots of 
tolerance profiles generated from either the 100-member ensemble or from 100 
independent runs on the fixed, crystallographic backbone. At each interface position, an 
amino acid type was considered to be allowed and/or preferred if it occurred in the 
experimental phage display sequences (pi) or computational predictions (X.75) with a 
frequency of >1% or >10%, respectively.  
 
3.3.7. Assignment of interface position tolerance levels.  
In order to discriminate interface positions having one or more amino acid residue 
types marginally exceeding the 10% preferred threshold from other interface positions 
displaying moderate and/or strong selection for preferred amino acid residues, we devised 
the following metric. (Entropies were not used as direct comparison as the experimental 
assays and computational predictions allowed differing numbers of amino acids to be 
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sampled at each position; note cysteine was not computationally allowed). At every 
interface position, the amount by which each preferred amino acid type exceeded the 
10% threshold was summed. If this value was <25, the interface position was labeled as 
having a high overall tolerance.  Interface positions having values between 25 and 50 
were classified as having medium tolerance and positions with a value >50 were 
classified as having low amino acid substitution tolerance. This process was implemented 
both for the sets of preferred amino acid residue types taken from the experimental phage 
display data, as well as for the sets computationally predicted by the fixed and flexible 
backbone protocols. 
 
3.3.8. Generation of a computationally designed library.  
At each interface position computationally predicted to have medium or low 
tolerance to substitution by the flexible backbone protocol, all amino acid residues 
identified as preferred were selected. While amino acids with strong biases in tolerance 
profiles could be selected for inclusion in a computational library by visual inspection (or 
setting the preferred threshold to a value differing from 10%), this process served to 
automate the predictions. 
 
3.3.9. Selection of a naive library.  
For each interface position, a “naïve” library was created by including all similar 
amino acid residue types in groups as defined below: 
(1) [D,E,N,Q] (2) [R,K,H] (3) [L,I,V,M] (4) [F,Y,W] (5) [P,A,G] (6) [S,T] 
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3.4. Use of near-native backbone ensembles improves the ability to 
predict the overall tolerated amino acid sequence space 
We used the protocol summarized in Figure 3.1 to computationally predict 
tolerance profiles for each of the 35 hGH interface positions examined in [43]. We first 
evaluated whether our protocol was able to generate sufficient sequence diversity to 
reflect the range seen experimentally. As the simplest measure, we compared the number 
of amino acid residue types experimentally observed at each interface position to the 
number computationally predicted with a small but observable frequency (“allowed” 
residues, experimental frequency pi or computational measure X.75 > 1%; see Table 3.1). 
The percentage of the experimental phage display sequences represented by the set of 
”allowed” residues selected by each protocol is also given in Table 3.1 and illustrated in 
Figure 3.3A. 
Both flexible and fixed backbone protocols predicted sets of allowed amino acid 
residues that effectively covered the experimental sequence space for most of the 35 
interface positions (Figure 3.3A; blue: flexible protocol; yellow: fixed protocol). On 
average, the fixed and flexible backbone protocols predicted sets of allowed amino acids 
that represented 89% and 92%, respectively, of the total phage display sequence space at 
each position. Notably, this result was not due to simply predicting all amino acid residue 
types to be allowed (Table 3.1), nor was it due to an overabundance of the native amino 
acid residue type in the phage display sequences (grey bars, Figure 3.3A). 
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 Allowed                             
Amino Acid Residues 
Preferred                          
Amino Acid Residues! 
 
Number 
% Occurrence in 
Phage Sequences 
Number 
% Occurrence in 
Phage Sequences Site 
Phage Flex  Fixed Phage    Flex        Fixed Phage  Flex  Fixed Phage       Flex        Fixed 
Measured 
&&G!! 
67T 8 8 7 - 85% 55% 4 6 5 81% 85% 55%  
171D 8 6 13 - 61% 84% 5 3  2 79% 49% 18% ! 
176F 8 15 15 - 92% 92% 3  5 3 74% 86% 69% !! 
61P 9 8 10 - 73% 75% 1 4 7 52% 71% 72% ! 
178R 10 17 13 - 100% 97% 2 5 1 80% 68% 19% !! 
183R 10 18 18 - 100% 100% 4 4 2 79% 2% 0%  
167R 11 16 17 - 94% 94% 2 1 1 47% 5% 5%  
172K 11 12 11 - 97% 97% 4 7 4 70% 85% 48% !! 
25F 12 16 16 - 96% 95% 5 4 3 68% 50% 47%  
179I 12 17 18 - 99% 100% 3 5 3 66% 59% 51% ! 
60T 12 14 13 - 75% 75% 2 8 3 47% 48% 50%  
175T 12 14 15 - 100% 100% 4 7 2 61% 37% 10% !! 
43S 13 18 18 - 99% 99% 3 - - 42% - -  
46Q 13 15 14 - 71% 70% 4 6 4 44% 38% 30%  
21H 14 13 15 - 87% 90% 3 3 4 50% 14% 14%  
45L 14 16 16 - 84% 90% 2 5 6 46% 62% 65% ! 
64R 14 16 17 - 98% 98% 4 4 4 55% 43% 43% !! 
29Q 14 18 18 - 100% 100% 4 5 - 47% 30% -  
44F 14 16 15 - 91% 88% 3 3 4 53% 44% 54%  
47N 14 18 18 - 97% 97% 3 2 - 44% 24% -  
66E 14 18 16 - 96% 78% 3 - - 41% - -  
14M 15 18 18 - 100% 100% 2 2 1 37% 11% 3%  
18H 15 18 18 - 100% 100% 3 4 1 38% 39% 17%  
28Y 15 17 16 - 95% 87% 2 4 4 40% 38% 31%  
41K 15 16 16 - 82% 82% 2 5 4 35% 42% 37%  
62S 15 19 19 - 100% 100% 4 2 - 50% 19% -  
63N 15 16 15 - 92% 82% 4 3 1 52% 18% 2%  
22Q 16 15 15 - 78% 78% 4 3 3 51% 16% 16%  
48P 16 17 10 - 86% 51% 3 4 4 45% 33% 10%  
65E 16 19 19 - 100% 100% 3 - - 50% - -  
164Y 16 16 16 - 95% 95% 2 - - 29% - -  
168K 17 16 15 - 84% 77% - 5 2 - 28% 15%  
174E 17 18 16 - 100% 92% 3 2 4 34% 10% 30%  
26D 18 18 18 - 100% 100% 1 - - 11% - -  
42Y 18 18 18 - 100% 100% 1 5 3 10% 33% 23%  
Allowed   10
39
  10
41 
 10
41
 - 92% 89%    
 Preferred  10
15
  10
17
  10
11
 50%    40% 31%  
Restricted  10
5
    10
9    
10
4
 66%         48% 29%  
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Table 3.1 Allowed and Preferred Amino Acid Sets at the 35 hGH-hGHR Interface Positions 
For each of the 35 hGH-hGHR interface positions (column 1), the number of amino acids determined to be 
allowed (see Section 3.3.6) by using either the experimental phage display sequences, the flexible 
backbone computational protocol, or the fixed backbone computation protocol are shown in columns 2–4. 
The percentage of phage display sequences represented by these sets of allowed amino acids are given in 
columns 5–7. Corresponding information for sets of amino acid residues selected as preferred is also shown 
(columns 8–13). Percentages over 75% and 50% are in red and blue font, respectively. Pink shading 
indicates interface positions identified by each method as ‘‘restricted.’’ Interface positions previously 
published as being hot (&&GALA-WT > 1.0 kcal/mol) and warm (0.4 < &&GALA-WT < 1 kcal/mol) spots are also 
indicated by !!  and !, respectively (column 14). Combinatorial sizes shown in the last 3 rows represent 
the total number of unique sequences if all combinations of allowed or preferred amino acid residue types 
were considered at all interface positions in a single library. 
Although both flexible and fixed backbone protocols predicted similar numbers of 
amino acid residues to be allowed at most interface positions, there were improvements 
in predicting tolerated sequence space by using backbone ensembles at several positions 
(Table 3.1; compare blue bars and yellow diamonds, Figure 3.3A). For most of these 
interface positions the flexible backbone protocol correctly selected one or more amino 
acid residue types that occurred in the phage display sequences but were not predicted as 
“allowed” by the fixed backbone protocol (several cases are discussed further below). In 
contrast, there was only a single instance, position 171D, where the fixed backbone 
protocol appeared to be substantially closer to the experimental data (Figure 3.3A). 
However, direct comparison of the tolerance profiles generated by the flexible and fixed 
protocols at this position (Figure 3.4F, blue and yellow box-plots, respectively; 
experimental frequencies in red) shows that the flexible backbone protocol in fact 
improves predictions for the two amino acid residues most frequently observed 
experimentally (Ser and Asp). In this instance, the apparent better performance of the 
fixed backbone protocol is achieved at the expense of an overall higher bias for amino 
acid residues not observed experimentally. 
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Figure 3.3 Ability of Fixed and Flexible Backbone Computational Protocols to Map the Allowed and 
Preferred Amino Acid Space 
The percentages of phage display sequences accounted for by amino acids selected as allowed by the 
flexible (blue bars) and fixed (yellow diamonds) protocols are shown for all 35 hGH-hGHR interface 
positions (A). Interface positions are sorted by the number of amino acid residues observed experimentally 
(see Table 3.1). The percentage of sequences accounted for by the native amino acid is denoted by gray 
bars. The frequency percentage of phage display sequences accounted for by the preferred amino acid 
residues at positions selected as ‘‘restricted’’ by the flexible (blue bars) and fixed backbone protocol 
(yellow bars) are shown in (B) and (C), respectively. Positions indicated in red in (B) and (C) are classified 
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as restricted using the experimental phage display data. Hot spots and warm spots are denoted by stars, as 
indicated. 
3.5. Design on a near-native conformational ensemble improves the 
ability to discriminate between restricted and plastic positions 
We next sought to evaluate the ability of the fixed and flexible backbone 
protocols to identify small subsets of “preferred” amino acids residue types from the total 
set of amino acid residue types predicted to be allowed at each interface position. Table 
3.1 shows, for each interface position, the number of preferred amino acid residue types 
observed experimentally and predicted computationally by both fixed and flexible 
backbone protocols (defined to be those occurring with a pi or X.75 value >10%, 
respectively). 
The sets of amino acid residue types selected as preferred by our computational 
protocols represented a significant reduction over the total allowed combinatorial 
sequence space (see estimates in last row, Table 3.1). On average, 3-4 “preferred” amino 
acid residue types were chosen at each interface site by the flexible and fixed backbone 
protocols, accounting for 40 and 31 %, respectively, of the experimentally phage display 
sequence space. We note, however, “preferred” amino acid types at some interface 
positions accounted for significantly more experimental phage display sequence space 
than others. We thus wanted to further test whether we could computationally classify 
such sequence positions based on whether they strongly preferred just a few amino acid 
substitutions. 
To accomplish this, we assigned each interface position a “tolerance” value of 
HIGH, MEDIUM or LOW based on whether the sum total by which all its preferred 
residue choices exceeded the 10% frequency threshold was <25, 25-50, or >50 (see 
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Section 3.3.7). We call high tolerance interface sites “plastic”, as they are predicted to 
show an approximately equal experimental tolerance to substitution to a large number of 
amino acid residues (see for example Figure 3.4A). In contrast, we call positions labeled 
as having either a low or medium tolerance “restricted”, as typically only a small subset 
of preferred amino acid residues accounted for the majority of experimentally observed 
sequences. Sample tolerance profiles of interface positions labeled as plastic or restricted 
are given in Figure 3.4 (see Supplementary Figure B.2 for full dataset). 
Over the entire dataset, the low/medium tolerance positions identified by the 
flexible backbone protocol favored interface sites experimentally determined as 
“restricted” (red coloring, Table 3.1 and Figure 3.3B) as well as positions previously 
determined by alanine scanning to be “hot” or “warm” spots [75, 76]. In contrast, the 
fixed backbone protocol misses 5 experimentally selected low/medium significance 
positions (176F, 183R, 179I, 60T, and 45L; see red coloring, Table 3.1 and Figure 3.3C) 
and incorrectly identifies more “hot” and/or “warm” spots as plastic/high tolerance. 
Further, the flexible backbone protocol selected restricted interface positions and sets of 
preferred amino acid types that accounted for, on average, a much larger percentage of 
the experimentally observed sequences than seen when using the fixed backbone protocol 
(29% and 48%, respectively for the fixed and flexible protocols). 
The percentage of phage display sequences accounted for by the amino acid types 
selected as “preferred” by the flexible protocol showed improvements in coverage of the 
experimental sequences over those chosen by the fixed protocol at five interface 
positions: 67T, 171D, 178R, 172K, and 48P (compare blue and yellow bars in Figure 
3.3B and Figure 3.3C). Despite the improved performance of the flexible backbone 
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protocol at several interface positions, the tolerance profiles predicted by both protocols 
matched the experimental data poorly at four of the 35 positions (21H, 22Q, 167R and 
183R; see Figure 3.3 and Table 3.1).  These positions are discussed further in the 
following section. 
 
3.6. Design on near-native ensembles improves the ability to 
qualitatively recapture experimental tolerance profiles 
We showed above that, for many interface positions, the design protocols 
adequately model sequence diversity as well as preferentially identify interface positions 
with restricted amino acid preferences. Further we showed that both of these capabilities 
may be enhanced by design on near-native ensembles. To illustrate the origins of these 
observations, in this section we discuss in detail several representative examples of 
tolerance profiles generated by the two protocols at key interface positions. 
Figure 3.4 compares representative tolerance profiles generated by the flexible 
(blue box-plots) and fixed backbone (yellow box-plots) protocols for seven interface 
positions (experimental profiles, red). Similar trends are seen throughout the dataset of 35 
interface positions (Supplementary Figure B.2). While the overall shapes of the tolerance 
profiles were often qualitatively similar for the flexible and fixed backbone protocols, 
tolerance profiles generated using the 100 ensemble backbones generally showed wider 
variations in the frequencies of amino acid residues selected than seen for the 100 
independent runs on the crystallographic backbone. This suggested that some subsets of 
backbone conformations favored certain amino acid residue substitutions not tolerated by 
other subsets of backbones.  (There were 4 positions (see for example 171D and 178R, 
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Figure 3.4) for which larger variation, due to the presence of two distinct sub-
distributions of selected sequences, was also observed for the fixed backbone protocol; 
see Section B.1.1 for details). The larger variation in the amino acid preferences observed 
in many of the tolerance profiles generated by the ensemble protocol directly resulted in 
the improved ability to distinguish plastic and restrictive positions and select sets of 
“preferred” amino acid residue types that more closely mimicked the experimental 
sequence preferences. For example, position 174E (Figure 3.4A) is correctly labeled as a 
“plastic” interface position by both the fixed and flexible backbone protocol. Note, 
however, that even while the two profiles appear qualitatively similar, the flexible 
backbone protocol shows some increased signal for at least two experimentally observed 
amino acid residue types (F and W). Likewise, the predicted profiles at positions 67T, 
172K, 48P, and 171D clearly show experimental preferences for a few amino acid 
residues and are identified as  “restricted” by both protocols (Figure 3.4B,D-F). In every 
instance, the flexible backbone protocol predicted the most frequently experimentally 
observed amino acid residue type to be preferred while the fixed backbone protocol did 
not (see amino acid types V, R, F, and S in Figure 3.4B, D-F, respectively). In contrast, 
similar amino acid residue types are selected as preferred by both protocols at position 
176F (Figure 3.4C), but the overall profile shape appears somewhat flat when predictions 
are made on the crystallographic backbone (yellow box-plots). This results in this 
position being incorrectly labeled “plastic” by the fixed backbone protocol but being 
correctly identified as “restricted” when the flexible backbone procedure (blue box-plots) 
is used. 
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Figure 3.4 Comparison of Computationally Generated and Experimentally Determined Tolerance 
Profiles 
(A–G) Computational predictions of amino acid tolerance profiles generated by either independent 
simulations on 100 near-native backbones (blue box-plots, left) or 100 independent simulations on the 
crystallographic backbone (yellow box-plots, right) for seven interface positions.  Experimental tolerance 
profiles are denoted in each plot by red lines. 
Lastly, we show a representative example of one of the four interface positions 
where both computational protocols poorly predicted the experimentally observed 
sequence preferences (Figure 3.4G; see also Table 3.1). At position 167, the native 
arginine was highly over-represented in the sequences chosen by both design protocols, 
leading to low signal at all other interface positions; this resulted in missing the 
experimental preference for asparagine. For position 183R, and 21H there was an 
incorrect computational bias for large aromatics (F, Y, H) that resulted in missing the 
strong experimental preferences (Supplementary Figure B.2F,O). Position 22Q 
(Supplementary Figure B.2AB), shown to be highly plastic and tolerant to amino acid 
substitutions experimentally, was incorrectly classified as restricted by both 
computational protocols. These prediction errors may be due to simplifications in our 
electrostatics model as well as general difficulties in modeling interactions of charged 
and polar residues in interfaces. We note that while our computational protocols failed to 
correctly predict highly preferred amino acid types at all four positions discussed above, 
the experimentally preferred amino acid residue types favored were nevertheless 
computationally predicted as “allowed” in each case. 
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3.7. Structural Analysis of Modeled Backbone Changes 
As we saw some significant improvements with the flexible backbone protocol, 
we investigated the modeled structural consequences of backbone flexibility at three 
positions: 171, 67 and 48. 
In the first case (Figure 3.5A), backbone flexibility around the D171 site appears 
to enable the formation of an altered polar interaction network around the D171 site. 
These changed side chain interactions may favor replacing the aspartate at position 171 
with serine, which is the most frequently observed amino acid residue at this site by 
phage display and included as “preferred” amino acid by the flexible backbone protocol 
(Figure 3.4F). Consistent with our predictions, some of the modeled altered polar 
interactions are also observed in a crystal structure of a hGH variant with 15 point 
mutations in complex with 2 hGHR molecules which included the D171S hGH mutation 
(pdb code 1KF9; Figure 3.5B). We should note that the backrub flexible backbone 
method used here only models relatively subtle backbone conformational changes and 
may therefore not capture some of the larger structural variations such as those observed 
in the 1KF9 crystal structure [77]. 
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Figure 3.5 Structural Illustrations of the Possible Consequences of Backbone Flexibility 
(A) Comparison of side-chain placement observed in the minimized crystallographic hGH-hGHR complex 
(PDB ID code 1A22, brown) to side-chain placement seen in three ensemble members (yellow, hGHR; 
blue, hGH) which prefer an aspartate at position 171. Residues with gray labels belong to hGH; residues 
with black labels belong to hGHR. Black and red dotted lines indicate hydrogen bonds in PDB ID code 
1A22 and the ensemble members, respectively. (B) Ensemble members that prefer mutation of aspartate to 
serine at position 171 are compared to a crystallographic structure of an hGH-hGHR complex with 15 
interface mutations, including 171S and 178N (PDB ID code 1KF9, gray). Hydrogen-bonding interactions 
(black and red dotted lines for PDB ID code 1KF9 and the ensemble members, respectively) and side-chain 
rearrangements observed for the ensemble members with the 171D-to-171S substitution mimic the 
interactions observed in the experimentally determined structure. Note the difference in the conformation in 
326D. Modeled subtle backbone flexibility may enable this change in the 326D rotamer, which favors the 
D171S substitution 
In a second example, the flexible backbone protocol correctly predicts that valine 
should be allowed at position 67 whereas the fixed backbone model misses this tolerated 
substitution. In this case, the hydrogen bonding interaction between 67T and a backbone 
nitrogen seen in the 1A22.pdb crystallographic backbone is frequently lost when 
modeling subtle (0.4Å C" RMSD) backbone flexibility, favoring the experimentally 
observed threonine to valine substitution (Supplementary Figure B.3A). 
In the third case, using the crystallographic structure 1A22, the substitutions 48Y 
and 48W are predicted to be stabilizing at the native 48P site. However, predictions made 
using the flexible backbone ensemble favor the observed 48F substitution over the larger 
tyrosine and tryptophan mutations. This could be due to side-chain rearrangements of 
49Q and 274Q enabled by backbone flexibility, resulting in a somewhat smaller pocket 
surrounding positions 48 (Supplementary Figure B.3B). 
As illustrated in these examples, our results predict modeled backbone flexibility 
can have a variety of consequences, including alternative side chain hydrogen-bonding 
networks as well as increasing and decreasing the volume at a given interface site. 
Similar results showing that backbone flexibility can lead to both prediction of increased 
or decreased side-chain flexibility have also been observed in an application of backrub 
ensembles to modeling side-chain flexibility and comparison to side-chain order 
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parameters determined by NMR [78]. It should be noted that in the case of hGH we 
cannot directly assess the accuracy of the flexible backbone predictions in Supplementary 
Figure B.3, as we lack crystal structures of point mutations. However, our analysis of the 
D171S mutation (Figure 3.5) appears consistent with structural data, as discussed above. 
In addition, we previously validated backrub-generated predictions of point mutant 
structures on a dataset of more than 2000 cases where experimental structures of both the 
wild-type and the variant were available [33]. 
 
3.8. Performance of computationally selected amino acid residues in 
a design library 
Finally, we evaluated the ability of a hypothetical design library, consisting of the 
“preferred” amino acid residue types at positions selected as “restricted” by our flexible 
backbone protocol, to recover a large percentage of the experimentally observed phage 
display sequences by comparing it to two other hypothetical libraries. As a “lower” 
bound, we considered a naïve library, consisting of amino acid residues chemically 
similar to the native amino acid (Section 3.3.9). As an “upper” bound we considered a 
“perfect” design library, having the same number of amino acid residue types at each 
position as in the design library but consisting of the amino acid residue types occurring 
most frequently in the phage display sequences. The amino acids selected in each library 
as well as the sum of the frequencies of the selected amino acid residue types in the 
phage display sequences are given in Table 3.2. 
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Table 3.2 Comparison of Computational, Naive, and Perfect Design Libraries 
Sixteen hGH-hGHR interface positions (column 1) and amino acid residue types (column 4) selected for 
inclusion in the computationally designed library (see Section 3.3.8) are shown. The native amino acid 
residue type for each selected position is given in column 2. For comparison, a perfect library (column 3) 
with the same number of amino acid residue types as chosen by the computational library and a naive 
library (column 5) are also shown. The experimentally observed frequency for the native residue (column 
6) as well as the sum of experimental frequencies for all library amino acid residues (including the native) 
are shown for each library (columns 7–9). Amino acid residue types are shown for the design library in the 
order by which they were selected computationally (column 4), excluding the native amino acid residue 
type. For position 167, only the native R was selected as ‘‘preferred’’ by both the fixed and flexible 
protocols. Superscripts for positions 183 and 22 in column 8 indicate that the native amino acid residue 
type was not selected as preferred in the computational library. Average percentages of phage display 
sequences sampled over all 16 positions are indicated below, together with the size of each library. 
!Percentage differs from that given in Table 3.2 due to inclusion of the native amino acid residue type. 
The library designed by the flexible backbone protocol performs about equal or 
better than a “naïve” library at 13 of the 16 selected interface position (Figure 3.6, 
compare blue bars with green triangles; grey bars indicate the frequency of occurrence of 
the native residue). The overall better performance of our design library suggests that the 
computational protocol is able to suggest non-intuitive amino acid substitutions. For 
instance, our predictions correctly identify the strong experimental preference for 
 Amino Acids Selected % Occurrence in Phage Sequences 
Interface 
Position 
Native 
“Perfect” 
Library 
Computational 
Library 
Naïve 
 Library 
Native 
 Native  
 + 
“Perfect” 
Native            
+ 
Computational 
Native  
 +  
Naïve 
67 T V S A I G A V S G D S 17% 93% 85% 36% 
171 D S A H S N E Q 14% 57% 49% 27% 
176 F Y L M H Y H M L W Y 53% 86% 86% 68% 
61 P V S A A G S A G 52% 76% 71% 63% 
178 R H Q K T M K Q L K H 61% 89% 68% 83% 
183 R A G K T F Y H M K H 33% 85% 35%! 43% 
167 R -- -- K H 5% 5% 5% 9% 
172 K R Q M I V A M I R Q A V R H 13% 86% 85% 41% 
25 F Y W A Y W R Y W 15% 58% 50% 47% 
179 I V Q T M H V K M V L M 12% 79% 59% 52% 
21 H G S F Y R K 6% 45% 14% 7% 
45 L F M W Y Y M F H I V M 16% 68% 62% 32% 
64 R F Y L F K H K H 15% 55% 43% 25% 
22 Q V E D H N S N E D 2% 43% 18%! 33% 
48 P F V L F Y H G A 6% 51% 33% 17% 
42 Y V F K D F H K R F W 9% 42% 33% 21% 
Combinatorial 
Library Size 6 "10
9
 6 "10
9
 9 "10
7
 
    
Average % 
Occurrence 
   
21% 64% 50% 38% 
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phenylalanine at positions 45L, 64R, and 48P. Likewise, the frequent observation of 
serine at position 171D, as well as methionine and glutamine at position 172K, are 
predicted computationally (Table 3.2) 
Comparison of the flexible backbone library to a “perfect” sequence set (Figure 
3.6, red circles) shows that, for the size of the library, our algorithm is making near 
optimal selections of amino acids in the majority of cases. Over the 16 interface positions 
selected, the computationally designed library identified sets of amino acid residues 
coming, on average, within approximately 14% of the observed sequence space covered 
by a “perfect” library of the same size. This can be compared to the “naïve” library, 
which, on average, only comes to within 26% of the perfect library. In total, 38, 50 and 
64% of the observed sequence space would be covered by the naïve, designed and 
“perfect” libraries, respectively (see Table 3.2). While the design library did occasionally 
select amino acid residue types never observed in the phage display sequences 
(predominately for the previously discussed positions 183R and 21H), we note that this 
may not be detrimental in actual experimental library selection applications, as long as 
other tolerated residue choices are included at the position in question. 
 
Figure 3.6 Performance of a Hypothetical Computationally Designed Library 
The percentage of experimentally observed sequences accounted for by the amino acids selected in a 
hypothetical computational design library (blue bars, as in Figure 3.3B) is compared to a naive (green 
triangles) and perfect (red circles) library (see main text). For reference, the frequency of the native amino 
acid residue, which is assumed to be included in all libraries, is shown in gray in bar-plot form.  
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3.9. Discussion 
We have developed a design strategy that selects sets of sequences consistent with 
an ensemble of backbone conformations and show that our protocol can (i) distinguish 
restrictive positions allowing only a few amino acid choices from highly plastic positions, 
(ii) predict tolerance profiles for restrictive positions that qualitatively match 
experimentally observed sequence preferences in many cases and (iii) be applied to 
design protein sequence libraries enriched in functional members. 
There are two main new aspects of this work. First, we compare our predictions of 
protein interface sequence plasticity to experimentally determined sequence profiles 
obtained under multiple selective pressures we can mimic computationally. Second, we 
employ a new method to model structural plasticity in response to sequence changes and 
binding interactions inspired by coupled side chain-backbone “backrub” motions 
observed in high-resolution protein crystal structures [32, 33]. Although we cannot 
directly assess the structural accuracy of the near-native backbone ensembles, several 
lines of evidence suggest that backrub simulations are a useful model to represent local 
protein motions. Applying small backrub moves as implemented here has been shown to 
improve the prediction of side chain conformations in point mutant structures [33] and 
side chain order parameters obtained from NMR measurements [79] while larger-
amplitude backrub-type moves have been shown useful for modeling protein loop 
motions [33] and obtaining backbone ensembles consistent with protein dynamics as 
measured by residual dipolar coupling (Greg Friedland & T.K., unpublished data). 
Finally, in contrast to other methodologies used to study protein conformational 
flexibility such as molecular dynamics, generation of backrub ensembles is 
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computationally very efficient and can be used in iterative backbone sampling and design 
simulations discussed below. 
Our study only uses a single dataset for assessment [43], and it would be ideal to 
have additional protein interfaces with equally comprehensive experimental 
characterization. We would like to note, however, that the applied methodology does not 
involve substantial optimization of parameters to the test system, other than defining the 
threshold values mentioned above to guide the sequence tolerance profile analysis. The 
scoring function used here was derived using a large dataset of point mutations in both 
monomeric proteins [29] and protein-protein interfaces ([28]; this set did include the 
HGH-hGHR interface as one of 19 protein complexes) and applied successfully to 
recapture native-like sequences in a different dataset of 20 multi-specific protein 
complexes [73]. The backbone sampling method was parameterized independently [33] 
and not altered here. We also tested the robustness of our method to filtering of 
backbones and variation in thresholds (see Section B.1.1). 
A simplification of the method in its described implementation is that it assumes 
independence of interface positions for compiling amino acid tolerance profiles. While 
we find good agreement with experimental data, this may be specific for this dataset, as 
the experimental study set out to avoid effects of co-variation as much as possible by 
choosing positions screened in each experimental library that were spatially separated in 
the interface. This is supported by the fact that we obtained similar results when 
designing one interface position at a time (while repacking a surrounding shell of 4Å) and 
computing tolerance profiles from Boltzmann-weighted scores over the backbone 
ensemble (data not shown). Independence of several positions in the hGH-hGHR 
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interface is further confirmed by a double-mutant-cycle analysis [80]. In such cases of 
minimal co-variation between positions, experimental selections targeting independent 
sites may be the most time-efficient approach if the main goal is to optimize interface 
affinity. Nevertheless, close agreement with extensive experimental datasets on tolerated 
sequence space for a protein interface, as shown here, is an important benchmark for 
assessing advances in computational design protocols. 
Our method contains a number of other simplifications in the selection of 
preferred amino acids by compiling the amino acids from just the top 25% of the 
predictions at each site. We note here that we could not pre-specify subsets of backbones 
by examining either the starting score of the ensemble backbones with the native 
sequence or the final score of the backbones with the accepted modeled sequence, but 
instead needed to rely on the difference between these two scores.  This occurred for two 
reasons. First, the ensemble backbones were generated with the native amino acid 
residues at every position in the interface. As we wished to provide opportunities for the 
ensemble to include backbones optimal for substitution with amino acid types 
considerably larger (or smaller) than native, some backbones with poor initial scores with 
respect to the native starting sequence were included in the ensemble. Secondly, the 
backrub procedure used to generate each member in the ensemble was global, allowing 
all residues within the hGH-hGHR complex to move, and likewise the ROSETTA 
scoring function was used to calculate a global score over all atoms in the hGH-hGHR 
complex. Thus an amino acid substitution could score better locally on a given ensemble 
backbone than on the starting crystallographic backbone, but the global score 
improvement from the substitution might not be sufficient to offset score changes due to 
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backbone movement distant from the interface position of interest. Both problems could 
be addressed by a protocol allowing local and independent optimization of the hGH-
hGHR interface backbone following all appropriate amino acid substitutions. As this 
would be impractical for the number of sequences examined in this work, we instead 
relied on examining the frequencies with which each (pre-generated) backbone accepted 
each considered amino acid substitution. 
While our current work suggests that simulations on backbone ensembles aid in 
capturing the experimentally observed sequence diversity in the hGH-hGHR interface, 
further developments may be needed in cases with substantial conformational coupling 
between backbone and side chain motions. Some important structural changes may only 
result from iteratively sampling backbone and side chain sequence moves rather than pre-
generating backbone ensembles as mentioned above. For more general design tasks, such 
as estimating the sequence diversity of interacting residues in a tightly packed protein 
core, simulations may moreover be complicated by the presence of a rugged energy 
landscape with several local minima where co-variation cannot be ignored. Therefore, 
our methodology may need to be extended to directly compute correlated changes in the 
designed sequences [68]. Work on predicting structural effects of single point mutations 
supports the idea that such coupled changes can aid in the prediction of structural effects 
of sequence changes [33]. 
The ability to distinguish restrictive from highly plastic positions is important for 
several reasons: First, in a biological context, these predictions indicate which positions 
may be sensitive to mutations and which ones are not [81]. Second, a comparison of 
predicted plastic and yet evolutionarily invariant positions may provide testable 
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hypotheses for identifying amino acid residues that are conserved for reasons other than 
structural stability or binding affinity. These may include determinants of specificity 
where any amino acid residue would be allowed in the given interface but a specific 
residue may be necessary either for mediating binding with secondary partners [73] or 
selected for to minimize unwanted crosstalk with another undesired partner. Third, this 
information may be useful for engineering specificity determinants to form preferred and 
avoid undesired interactions within a set of possible partners [6, 10, 11, 81]. Finally, 
similar methods may also be useful to engineer enzyme active sites plastic enough to 
accommodate a variety of substrates; this substrate promiscuity may be an intrinsic 
property of naturally occurring enzymes and may confer evolvability [59]. 
Perhaps the broadest use of our described method is the design of sequence 
libraries enriched in functional members [69, 70]. This may be especially crucial for 
difficult engineering tasks where design methods are likely not accurate enough to predict 
a single functional sequence with high confidence. Here, combining computational 
design libraries with experimental screens may substantially increase the success rate 
over both testing individual sequences and unbiased screens [70]. In addition, the ability 
to select protein sequences for multiple criteria, such as fold stability combined with 
selectivity or multi-specificity towards several partners [73] could provide distinct 
advantages in applications where the goal is to generate designed proteins with several 
specified functional properties. While some desired properties, such as flexibility, 
interaction on- and off-rates, are difficult to include directly (and accurately) into design 
fitness function, designing a set of sequence and screening for desired properties may 
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yield a family of protein parts with a range of specifications desired for engineering and 
synthetic biology applications. 
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Chapter 4  
Prediction of the mutational 
tolerance of HIV-1 Protease 
 
 Fast-evolving viral proteins such as HIV protease, under adaptive pressure to resist 
drug treatments provide ideal systems in which to examine mutational tolerance within 
the constraint of maintaining fold stability and native function.  Here I test the ability of 
RosettaDesign to pro-actively predict the total sequence space tolerated by the HIV-
protease fold in order to function under neutral (no selective pressure) conditions as well 
as mutations predicted to be sampled when a particular pressure (or drug) is applied.  
Other published work on HIV-Protease drug resistance typically examines a limited set of 
mutations near the binding pocket in the context of a single pressure (e.g. drug binding).  
In contrast, this work attempts to integrate the multiple the multiple structural and 
functional constraints (e.g. folding stability, dimer interface stability, native substrate 
binding and cleavage) acting on every sequence position of HIV-1 protease in order to 
make predictions of the total mutational space able to be tolerated. This work should 
provide useful insights into the mechanisms of mutational pathways, both for analyzing 
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viral evolution as well as predicting pathways to selectively engineer new protein 
functionality.   
 
4.1. Introduction 
Proteins appear to tolerate considerable sequence changes while still maintaining 
some of their native functional capabilities [82]. A fraction of the intrinsic sequence 
variability present in a protein population may become advantageous when conditions 
change to make a new secondary function more desirable [83, 84]. Directed evolution has 
been used to select new enzymatic capabilities without substantial loss of native activity 
[85-87]. Likewise, existing sequence variation in a population of functional proteins may 
provide the raw material from which resistance mutations can be rapidly selected after 
inhibitor treatment [88]. Thus, the ability to predict the extent to which proteins 
accommodate mutational changes could play a key role in forecasting the emergence of 
drug resistance or facilitating the engineering of new protein functions.   
Here we test the idea of using computation to predict the accessible mutational 
space of proteins while preserving their natural function, as well as when selection 
pressures change. Using the fast-evolving viral protein HIV-1 protease as a model 
system, we develop a computational approach to predict mutations compatible with 
native fold and function but free to contribute to alternative functionality such as reduced 
inhibitor binding. To validate our model, we compare predictions of the sequence space 
sampled by HIV-1 protease under neutral and selective pressure to a collection of more 
than 50,000 HIV-1 sequences collected from untreated and treated HIV patients[89]. 
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HIV-1 protease is a 99 residue dimeric aspartyl protease essential for correct 
processing and maturation of the HIV virus [90, 91]. In order for the HIV viral life cycle 
to be viable, the sequence of HIV protease must properly fold and dimerize, as well as 
recognize and cleave at least 10 endogenous pol and gag peptide sequences [92, 93]. 
Modeling the mutational space accessible to HIV protease is Due to the low fidelity and 
high error rate of HIV reverse transcriptase [94, 95], the HIV protease sequence mutates 
rapidly and the appearance of drug resistant mutation strains has greatly limited the 
overall effectiveness of HIV treatment [96]. It is known that higher levels of drug 
resistance are often correlated with an increasing number of protease mutations [97-99]. 
Several studies have investigated the effects of HIV-1 protease mutations located directly 
within the active site on inhibitor binding [100, 101]. While the contributions towards 
resistance of common non-active site mutations are generally less well understood, they 
have in a few cases been directly implicated in reduced inhibitor binding [102, 103]. 
However, a complete picture of the emergence of drug resistance may also require an 
understanding of the role active site and peripheral mutations play in overall viral fitness 
through exerting effects on the structure and function of HIV-1 protease.  
We show integrating structural constraints on fold and dimer stability with 
functional constraints of peptide recognition can result in a computational prediction of a 
functionally tolerated mutational space very similar to that observed in HIV-1 clinical 
protease sequence variants [89]. The model we present successfully discriminates HIV-1 
protease sites experimentally known to be intolerant to mutation with high fidelity, and 
narrows the possible mutational space down at sites more tolerant to mutation to a small, 
experimentally observed, subset of amino acid types. Surprisingly, without incorporating 
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any knowledge of the size or structure of possible inhibitors, the model predicts ~80% of 
known major and minor drug resistance mutations. Together, these simulations suggest 
that structural and functional constraints might be sufficient to predict functional HIV-1 
protease sequence mutations from which specific drug resistance mutations may be 
selected during protease inhibitor treatment. This work suggests computational models of 
accessible mutational space, such as the one presented here, may prove to be generally 
applicable to modeling the evolvability of proteins by forecasting the emergence of 
mutations that can enable drug resistance or other new protein functionality.  
4.2. Computational prediction of HIV-1 mutational frequencies based 
on structural and functional constraints 
We set out to test whether modeling structural and functional constraints on 
sequence alone, without considering information of bound protease inhibitors, would 
enable prediction of the wide variety of escape mutations frequently observed after 
protease treatment. We hypothesized that in a population of fast-evolving viruses, such as 
HIV, there might already exist some significant sequence variability, even within a 
neutral setting, that might be selected from during inhibitor treatment. We used the 
program RosettaDesign [7, 28, 68] to estimate the effect of every possible point mutation 
on the stability of the HIV-1 protease fold, dimer interface, and recognition of 
endogenous substrate peptides. We varied the relative importance each mutation was 
required to make towards satisfying each of these structural or functional constraints in 
order to give two computational models. For predicting mutations likely to occur in the 
absence of any selective pressure, we chose a “neutral” model in which the importance of 
all constraints was weighted approximately equal (WFOLD, WDIMER, WPEPTIDE in 
  98 
Supplementary Table C.3).  In order to simulate pressure to accumulate mutations near 
the dimer and peptide binding sites, we also examined a “selective” model where dimer 
and peptide functional contributions were weakened relative to fold stability (by 1/4 and 
1/8, respectively).  
Proteins often adjust their conformations in response to sequence mutations, and 
backbone rearrangements have been shown to be important in several previous studies of 
HIV-1 protease point mutants [104, 105]. To account for such effects, we incorporated 
structural flexibility in two different ways. We first performed calculations independently 
on an ensemble of crystallographic backbone conformations. However, many of the 
crystallographic ensemble members originally contained one or more mutations as 
compared to the HIV-1 protease consensus “wild-type” sequence (subtype B, see Section 
4.3.1). Thus we also later repeat our analysis for an ensemble of backbones 
computationally generated from structures crystallized in the absence of any mutation. 
Our computational protocol is illustrated for a single protease site in Figure 4.1 and 
described in greater detail below.  
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Figure 4.1 Mutational tolerance calculations for residue 50I.  
19 amino acid types were computationally modeled onto a crystallographic ensemble of backbones with 
peptide absent (A, top, middle) or containing one of 10 endogenous substrate peptides (A, bottom). For 
each structure, the Rosetta++ per-residue contribution of each substituted amino acid types was recorded 
with respect to fold stability (blue, ERESFOLD), dimer stability (green, ERESDIMER) and peptide stability 
(red, ERESPEPTIDE). The best ERES scores calculated among all members of the ensembles (A, open 
squares and filled squares; variation among ensemble members not shown for peptide calculations) was 
input into Eq(1) (see main text), using either “neutral” or “selective” model parameters. For both models, 
each amino acid was assigned a final weighted sum (B). WSUM values for all amino acids requiring more 
than one mutation at the nucleotide level from the consensus native amino acid type were set to zero. WSUM 
values in (B) were then Boltzmann weighted to give predicted amino acid frequencies for each model (C). 
The frequency of mutation observed within the HIV Stanford database HIV-1 protease sequences as site 
50, before and after protease inhibitor treatment, is also given in (C). Note that the scales of WSUM value are 
of different magnitude for the “neutral” and “selective” models.  
For predicting mutational effects on fold and dimer stability, we compiled a set of 
263 dimeric HIV-1 crystallographic structures available in the protein database and 
removed all bound peptides and/or inhibitors from each structure (Supplementary Table 
C.1). For estimating the effect of mutations on interactions with protease substrates, we 
compiled a second set of 19 crystallographic structures and structural models of HIV-1 
protease bound to 10 known peptide cleavage sequences (Supplementary Table C.2). The 
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sequences of all crystallographic structures were computationally reverted to the 
consensus wild type prior to making any calculations.  
For each protein backbone, we then computationally mutated every position in the 
HIV-1 protease sequence, one position at a time, to each of 19 amino acid types 
(excluding cysteine) and optimized the side-chain conformations of neighboring residues 
using a rotamer library. The two sequence sites containing a native cysteine (67 and 95) 
and the site containing the catalytic aspartate (25) were omitted. For all 263 structures in 
the absence of peptide, we recorded the per-residue contribution of each mutation 
towards fold stability (ERESFOLD, all intra- and inter- residue contributions) and dimer 
stability (ERESDIMER, pair-wise score contribution with neighboring residues on the 
opposite dimeric chain). For each of the 19 structures containing a peptide, per residue 
score contributions each mutation made to the stability of each bound substrate 
(ERESPEPTIDE, pair-wise score contribution between the residue and all neighboring 
residues located on the substrate peptide) were also recorded. Each mutation was 
modeled simultaneously on both chains of HIV-1 protease, and ERES score contributions 
from both chains were taken into consideration by summing the values. In three peptide 
simulations, a portion of the HIV-1 protease sequence was itself a substrate (transframe 
region and HIV-1 protease cleave site (TF-PR), HIV-1 protease and reverse-transcriptase 
cleavage site (PR-RT), and the auto-proteolysis cleavage site (AutoP); see Supplementary 
Table C.2). For these simulations, each relevant mutation was modeled simultaneously 
onto both chains of the HIV-1 protease scaffold as well as onto the peptide backbone.  
We observed that there was often a considerable variation in ERES score values 
calculated for amino acid substitutions modeled onto different backbones in the ensemble 
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of crystallographic structures. This was especially true for ERESFOLD and ERESDIMER 
scores (see, for example, Figure 4.1A, blue and green box-plots, respectively; variation in 
ERESPEPTIDE scores not shown). We thus chose to assign a single ERES value (denoted 
) for each constraint by taking the lowest (e.g. most favorable) predicted per-
residue contribution for a given substitution observed over all ensemble members (see 
squares, Figure 4.1A). We reasoned that this process would allow the crystallographic 
backbone best suited for each individual substitution to be automatically selected.   
After estimating the contribution of each amino acid substitution to fold stability, 
dimer stability and peptide binding, we integrated the functional and structural constraints 
predicted for each mutation by taking a weighted sum (WSUM) of the calculated  
values. In order to focus our analysis on mutations accessible by a single mutational step, 
we set the weighted sum term to zero for all mutations that involved more than one 
nucleotide change from the native (using MUTPROB, see Supplementary Table C.4). For 
all other amino acid types, the relative weighting of each constraint (WFOLD, WDIMER, and 
WPEPTIDE) varied between our “neutral” and “selective” models as discussed above and 
detailed in Supplementary Table C.3. To set an overall mutational frequency, we favored 
the WSUM value of the native residue type at each of the 99 HIV-1 protease sites by a 
constant amount (FAVORNATIVE). We also modeled a possible selection for protein 
solubility, which may oppose pure selection for protein stability, by disfavoring the WSUM 
value mutations substituting a polar native residue with a hydrophobic amino acid type 
(PENALTYPOLAR
!
HP). These calculations are summarized in Eq (1) and illustrated for a 
single residue site in Figure 4.1B.  Parameter values are as given in Supplementary Table 
! 
ERES
! 
ERES
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C.3-4 and details on the sensitivity of the overall results to these parameters are given in 
the Supplementary Figure C.1. 
  
! 
EQ (1)    
       IF MUTPROBi,j = 0 ,        WSUM i, j = 0
       ELSE
        WSUM i, j  =
ERESFoldi , j
WFold
+
ERESDimeri , j
WDimer
+
ERESPeptidei , j ,k
k=1
10
"
WPeptide
+ FAVORNative + PENALTYPolar#HP
     where MUTPROBi, j encodes whether amino acid type j can be reached by one nucleotide mutation at site i, WFold , 
     WDimer , and WPeptide are the weights for each model constraint considered; ERESFold i, j , ERESDimeri, j , and 
    ERESPeptidei, j,k are the best per - reisude constraint contributions at site i for amino acid j among all ensemble 
     members, and FAVORNativeand PENALTYPolar#HP are as described in the text.  
 
In the final step of our calculations (Figure 4.1C), the weighted sum of ERES 
values was Boltzmann weighted at each HIV-1 protease site, giving rise to amino acid 
mutational frequencies predicted by both the “neutral” and “selective” computational 
models.  
4.3. Methodology 
4.3.1. Determination of mutational frequencies observed in patients 
The “wild-type” HIV-1 protease sequence for subtype B, defined by the Stanford 
HIV database as the consensus sequence, is as follows: 
PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGI
GGFIKVRYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF  
Frequencies of mutation observed in patients after protease treatment at each of 
the 99 HIV-1 protease sites were obtained online from the Stanford HIV drug resistance 
database (Genotype-Treatment Correlations/Treatment Profiles, see 
http://hivdb.stanford.edu/cgi-bin/PRMutSummary.cgi) by using the following settings: # 
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of PIs: 1-9, subtype: B, reference profile: subtype B untreated, exclude single 
occurrences: yes, include mixture: no, one mutation per person. Frequencies under a 
neutral setting were taken from the reference profile (subtype B, untreated) generated 
using the profile settings described above.  Amino acid substitutions occurring in >=0.5% 
of sequences after protease inhibitor treatment are as given in Table 4.1.  
 
4.3.2. Selection of crystallographic structures used for predictions of fold and 
dimer stability  
386 crystallographic structures of HIV-1 protease were obtained from the protein 
databank (PDB) by using the search by sequence feature (Blast e-value 0.001) to retrieve 
structures with sequences similar to 1PRO.pdb (chain A).  Structures which contained 
more than 12 mutations from the HIV-1 subtype B consensus sequence defined above, 
contained only one chain of the HIV-1 dimer, or with cysteine residues replaced 
(heteroatom residue codes ABA, CME, CSO, or DBU) were eliminated. Structures 
determined to be either HIV-2 protease, SIV, Rous sarcoma virus, or tethered dimeric 
HIV-1 were also eliminated. 263 dimeric HIV-1 crystal structures remained (see Supp. 
Table 1) and were collectively used as a crystallographic structural ensemble. The 
majority of structures contained 1-7 mutations (85% or 223/263) and had a 
crystallographic resolution within the range of 1.0 to 2.5 Angstroms (87% or 230/263).  
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4.3.3. Selection of crystallographic structures and generation of model structures 
used for predictions of substrate stability  
16 dimeric, crystallographic structures crystallized with one of 7 endogenous 
peptide substrates were used for all calculations of substrate stability (Supplementary 
Table C.2). We generated structural models for each of the three peptide cleavage 
sequences without crystallographic structures (CTLNF-PISPI, PQITL-WQRPL, and 
VSFNF-PQITL) by computationally threading each peptide cleavage sequence onto each 
of the 16 crystallographic structures (sequence positions for which there was missing 
crystallographic density on any of the 16 peptide template structures were omitted), 
performing an initial round of side-chain minimization, and selecting the structural 
template for which the resulting Rosetta interface score (sum of score contributions over 
all pair wise interactions between residues i and j, where residue i was located on HIV-1 
protease and residue j was located on the bound peptide) was lowest. 1MT9.pdb was 
found to be the best template for both peptides CTLNF-PISPI and PQITL-WQRPL, 
while 1F7A.pdb was selected as the optimal template for VSFNF-PQITL. Peptide 
interface scores for the resulting three models (-18.3 to -25) were within the range 
observed for 16 crystallographic peptides (-18.5 to -33).  
 
4.3.4. Generation of backrub structural ensembles 
Computational ensembles of “near-native” backbones were generated starting 
from one of 11 crystallographic structures originally crystallized with the native 
consensus sequences (1A8G.pdb, 1EBY.pdb, 1HXW.pdb, 1IZH.pdb, 1PRO.pdb, 
1SBG.pdb, 1VIJ.pdb, 1VIK.pdb, 4PHV.pdb, 5HVP.pdb and 9HVP.pdb) by using a 
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previously described backrub protocol [33].  Briefly, the backrub protocol consisted of 
repeatedly selecting C" atoms of two residues (separated by 1-10 intervening residues), 
performing a rigid body rotation of the selected protein segment (of up to 40 degrees), 
optimizing the location of related C# and hydrogen atoms, and accepting or rejecting the 
backbone move based on the Rosetta scoring function and the Monte Carlo Metropolis 
criterion. Using the atomic coordinates of each crystallographic structure above as a 
starting conformation, 100 independent backrub simulations were run at two separate 
Monte Carlo temperatures (kT=0.6 and kT=1.2) until a total of 10,000 moves per 
simulation had been sampled. At each temperature, the lowest energy conformation 
sampled as well as the last conformation accepted during each simulation were saved and 
used to generate a computational ensemble of 400 backbone conformations per starting 
crystallographic structure.  
Average RMSD values of backrub generated conformations relative to the starting 
crystal structures were dependent on the starting template and Monte Carlo temperature 
used, but typically and ranged, on average, from 0.2 to 0.6 for conformations generated at 
a kT of 0.6 and 0.3 to 0.8 for conformations generated at a kT of 1.2.  
 
4.3.5. Energy Function and Preparation of Crystallographic Structures: 
All computational calculations were performed using the Rosetta scoring 
function, which is dominated by attractive and repulsive Lennard-Jones interactions [29], 
an orientation-dependent hydrogen bonding term , and an implicit solvation model  [30]. 
Simulations consisted of sampling and scoring side chains, taken from a rotamer library 
including the native amino acid PDB conformation and with additional rotamers around 
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the chi1 and chi2 side-chain torsion angles, [5] using a Monte-Carlo simulated annealing 
optimization protocol as described in [73].  Minimization and optimization protocols 
were with respect to the sum of the total score over all atoms within the dimeric HIV-
protein (or dimeric HIV-protein substrate) complex.  
In preparation for calculations of fold and dimer stability, all water molecules, 
heteroatoms, bound inhibitors or substrates and hydrogens present in the original 263 
crystallographic PDB structures were removed, and hydrogen atoms were added as 
previously described [73].  An initial round of side-chain optimization was performed 
using the Rosetta scoring function as described above, keeping all amino acid identities 
and backbone coordinates fixed, while selecting for the optimal rotamer at each side-
chain position from the rotamer set described above. After this initial minimization, all 
structures containing amino acid identities differing from the consensus HIV-1 subtype B 
sequence (see above) were computationally reverted to the consensus sequence and the 
structures were side-chain minimized a second time. In preparation for calculations of 
peptide binding stability, a protocol identical to that described above, except leaving all 
bound substrates present, was repeated separately for the 19 crystallographic and model 
structures listed in Supplementary Table C.2.  
4.3.6. Selection of model parameters:  
Optimal values for the six model parameters (WFOLD, WDIMER, WPEPTIDE, 
FAVORNATIVE, FAVORPOLAR NATIVE, and PENALTYNATIVE POLAR, HYDRO) were selected 
by simultaneously varying each model parameter (Supplementary Table C.3) and 
computing predicted amino acid frequencies over 97 (non-cysteine) HIV protease sites. 
For each combination of parameters, the 99 HIV-1 residue sites were computationally 
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classified as displaying either low (1-5%), medium (5-20%), or high (>20%) mutation 
rates and the number of residue sites correctly matching the experimentally observed 
mutation rates was calculated. The percentage of sites correctly determined for each bin 
was then averaged and used to determine a parameter set for both the “neutral” and 
“selective pressure” computational models (see Supplementary Figure C.1 and 
Supplementary Table C.3).  
   
4.3.7. Evaluation of ROC curves and AUC values: 
True positive rates (TPR) and false positive rates (FPR) of mutation recovery 
were calculated by using the parameter values determined above for a “neutral” and 
“selective pressure” computational model (Supplementary Table C.3) and considering all 
mutations computationally predicted to occur at frequencies greater than or equal to the 
following cutoffs: 10%,9%,8%,7%,6%,5%,4%,3%,2%,1%,0.5%,0.1%, and 0.01%. 
Mutations determined to occur at an experimental frequency of >0% (e.g., greater than a 
single occurrence), >=1% and >=5% were considered as true positives in constructing 
ROC curves. ROC curves were constructed for mutations observed within the HIV-1 
Stanford HIV-1 database after treatment with 1-9 protease inhibitors (Figure 4.3). AUC 
values were calculated for each ROC curve by implementing the trapezoid method.   
TPR and FPR rates were calculated for two null models by considering at each of 
the 99 HIV-1 residue sites (1) the set of mutations one nucleotide mutation away from the 
native codon and (2) the set of all mutations to amino acid types chemically similar to the 
native, grouped as follows: (A,G,P),(D,E,N,Q),(F,W,Y), (L,I,V,M),(R,K,H),(S,T), see 
also Supplementary Table C.4. 
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4.4. Discrimination between low, medium, and high frequency 
mutational sites for “neutral” and “selective” models 
We first examined the general ability of the neutral and selective computational models 
to discriminate HIV-1 protease sites tolerant to mutation from other sites observed to 
rarely or never mutate. We calculated how often each model predicted non-native amino 
acid types at every sequence site, and mapped these predictions to the HIV-1 protease 
structure (Figure 4.2B, neutral model; (Figure 4.2D, selective model; red, predicted 
mutational frequencies >20%, red; 5%-20%, orange; 1%-5% yellow). Structurally, the 
computational models qualitatively reproduced the pattern of mutational tolerance 
observed within the HIV Stanford Drug Resistance Database sequences by showing an 
increased frequency of mutation after protease treatment at the substrate interface and at 
the dimer flaps (Figure 4.2A, pre-protease treatment; (Figure 4.2C following inhibitor 
treatment).  
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Figure 4.2 Predicted and Observed HIV-1 Protease Mutational Tolerances.  
Total percentages of non-native amino acid types observed within the HIV-1 Stanford database sequences 
before (A) and after (C) protease treatment are mapped onto the HIV-1 protease structure at every site 
(excluding 25D, 67C, and 95C). Total percentages of non-native amino acids predicted by the neutral (B) 
and selective (D) computational model are also shown. Colored spheres indicate observed and predicted 
frequencies of mutation: >20%, red; 5-20%, orange; and 1-5% yellow. Sites with predicted or observed 
mutation to non-native amino acid types <1% are shown only in cartoon. For clarity spheres are shown 
only on chain A. Tables show the overlap between predicted and observed mutational frequencies. Grey 
shading denotes the number of sites for which the computational model under-predicted mutational 
tolerance with respect to the database sequences. Brown shading depicts sites predicted to have a higher 
tolerance to mutation than observed in the database sequences.  
 
Both models correctly identified ~72% of the sites at which mutation in the database 
sequences was rare or altogether absent (identifying 45/63 sites and 31/43 sites for the 
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neutral and selective models, respectively). Equally important, the neutral model 
identified 5 out of the 7 sites most frequently mutated prior to protease treatment (35, 37, 
62, 63, and 77) and the selective model identified 8 out of 14 sites most frequently 
mutated after treatment (10, 35, 37, 46, 62, 63, 71, and 77).  It was rare for the 
computational model to predict a site to have low or no tolerance to mutation while the 
Stanford database indicated otherwise (grey shading  
Figure 4.2E, F).  However, a few cases of under-predictions of mutational 
tolerance did occur, most notably at site 93 for the neutral model (predicted 0.8%; 
database 33.7%) and site 90 for the selective model (predicted 0.01%; database 30.7%).  
Both models had a weak tendency to over-predict mutational frequencies when compared 
to the available sequence mutation database (brown shading,  
Figure 4.2E, F), especially at the beta-sheet pairing of the dimer interface and 
dimer flaps. In the case of the neutral model, some of these mutations appear to be at 
least marginally tolerated by the protease fold, as they become more frequently observed 
after protease inhibitor treatment (such as at sites 30, 74, 45-47, 55, and 88).  Likewise, 
many mutations at sites that remain “over-predictions” even in the selective model did 
occur, though at a very low frequency, within the Stanford HIV sequence database (data 
not shown). We discuss over-predictions of the model further in detail below.   
 
4.5. Evaluation of prediction of specific amino acid types tolerated at 
each site 
Having shown that each model is able to successfully discriminate the overall 
tolerance to mutation at many HIV protease sites, we next evaluated whether the models 
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were able to correctly capture the specific amino acid types observed in the Stanford 
database. We focused on evaluating the performance of the selective pressure model, as 
the mutations observed in the absence of protease are primarily a smaller subset of the 
mutations observed and predicted under selective pressure (data not shown).  
Table 4.1 gives a complete listing of mutations predicted by the selective model 
and compares the predicted frequencies to those observed in the HIV Stanford database 
after protease inhibitor treatment.  Mis-sense mutations experimentally found in to 
display a wild-type phenotype for peptide cleavage and HIV viral replication are also 
shown [106]. This study evaluated roughly 50% of all mutations reachable by a single 
nucleotide change from the HIV-1 protease consensus sequence. Model predictions 
matching amino acid types observed in the Stanford database sequences or the set of 
experimentally characterized point-mutants displaying wild type behavior are shown in 
bold, red typeface. Residue types unlikely to be predicted by the selective model, as they 
are greater than one nucleotide mutation away from the native residue type (WSUM = 0), 
are shown in blue.  
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Table 4.1 Comparison of computationally predicted HIV-1 protease mutations to clinical mutations 
and mutations with a wild-type phenotype after mis-sense mutagenesis 
The subtype-B consensus amino acid type for each of the 99 HIV-1 protease sequence positions is listed in 
column 1.  Non-consensus amino acid types computationally predicted to be tolerated by the selective 
model are given in column 3.  Superscripts denote predicted frequencies of occurrence..  Column 2 gives 
the predicted frequency with which the native amino acid will mutate at each site (1-probability(native)).  
Column 4 lists the predicted mutational frequency of each site, as given by the Stanford database (see 
Section 4.3.1). The frequency of occurrence of all mutations found at each site within the Stanford database 
is given in Column 5. Only amino acids predicted by the model or observed within the database at a 
frequency greater than 0.5% are shown.  Column 6 lists amino acid types experimentally observed to 
display the wild-type phenotype at each position, as taken from [106].  This study tested approximately half 
of  all possible mis-sense mutations.  Red coloring denotes a computationally predicted amino acid type 
Selective Model Stanford Database
Mis-Sense 
Mutagenesis
% Non-
Native
Predicted 
Mutations
% Non-
Native
Observed 
Mutations
Observed 
Mutations
51G 0 -- 0.1 -- --
52G 0 -- 0 -- --
53F 3.9 Y4 3.9 L4 Y I L V
54I 1.1 V1 21.9 V18 L2 M1 T1 A1 L
55K 22 T9 N5 I4 Q2 R1 E1 2.5 R3 R T I N Q
56V 0.6 F1 0 -- --
57R 0.5 K1 9.2 K9 K  
58Q 18.0 K8 E7 R3 3.4 E3 E 
59Y 0 -- 0 -- --
60D 8.9 N7 E1 8.7 E9 E
61Q 4.2 K1 R1 E1 4 E3 H1 N1 R 
62I 20.3 V20 29.7 V30 L
63L 88.2 P83 Q2 I1 V1 85.1 P72 S4 A4 T3 Q2 H1 I V P R
64I 3.0 V3 22.9 V20 L2 M1 L 
65E 26.1 V14 D11 K1 Q1 1.7 D2 --
66I 0.5 V1 1.5 F1 L V F 
67C NA NA NA NA NA
68G 0.1 -- 0.3 -- --
69H 59.1 Y20 Q18 L13 D3 R3 N1 7.5 K3 Q2 Y1 R1 N1 R L Y Q
70K 9.0 R4 T4 Q1 N1 3.2 R3 T N 
71A 81.8 T55 V24 S2 38.9 V27 T10 I2 L 
72I 79.4 R48 K21 S4 V3 N2 M1 T1 14.6 V8 T3 M1 L1 E1 T L V
73G 0 -- 10.3 S8 T2 --
74T 4.7 K2 S1 R1 6 S4 A1 P1 S
75V 0.3 -- 0.7 I1 --
76L 1.4 F1 1.4 V1 --
77V 28.3 F24 I4 32 I32 --
78G 0 -- 0 -- --
79P 0 -- 0.7 -- --
80T 13.5 S13 0 -- --
81P 0.5 -- 0 -- --
82V 7.1 A2 M2 E1 I1 G1 26.4 A20 T3 I2 F1 S1 I L T 
83N 2.5 D1 K1 0.2 -- --
84I 3.1 V2 L1 11.3 V11 --
85I 5.2 V4 L1 2.8 V3 --
86G 0 -- 0 -- --
87R 0 -- 0 -- --
88N 9.2 K6 D2 S1 9.4 D7 S2 --
89L 0 -- 2.6 M1 V1 V
90L 0 -- 30.7 M31 --
91T 4.3 S2 A1 R1 0.1 -- A N
92Q 3.2 L1 E1 R1 2.5 K1 R1 L 
93I 7.5 L7 T1 33.7 L34 M V F 
94G 0 -- 0 -- --
95C NA NA 0 NA NA
96T 0.4 -- 0 -- --
97L 0.3 -- 0 -- --
98N 61.3 T48 I5 S5 D2 K1 0 -- S
99F 0.4 -- 0.1 -- L 
Selective Model Stanford Database
Mis-Sense 
Mutagenesis
% Non-
Native
Predicted 
Mutations
% Non-
Native
Observed 
Mutations
Observed 
Mutations
1P 15.8 Q11 R2 T1 L1 S1 0 -- L H
2Q 1.6 K1 E1 0.1 -- E
3I 4.0 V3 L1 0.1 -- L N 
4T 1.2 S1 0.1 -- S
5L 0.2 -- 0 -- --
6W 80.4 S45 L29 R5 0.1 -- G L
7Q 0.2 -- 0.3 --  H
8R 0.3 -- 0 -- --
9P 0 -- 0 -- S
10L 21.55 I11 V9 M1 F1 42.7 I33 V4 F4 R1 I V
11V 0 -- 0.8 I1 I 
12T 7.0 P4 K1 R1 9.2 S3 P2 A2 I1 K1 N1 S I
13I 1.9 V1 19.3 V20 V 
14K 16.9 I6 T5 R1 Q2 8.6 R9 T M N Q 
15I 1.6 M1 V1 17.3 V17 V
16G 0 -- 3.6 E3 A1 --
17G 0 -- 0.8 -- --
18Q 3.2 L2 E1 K1 1.6 H1 L H R
19L 17.0 V7 I4 F3 Q1 R1 P1 9.8 I7 V1 Q1 T1 T
20K 6.7 R3 Q3 T1 18.4 R8 I5 T3 M2 M 
21E 9.0 V4 Q3 K1 0 -- Q V K
22A 3 S3 0.4 -- --
23L 0.7 -- 0.8 I1 --
24L 8.4 I8 V1 5.1 I5 --
25D NA NA NA NA NA
26T 0.6 S1 0 -- --
27G 0 -- 0 -- --
28A 3.6 S4 0 -- --
29D 0 -- 0 -- --
30D 15.8 E6 H5 N4 12.0 N12 E 
31T 0 -- 0 -- --
32V 21.3 I21 3.7 I4 L  
33L 0.5 -- 7 F4 I1 V1 V  
34E 12.2 K7 D2 Q2 G1 1.4 Q1 A
35E 35.6 D21 G12 Q2 29.5 D30 G1 S 
36M 5.0 I3 T2 V1 28.7 I26 V2 L1 I
37N 30.6 D30 32.8 D14 S11 E3 T3 H1 A1 --
38L 0.8 I1 0 -- --
39P 3.6 T3 S1 2.0 S1 Q1 T 
40G 0 -- 0 -- --
41R 7.2 K4 G2 18.9 K19 K I
42W 0.1 -- 0 -- G
43K 37.0 T21 Q12 E2 N2 R1 2.74 T3 R1 N Q 
44P 0.3 -- 0 -- T R
45K 17.8 R11 T5 Q2 2.4 R2 R T Q
46M 98.2 I42 L30 V24 T2 K1 27.5 I18 L9 L
47I 100 T82 V18 1.7 V2 --
48G 0 -- 3.8 V4 S H 
49G 0 -- 0 -- --
50I 4.8 L3 V1 1.5 V1 L1 L
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that was also observed either in the database or the mis-sense mutagenesis study.   Blue coloring denotes 
amino acid types unlikely to be predicted computationally as they require two mutations at the DNA level.  
In contrast to other studies that focus on the substrate and inhibitor binding sites 
to model emergence of HIV-1 resistance mutations [100, 107], the selective model we 
present here was able to predict a wide variety of specific amino acid types observed at 
all sequence sites, regardless of structural location.  At many positions distant from the 
substrate binding site (10-20, 31, 33-45, 55-79, 83, 85, and 88-89) the amino acid types 
selected by the model showed strong agreement with the observed sequence tolerances. 
Sites such as 11V, 17G, 31T, 38L, 40G, 42W, 44P, 56V, 59Y, 68G, 75V, 78G, and 79P 
were correctly predicted to be intolerant or barely tolerant to mutation while other sites 
such as 10L, 12T, 14K, 19L, 20K, 35E, 36M, 37N, 39P, 43K, 45K, 55K, 63L, 69H, 70K, 
71A, 85I and 88N had strong overlaps in the predicted and observed amino acid types. 
(Note that we denote sites by the sequence position followed by the one-letter-code of the 
amino acid residue present in the consensus sequence).  Model performance at sites near 
the substrate-binding site (23-30, 32, 80-82, 84, and 86-87) and dimer flaps (46-54) was 
also strong. Sites of low or no tolerance to mutation were correctly identified both within 
the binding site (23L, 26T, 27G, 29D, 81P, 86G, 87R) as well as within the glycine rich 
dimer flaps forming the upper portion of substrate binding cavity (49G, 51G, 52G; 48G 
was incorrectly predicted to be intolerant to mutation by the model). Sites frequently 
shown to mutate after inhibitor treatment either within the substrate-binding site (24L, 
30D, 32V, 82V, and 84I) or dimer flaps (46M, 47I, 50I, 53F, and 54I) were also 
identified with high fidelity. For each of these sites, the model was able to correctly 
predict all specific amino acid types observed in the mutational database, with a few 
exceptions at sites 53, 54, and 82.   
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As noted above, the model performed less well for several sites within the beta 
sheet pairing of the dimer interface (1-9 and 90-99). Database sequences showed almost 
no tolerance to mutation at these sites, with exceptions at sites 90 and 93. In contrast, the 
model predicted a moderate or high tolerance to mutation at numerous dimer interface 
sites (2Q, 3I, 4T, 91T, and 92Q, showed moderate to small over-predictions while 1P, 
6W and 98N showed large over-predictions) while under-predicting tolerance to mutation 
at sites 90 and 93.  In some cases, amino acids at the dimer interface predicted by the 
model but not observed in the Stanford database sequences were functionally tolerated 
when sampled during the in vivo screen.  
With the exceptions noted above for the beta-sheet dimer interface sites, the 
overall frequencies of mutation predicted by the model matched the mutational 
frequencies observed within the Stanford database fairly well. The model correctly 
predicted every mutation observed in 3% or more of the database sequences, except in 
nine cases. Mutations T12S, L33F, N37S, F53L, and L90M were predicted by the model 
at a very low frequency (0.01%-0.03%; Table 4.1 shows only predicted and observed 
frequencies >=0.5%) and mutations G16E, K20I, G48V, and G73S were not tolerated at 
all by the model. Other under predictions of mutational tolerance occurred for four 
mutations distal to the binding site (I13V, I15V, M36I, and I64V) and two positions near 
the substrate binding site or dimer flaps (I54V and V82A), where the model predicted 
mutations at much lower frequencies (1%-3%) than observed within the database 
sequences (17%-26%). A possible explanation for the low predicted frequencies at these 
sites may be that the experimentally observed mutations are highly destabilizing or 
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require the presence of additional compensatory mutations, whereas our model only 
considers single, independent mutations  
As discussed above, over-predictions of tolerance to mutations by the model with 
respect to the Stanford database sequences also occurred at several sites. The majority of 
such over-predictions occurred for solvent exposed residues (21E, 43K, 45K, 55K, 65E, 
69H, and 72I). At many of these sites, amino acids predicted by the model were found 
within the experimental mis-sense mutagenesis data, suggesting that the model might be 
predicting mutations functionally tolerated by HIV protease but not observed at high rates 
clinically. Over-prediction at other structural sites was rare, but did occur for two 
positions contacting the substrate-binding site (32V, 47I), one position in the dimer flap 
(46M) and one core residue (71A). Finally, we note that some computationally predicted 
mutations not currently observed with the Stanford sequence database might be yet to be 
recognized resistance mutations. At least three mutations (M46V, F53Y, and N83D) 
predicted by the selective computational model, but not appearing in the database 
sequences at appreciable frequencies, have now been identified as HIV drug resistant 
mutations[108, 109]. 
 
4.6. Evaluation of Overall Model Performance  
In order to quantify the overall performance of the selective model using a 
standard metric, we calculated true positive (TPR) and false positive (FPR) rate of 
identifying HIV Stanford database mutations occurring at three different frequencies 
(Figure 4.3, black curves; grey curves will be discussed below). Each of 1,746 possible 
mutations (18 amino acid types, excluding the native amino acid residue and cysteine, 
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allowable at 97 sites) was computationally classified as either tolerated or forbidden 
based on whether their predicted frequency was greater than a given computational 
threshold (see Section 4.3.7). These predictions were then compared to the set of 
experimental frequencies, and receiver-operator characteristic (ROC) curves were 
constructed.  
 
Figure 4.3 Model ROC curves and AUC values.  
Receiver operator curves (ROC) were constructed to determine the overall model performance in 
identifying mutations observed within the HIV-1 Stanford database sequences above three thresholds. ROC 
curves for predictions of mutational tolerance generated by calculating optimal ERES scores calculated 
from a crystallographic ensemble of structures are depicted by black circles in all panels in (A) and (B). 
Panel (A) also shows 9 representative ROC cures, depicted by grey circles, for predictions of mutational 
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tolerance made using ERES scores taken from fixed backbone structures crystallized in the absence of 
mutation. Each of these fixed backbone structures was used as a starting template to computationally 
generate a “backrub” ensemble of structures as described in Section 4.3.4. Panel (B) shows the resulting 
ROC curves when predictions of mutational tolerance were calculated using the optimal ERES scores 
observed among each of 9 representative “backrub” ensembles (grey circles). Area under the ROC curves 
(AUC) are shown for predictions made using the full crystallographic ensemble (black triangles in (A) and 
(B)), predictions made independently using each of the 263 crystal structures as a single fixed backbone 
template (grey box-plots in (A)), and predictions made using 11 backrub ensembles, each generated from a 
different structure originally crystallized in the absence of mutation (grey box-plots in (B)). The two null 
models described in the text (single mutation at the nucleotide level and amino acid types chemically 
similar to native) are denoted by a square and asterisks, respectively. 
 
The selective model was very successful at identifying mutations appearing in 
over 5% in the inhibitor treated database sequences, finding over 85% of mutations 
correctly with a FPR of under 10%.  The model performed somewhat less well at 
predicting mutations occurring in >1% or >0.01% of sequences within the database, but 
still identified around 80% of known mutations, with an error rate just under 20%. For 
comparison, we also calculated TPR and FPR for two simplified null models by selecting 
amino acids at each sequence site that (i) were chemically similar to native or that (ii) 
were accessible by a single base change at the nucleotide mutation level from the native 
(subtype B consensus) sequence (asterisks and squares, respectively, in Figure 4.3; see 
also Supplementary Table C.4). The null model consisting of selecting only amino acids 
chemically similar to native eliminated a much larger fraction of the total possible 
mutational space than the null model of nucleotide substitution. This resulted in the 
chemically similar null model incorrectly eliminating many mutations observed within 
the database sequences, and resulted in a TPR ~20-30% less than the null model of 
nucleotide substitution. On the other hand, while the set of amino acids one mutation 
away from native at the nucleotide level contained the more of the experimentally 
observed mutations, it also contained ~30% more false positives than seen when taking 
only amino acid types chemically similar to native. In contrast, the selective 
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computational model, which uses estimates of mutational effects on stability and function 
to select tolerated amino acid types, selects less false positives (~20% less) than the null 
nucleotide mutational model while, at the same time, selecting more true positives (~10-
20% more) than a null model of chemically similar amino acid types.   
 
4.7. Prediction of known major and minor drug resistance mutations 
(DRMs) 
We next examined in detail the trade-offs in fold, dimer, and substrate stability 
predicted by the model for several known major and minor drug resistance mutations 
(DRMs) [110]. Major and minor DRMs typically both show an increased frequency of 
mutation after protease inhibitor treatment, while only major DRMs are defined as those 
that have been directly implicated in inhibitor resistance.  Figure 4.4 shows mutations 
identified by [110] to be major (black squares, Figure 4.4D) or minor (grey squares, 
Figure 4.4D) DRMs with respect to 8 protease inhibitors used in the clinic (data for all 
drugs except Nelfinavir (NFV) are considered in the context of combination with a 9th 
protease inhibitor, Ritonavair (RTV)). For each major and/or minor DRM, the predicted 
change in  score, relative to the native residue type, for fold stability (Figure 4.4A), 
dimer stability (Figure 4.4B), and peptide binding affinity predicted by the model (Figure 
4.4C) is shown.  With the exception of a small number of DRMs strongly 
disfavored by the model for requiring more than one nucleotide mutation from native 
(blue labels, 3 major DRMs and 6 minor DRMs), the model was able to predict 
mutational tolerance for 80% of the known minor DRMs and major DRMs (16/20 and 
! 
ERES
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34/42, for major and minor DRMs, respectively; red labels, predicted tolerated; black 
labels, predicted not tolerated).   
Most major DRMs were predicted to have a large, destabilizing effect on at least 
one of the 10 tested endogenous peptides (ERESPEPTIDE score changes are shown as the 
change in the sum of scores for all 10 peptides before and after introducing the mutation). 
This suggests that at least in some cases DRMs may be able to appear and cause 
disruptive changes even within the “substrate envelope” (put forth in [111] and [112] as 
the consensus volume occupied by the set of natural substrates). It has been shown that 
HIV-1 protease peptide cleavage sequences can, in some cases, co-evolve along with the 
appearance of DRMs, and this mechanism may allow for some compensation of this 
predicted peptide destabilization[113, 114] [115-117]. In addition, a few major DRMs 
predicted to have destabilized peptide affinity were also predicted to have additional 
negative effects on fold and/or dimer stability. Mutations at sites 47 and 50 were 
predicted to greatly destabilize the dimer interface, while other mutations were predicted 
to either moderately (82F/L/I/A, 47V, 84V) or strongly (48V, 47A and 53L) destabilize 
the protease fold. At least some of these predicted destabilizing effects may require the 
presence of minor DRMs or other stabilizing mutations in order to maintain native viral 
efficiency.  
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Figure 4.4 Model prediction of major and minor DRMs.  
Calculated changes in ERESFOLD, ERESDIMER, and ERESPEPTIDE scores (relative to that native, consensus 
subtype B) are given in (A), (B), and (C) for each drug resistance mutation identified by REF. Mutations 
identified as major (black squares in (D)) or minor (grey squares in (D)) drugs resistance mutations are 
shown with respect to each of 8 drugs (ATZ, Atazanavir + Ritonavir; DRV, Darunavir + ritonavir; APV, 
Fosamprenair + Ritonavir; IDV, Indinavir + Ritonavir; LPV, Lopinavir + Ritonavir; NFV, Nelfinavir; 
SQV, Saquinavir + Ritonavir; TPV, Tipranavir + Ritonavir). ERESPeptide score changes are shown as the 
change in the sum of scores for all 10 peptides before and after introducing the mutation. Note that reliable 
ERESPEPTIDE scores could not be calculated for mutations at residue 47 due to a large steric clash between a 
modeled peptide and the native residue at that site.  Blue labels denote mutations not predicted as tolerated 
by the selective computational model, as the required two DNA mutations from native.  
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For a few major DRMs (90M, 76V, 54M/L and 33F) there were no predicted 
destabilizing effects at the substrate-binding interface. Instead each of these mutations 
was predicted to be strongly destabilizing to protease fold stability, and in two cases 
(90M, 54M) also predicted to be destabilizing to the dimer interface. This suggests that 
larger scale structural changes or the presences of compensatory co-mutations might also 
be necessary in order for the HIV protease fold to accommodate these major DRMs. 
Interestingly, there were also a few DRMs at sites which neither contact the peptide 
substrates nor form the dimer interface. These DRMs were predicted to either stabilize 
(46L, 46I, 58E) fold or peptide stability or be mostly neutral (88S, 74P) with respect to 
all structural and functional constraints considered. These predicted neutral mutations 
may play a role correlated with other DRMs in affecting fold, dimer or peptide stability. 
Moreover, the predicted stabilizing mutations may be important in alleviating the 
negative effects of other simultaneous sequence changes.  
For the minor DRMs, we observed a different pattern of stability effects. 
Approximately half of minor DRMs were predicted to have large to moderate 
destabilizing effects on fold stability (such as 36I/L/V, 11I, 16E, 33F, 54V/T), while the 
other half were predicted neutral or stabilizing with respect to fold stability (such as 83D, 
77I, 20T, 20R, 62V, 71I/T/V). The predicted destabilizing effects of at least a few minor 
DRMs could be relieved by the presence of additional compensatory (or correlated) 
mutations while the stabilizing minor DRMs could themselves play a compensatory or 
complementary role to the destabilization seen in the major DRMs. Of the minor DRMs, 
mutations at site 54 and 93 were predicted to destabilize the dimer stability. Whether this 
dimer destabilization would be able to be compensated for by additional accumulation of 
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mutations, or whether the destabilization itself is playing a functional role in drug 
resistance is unclear.  
 
4.8. Importance of backbone flexibility: Crystallographic versus 
computationally generated conformational ensembles  
Finally, we compared predictions made using multiple structural backbone 
templates (representing various conformational “snapshots” of HIV-1 protease backbone 
flexibility), to predictions made by selecting just one HIV protease backbone to use as a 
template for the calculations. To test this, we compared predictions of mutational 
tolerance made using ERESFOLD and ERESDIMER scores obtained from a single crystal 
structure (fixed backbone) with the previously presented model results which had 
calculated optimal FOLD and DIMER scores over a set of crystallographic 
ensemble members (identical PEPTIDE scores and parameters were used in all 
calculations). As noted above, many of the HIV-1 protease ensemble members originally 
contained a small number of non-native substitutions. Thus it is possible that at least 
some of the variation observed among the crystallographic ensemble members might be 
due to structural changes and/or accommodations directly resulting from the original 
presence of non-native substitutions. To remove any such “memory” of mutations 
originally present at crystallization, we examined fixed backbone predictions made on 
each of 11 structures originally crystallized with the native subtype B sequence 
Independent of which single crystallographic structure was used for the 
calculations, we found ROC curves from each fixed backbone model to perform much 
worse than the original model, which incorporated structural information over an 
! 
ERES
! 
ERES
! 
ERES
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ensemble of backbones (Figure 4.3A, grey lines show 9 representative ROC curves, each 
generated using a single crystallographic HIV-1 protease structure). Comparison of the 
area under the ROC curves (AUC) generated by every possible single backbone 
computational model (Figure 4.3A, grey box plots, AUC calculated for predictions made 
on each of the 263 crystallographic ensemble structures as a single fixed backbone) to the 
AUC obtained from the original ensemble model (Figure 4.3A, black triangle), showed 
that predictions made using a single fixed backbone structure were in no case able to 
match the performance seen by using the entire ensemble of structures.  
We then asked whether, starting from a single fixed backbone structure, we could 
computationally generate an ensemble of structures that would convey structural 
information similar to that seen in the original crystallographic structural ensemble. If 
true, this would enhance the general applicability of the model presented here for 
predicting mutational tolerance in other protein targets for which there might not be as 
large an ensemble of crystal structures available. Using each of the 11 HIV-1 protease 
structures crystallized in the absence of mutation as independent starting templates, we 
computationally generated ensembles of “near-native” backbone conformations by using 
a backbone flexibility move termed “backrub” [33] (see Section 3.3.3; the RMSD of each 
ensemble member to the original starting template varied, but was less than 0.5 
Angstroms for most backbone conformations, and never exceeded 1.4 Angstroms for any 
ensemble member; for RMS fluctuations see Supplementary Figure C.5). Each 
computational ensemble was used to model all single-point mutations as described above 
for the crystallographic ensemble and the lowest ERESFOLD and ERESDIMER scores seen 
among the backrub ensemble members were selected and used in Eq(1) and Eq(2) to 
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predict mutational tolerance. Remarkably, independent of which starting fixed backbone 
structure had been used, model predictions made on any of the 11 computationally 
generated ensembles resulted in ROC curves and AUC values virtually indistinguishable 
from predictions made using the original crystallographic ensemble (Figure 4.3B).  
 
4.9. Structural and energetic implications for representative 
mutations  
In order to gain insight into how structural flexibility might improve predictions 
of HIV-1 protease mutational tolerance, we examined model predictions at several sites 
in greater detail. We focused on several mutations that had been originally present in at 
least one of the 263 HIV-1 protease crystal structures (all such sites, including the 
number of crystal structures originally containing each specific mutation, are given in 
Supplementary Figure C.3 and Supplementary Figure C.4). Predictions made using the 
full crystallographic ensemble, which included one or more structures containing a 
backbone conformation originally crystallized with the amino acid substitution under 
consideration) were then compared to predictions made using single fixed backbone 
structures crystallized in the absence of any mutations.   
Figure 4.5A shows two mutations (I62V and M46I) for which predictions made 
on a crystallographic ensemble, single fixed backbone, or backrub generated ensemble 
were all equally accurate in predicting the frequency with which a mutation was observed 
in the HIV Stanford database (red bars). At such sites the predicted frequency of mutation 
made using the full crystallographic ensemble (black bars) was similar to the median 
prediction resulting from using any one of 11 single fixed backbone structures (grey 
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bars). Further, computational introducing flexibility by generating a backrub ensemble 
from each of the fixed backbone structures (grey striped bars) resulted in virtually 
identical predictions.   
 
 
Figure 4.5 Comparison of predicted frequencies with and without backbone flexibility.  
The frequency with which 8 mutations were predicted when using either an ensemble of backbones or a 
single fixed backbone structure are compared with the frequency with which each mutation was observed 
to occur in patients treated with HIV-1 protease inhibitors in the Stanford database (red bars). Black bars 
denote predicted mutational frequencies observed when using optimal ERES scores calculated using the 
full ensemble of 263 crystal structures. Grey bars give the mean mutational frequencies observed when 
ERES scores were taken from 11 fixed backbone structures, crystallized in the absence of mutation. Grey 
striped bars depict the mean mutational frequencies observed after each of the 11 fixed backbone structures 
was used to computationally generate an ensemble of “backrub” structures, and these ensembles were used 
to predict optimal ERES values. Vertical bars denote the maximum and minimum mutational frequency 
observed.  
At other sites, we observed that incorporation of flexibility (via using either a 
crystallographic or backrub ensemble) resulted in mutational frequencies more inline 
with frequencies observed in the Stanford database (Figure 4.5B). In many such cases, we 
observed ERES scores calculated on single fixed backbones were often fairly “flat” (e.g. 
similar for all 19 amino acid types) in comparison to  scores calculated over 
crystallographic or computational ensembles of backbones (data not shown). This 
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phenomenon was likely responsible for the significant reduction in the FPR rate observed 
for backrub ensembles as compared to fixed backbone in Figure 4.3. (Note that in a few 
cases the FPRs for fixed backbone models were actually greater than the null model of 
nucleotide substitution; this indicates that fixed backbone predictions at some sites had 
ERES values so flat that amino acid types with WSUM values set to zero were 
occasionally selected as tolerated).   
In a few cases, flexibility appeared to be crucial for correctly predicting tolerance 
to mutations observed within the Stanford database. Figure 4.6 shows two cases where 
large to moderate clashes are observed upon modeling a mutation onto fixed backbones 
structures (top row; 71V, left-side panel and 93L, right-side panel). In each case, the 
clashes were resolved when the mutation was modeled onto a backbone computationally 
generated from each fixed backbone structure (middle row). Further, the mutations 
modeled onto the computationally generated backbones had structures and ERESFOLD 
scores comparable to those seen in crystallographic structures, which had originally 
contained the mutation (bottom row; ERESDIMER and ERESPEPTIDE scores not shown). 
Figure 4.5C confirms that the mutations 71V and 93L were predicted to be tolerated 
when modeled onto either crystallographic or backrub ensembles, but never when 
modeled onto a single fixed backbone crystallized in the absence of mutation. Other 
mutations for which we observed a similar trend included 24I and 77I.    
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Figure 4.6 Example A71V and M93L structural models.   
Mutations A71V (left) and M93L (right) result in large to moderate steric clashes when modeled onto two 
fixed backbone structures, crystallized in the absence of any mutations (top row). Each fixed backbone 
structure was used as a starting template to computationally generate an ensemble of backrub backbones. 
The optimal “backrub” backbone (e.g. the one with the lowest calculated ERESFOLD score), alone with its 
calculated ERESFOLD score, selected when using each of two fixed backbone starting structures is shown 
for each mutation (middle row). For comparison, ERESFOLD scores and structures are shown for two 
members within the crystallographic ensemble that had originally contained A71V or M93L at the time of 
crystallization (bottom row).   
 
Finally we noted that several mutations within the Stanford database sequences 
that had been poorly predicted when using the full crystallographic ensemble were 
observed to be tolerated when using computationally generated ensembles (Figure 4.5D; 
note 33F and 12S were discussed above as representative “failures” of the selective 
model). These mutations were also predicted (at much smaller frequencies) by a few 
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fixed backbone structures. This same trend was further observed in other mutations 
under-predicted by the crystallographic model including 13V, 15V, 53L and 64V 
(Supplementary Figure C.3).  
 
4.10. Discussion 
We have shown an all-atom, computational model that incorporates structural and 
functional constraints on mutational tolerance is able to predict a large portion of the 
clinically observed HIV-1 protease sequence space. We note that we have used a 
previously published and established energy function and design protocol, and that there 
was no explicit parameterization with respect to the actual identities of amino acids 
selected to be tolerant or intolerant to mutation at each protease site. Instead, only the 
relative frequencies with which the various structural and functional constraints operated 
(as well as a new solubility parameter PENALTYPOLAR->HP) were optimized in order to 
best predict overall mutational tolerance (Supplementary Figure C.1).  
The model we present makes testable hypotheses about the effects of specific 
mutations on the stability of HIV-1 protease fold, dimer interface, and substrate binding 
that, in some cases, can be experimentally verified.  For example, the model predicted 
large substrate destabilization effects for V47A and V82A/F/T and these mutations are 
known to display increased viral replication in viruses with mutations in either the NC/p1 
or p1/p6 cleavage sites [90, 117, 118]. Likely, these cleavage site mutations are relieving 
destabilizing clashes predicted by the model at the substrate-binding interface. In another 
example, incorporating A71V (predicted by the model to stabilize the protease fold) into 
double and triple mutants with reduced replicative ability containing either 36I/54V or 
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36I/54V/82T (all predicted to be destabilizing) has been shown to improve replication to 
better than the wild-type virus levels [119]. While the exact magnitude of stabilizing and 
destabilizing trade-offs predicted by the model for each individual mutation is only an 
estimate, the patterns of compensatory effects and functional tradeoffs may nevertheless 
be informative in understanding the numerous sequence mutations observed with HIV-1 
protease.  
It is important to note that the model presented here attempts to explain the 
complex mutational patterns observed within clinical HIV-1 protease sequences only by 
considering additive effects of independent, single point mutations. While we have 
shown this simplifying assumption can still lead, in many cases, to good predictions of 
HIV-1 protease mutational tolerance, correlations among the appearance of HIV drug 
resistance mutations have been widely observed [120, 121].  In a few cases, under-
predictions in the model may be due to ignoring non-additive effects of correlated 
mutational changes. For example, the mutations 30N and 88D have been found to co-
vary, and while the model predicts mutational tolerance for both mutations, the 
frequencies predicted are less than seen in the database sequences for each mutation.  We 
are exploring methods to expand the current model by more directly including and 
modeling non-additive mutational effects.  
In several cases, non-active site mutations have been hypothesized to play a role 
in inducing conformational changes that would directly allow active-site mutations to be 
structurally tolerated. This idea could also be easily explored by using an iterated version 
of the model of computational flexibility already presented. An initial mutation could be 
computationally introduced and this mutated structure could be used as a structural 
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template for generating an ensemble of “backrub” backbones. ERES scores for a 
secondary mutation on this ensemble could then be compared to the ERES scores 
observed when scored on an ensemble generated the absence of any initial mutation.  
One of the strongest conclusions from the work we present here is the importance 
of incorporating backbone flexibility in predicting the mutational tolerance of HIV-1 
protease. Structural changes to accommodate mutations have been noted in several 
crystallographic studies [122]. Flexibility has also been shown to be important in 
accurately predicting substrate docking and protein-inhibitor binding energies of HIV-1 
point mutants, and changes in protein dynamics after mutation has been widely observed 
in several molecular dynamics studies [123, 124]. We provide evidence that the protocol 
presented here for computationally generating backbone flexibility may be able to 
directly mimic structural information contained within a set a diverse crystallographic 
structures, as predictions of HIV-1 mutational tolerance were similar regardless of 
whether an ensemble consisting of crystallographic or computationally generated 
structures was used. This was surprising, as the conformational variation included within 
the ensemble of crystallographic backbones included changes induced by substrate and 
inhibitor binding, as well as structural changes induced by over 65 mutations, some 
crystallized as point mutations and others in the context of multiple mutations. Use of 
crystallographic ensembles to model protein conformational flexibility has been 
described by Vendruscolo and coworkers and shown to be consistent with protein 
dynamics detected using nuclear magnetic resonance [125]. In this work B-factors 
calculated over the computationally generated “backrub” ensembles showed a striking 
similarity to B-factors calculated over the ensemble of crystallographic structures 
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(Supplementary Figure C.5), as well as to B-factors observed in previous molecular 
dynamics studies (data not shown, see for example [126]). Thus it is plausible that 
“backrub” ensembles are sampling a significant portion of dynamic conformations 
accessible to HIV-1 protease. Finally we note that previous studies on a variety of other 
protein systems have found computationally generated “backrub” ensembles to improve 
predictions of side chain dynamics [78], conformations of single point mutations [33], 
and sequence diversity at protein-protein interfaces [2].  
The approach we present here differs from numerous other studies that have 
studied the structural [127, 128] and functional effects [105, 129-131] of HIV-1 protease 
mutation on inhibitor binding, by instead making predictions of the mutational effects on 
the HIV-1 protease structure and function in the absence of any bound inhibitor structure. 
We imagine the two approaches may be complementary. At least one study so far has 
shown incorporation of site-specific sequence variability (determined from sequence 
conservation) may improve the ability of computation to correctly predict drug resistance 
mutations over consideration of changes in inhibitor binding energies alone [132].  
This work also addresses HIV-1 protease substrate recognition and binding from 
an approach that may complement other studies predicting plasticity among the peptide 
sequences recognized and cleaved by the native HIV-1 protease sequence [133, 134]. 
Several non-native mutations predicted by our model are predicted to have significant 
destabilizing effects on substrate binding. Predictions of mutational changes to substrate 
peptide sequences that could offset predicted destabilizing effects of non-native HIV-1 
protease mutations could prove useful for examining co-evolution between the sequences 
of HIV-1 protease and its endogenous substrates. Further, overall model performance, 
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especially at the beta-paired dimer interface, might be improved by the use of any 
number of established peptide docking or modeling tools. In this work we modeled three 
HIV-1 protease-bound peptide complexes by using simple sequence threading. Use of 
more sophisticated protein-substrate modeling techniques could help resolve several large 
to moderate clashes we observed in our modeled complexes, most notably at site 47, for 
which the native residue was found to have lowered tolerance or not be tolerated at all.  
Finally, while our model does not directly make predictions for improved 
inhibitors to evade HIV-1 drug resistance, it may complement the strategies put forth by 
several other groups. Work seeking to develop inhibitors better able to evade resistance 
mutations, either by designing inhibitors to more strictly encompass the spatial pocket 
spanned by natural HIV-1 substrates (the substrate envelope hypothesis [112, 135]) or by 
increasing inhibitor binding affinity to wild type and/or mutant proteases [136, 137], may 
be strengthened by selectively increasing inhibitor interaction with HIV protease residues 
intolerant to mutation. The model we present here could complement such an approach, 
as it successfully predicts HIV-1 protease sites experimentally determined to be 
structurally and/or functionally intolerant to mutation with high fidelity.  
 
4.11. Conclusion 
We have presented a computational model able to predict mutational patterns 
observed in HIV-1 protease patients, both before and after protease inhibitor treatment. 
This model makes testable predictions about the structural and functional effects, and 
possible compensatory trade-offs of specific mutations. Further, it incorporates a 
computational model of protein flexibility that we show is able to mimic structural 
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plasticity observed within a large number of crystallographic structures. This model could 
easily be extended to predict mutational tolerance for any number of other protein 
systems, but also may offer some unique insights on the problem of predicting HIV-1 
drug resistance mutations.  
While some drug resistance mutations are shared among the 9 protease inhibitors 
currently in use, novel drug resistance mutations have appeared with the introduction of 
each new clinical drug. These mutations could often not be predicted in advance by 
extrapolating from then currently available inhibitor-protein complexes. The model we 
present here could provide useful in the prediction of yet undiscovered resistance 
mutations by suggesting mutations structurally and functionally tolerated by the HIV-1 
protease fold and free to contribute to destabilization of new clinical inhibitors.  The 
model predictions could also prove useful for generating a stabilized HIV-1 protease 
sequence, into which other destabilizing mutations that have the potential to cause loss of 
inhibitor binding, could be screened.  Finally, while we have examined HIV-1 sequence 
changes predicted starting from the subtype B consensus sequence in this work, the 
model could easily be extended to using other subtype sequences, and thus could prove 
useful for exploring the different mutational pathways observed in various HV-1 protease 
subtypes.  
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Chapter 5 Conclusion 
 
In this work, I presented a series of computational tools to predict protein 
sequences compatible with a given three-dimensional protein structure and a set of 
structural or functional constraints.  Section 5.1 describes how these tools have been used 
thus far and gives a summary of the major findings to date.  Section 5.2 discusses several 
ways in which the work presented here could be expanded and modified for future use in 
protein sequence prediction and design.  Examples of ongoing research projects within 
the Kortemme lab at UCSF, which directly build upon the computational tools presented 
in this work, are also given.   
5.1. Summary 
First, I described how a multi-constraint protein design protocol could be used to 
design protein interface sequences predicted to bind to multiple interaction partners, and 
then compared computationally designed interface sequences to naturally occurring 
amino acid sequences for a number of multi-specific signaling and structural proteins.  
For proteins with large, flat interfaces that had 3 or more structurally characterized 
binding partners, the sequences predicted as optimal by the multi-constraint protocol 
were found to be very native-like, both in terms of amino acid sequence identity as well 
as in predicted binding affinity of each partner.  In contrast, single-state design of the 
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same interfaces for binding only a single interaction partner at a time (ignoring sequence 
preferences of all other characterized binding partners) resulted in low native sequence 
recovery and predicted binding affinities much stronger than calculated for the native 
interface sequence. Thus the multi-constraint algorithm presented in this work appears to, 
at least in some cases, successfully integrate or “add up” diverse sequence preferences 
seen among several characterized binding partners.  How the distinct sequence 
preferences observed among differing binding partners may be exploited in order to re-
design protein interfaces or develop small molecules with specific binding preferences 
will be discussed in the Section 5.2.1.  Further, the finding that multi-constraint designed 
sequences had weaker predicted binding scores overall than single-constraint designed 
sequences suggests that it might be a general overall trend that multi-specificity may 
come at a cost of affinity.  Thus the transient nature observed in the multiple interactions 
of many signaling protein interactions may not need to be explicitly considered during 
sequence design or evolution.   
Next, using the hGH-hGHR interface as a model system, I examined whether 
computation tools originally developed to predict a single, optimal sequence for a set of 
functional constraints could be further developed to predict sets of amino acids tolerated 
at each position in a protein-protein interface.  I modified the previously presented 
computational multi-constraint algorithm to predict amino acid tolerances and showed 
that this modified protocol was able to correctly discriminate several positions within the 
hGH-hGHR interface that had been experimentally shown to tolerate substitution to a 
wide variety of differing amino acid types.  However, several positions within the hGH-
hGHR interface were experimentally found to tolerate only a few non-native amino acids, 
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and predictions made using a fixed backbone often failed to identify some of these non-
native amino acid substitutions as tolerated.  Prediction of amino acid tolerance at such 
“restricted” sites was found to be improved by incorporating backbone flexibility by 
using a set of computationally generated “near-native” backbones for design.  Several 
structural examples for fixed backbone prediction failures, including sterics and subtle 
changes in backbone conformation enabling altered hydrogen bonding networks, were 
then discussed.  Finally, based on the use of flexible backbone design, a protocol for 
automatically discriminating sites with restricted tolerances and outputting a library of 
computationally designed amino acid choices for each site under consideration was 
detailed.  Section 5.2.2 discusses several ways in which the flexible backbone design 
protocol presented in this work could be expanded and improved, and Section 5.2.3 
outlines how computational design libraries could be developed to “design in” new 
functionality or enhance existing properties of protein sequences.   
Finally, I presented a protocol for predicting single amino acid substitutions 
tolerated for a protein of great biological relevance, HIV-1 protease.  Here, I incorporated 
multiple structural and functional constraints, by computationally predicting how amino 
acid substitutions would effect overall protein fold stability, the stability of the dimeric 
HIV-1 protein interface, and the binding and recognition of each of the 10 known HIV-1 
protease substrates.  For each site in the HIV-1 protein sequence, a reduced set of amino 
acid mutations (able to be reached by a single mutation at the nucleotide level) was 
considered and tolerance to mutation at each site was calculated independently. Even 
with the simplifications inherent in the model, approximately 80% of amino acid 
substitutions that occurred in 1% or more of clinical HIV-1 protease sequences were 
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predicted as tolerated by the structural and functional constraints considered in the 
computational model.  In contrast, the model predicted mutations not yet observed in 
clinical sequences with a false positive rate of only ~20%.  Interestingly, this work also 
demonstrated that use of a single, fixed backbone as a structural template for design 
resulted in overall poorer predictive performance than designing on an ensemble of either 
crystallographically determined or computationally generated backbone structures.   
Section 5.2.4 discusses some future directions for examining HIV-1 protease mutational 
tolerance that build upon the tools presented within Chapter 4.   
5.2. Future Directions 
5.2.1. Multi-State Design Successes: Rewiring Protein Signaling Interaction 
Networks and Engineering of Conformational Stability 
The multi-state design algorithm presented in Chapter 2 was examined in the 
context of predicting interface sequences optimized for binding to multiple interaction 
partners, but can easily be generalized to predict sequences optimal for or against any set 
of enumerable constraints.  Since the work in Chapter 2 was published, the same multi-
state design algorithm has been successfully used within the Kortemme lab by Mariana 
Babor to examine backbone flexibility during the maturation of H3 antibody loops [138] 
and by Noah Ollikainen to predict mutations in the sequence of the small GTPase Ran to 
specifically disrupt binding with some interaction partners and not others (data not yet 
published). These initial successes indicate that the algorithm presented here should 
prove useful for future design projects, such as designing a single protein sequence for 
stability in two or more different backbone conformations or incorporating negative 
design to redesign multi-specific protein interfaces to have specific binding interactions.   
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Finally, the multi-state design protocol presented in Chapter 2 could easily be 
modified to perform orthogonal interface design.  Here the starting interface sequence 
between a protein pair, A-B, would be scored and used to estimate the strength of the 
starting, or wild-type interaction.  Both sides of the protein-protein interface could then 
be designed simultaneously, with each interface sequence design would be scored with 
respect to its ability to destabilize the wild type-design interfaces A*-B and A-B* while 
stabilizing the novel orthogonal interface A*-B* (here *’s represent a designed interface 
sequence for either the protein A or B, while lack of stars indicates the original, native 
interface sequence).  This protocol should be more efficient than previous step-wise 
methods which require the selection of a mutation(s) on a single side of the protein-
protein interface predicted to destabilize the native interaction, followed by 
computational prediction of mutations on the alternate interface side that would restore, 
or compensate, the original loss of binding.   
5.2.2. Future directions for flexible backbone protein design 
Chapters 3 and 4 provided evidence that incorporating signal from design on an 
ensemble of backbones improves overall prediction of tolerance to amino acid sequence 
changes.  In Chapter 4, evidence was provided that predictions made on a set of 
computationally derived backbones, generated from a single crystal structure, are 
comparable to predictions made using a set of experimentally determined backbone 
structures that have been crystallized under a variety of conditions, including the 
presence of several known substrates and inhibitors.  This surprising finding opens up 
exciting avenues to continue development of the “backrub” backbone flexibility protocol 
in order to further improve the accuracy of protein design predictions.   
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The work presented in this thesis was focused on overall prediction of amino acid 
tolerances, and as such pre-generation of backbone ensembles for design predictions was 
found to be necessary in order to perform quick and large-scale calculations.  However, 
in some cases, local and independent optimization of a backbone structure for each 
specific amino acid change may enhance predictive power.   In particular, a procedure, 
iterating selection of amino acid sequence changes with backrub backbone flexibility 
moves, could be expected to yield more accurate structural models and Rosetta design 
scores.  Such an iterative protocol, using fragment insertion to incorporate backbone 
flexibility, was successfully used in the design on the novel protein fold, Top7 [7].   
Finally, different magnitudes of protein movement may be appropriate for 
differing protein design tasks.  The redesign of tightly packed protein cores, as well as 
some sites within a protein-protein interface, may require only the introduction of subtle 
backbone moves.  In contrast, modeling loops or larger scale conformational changes that 
occur at some protein-protein interfaces could require the generation of larger, more 
structurally diverse backbone moves.  Research is ongoing within the Kortemme lab to 
explore the utility of varying Monte Carlo simulation temperatures during backrub 
simulations, as well as incorporating alternative backbone flexibility move-sets such as 
analytical loop closure, into protein design.   
5.2.3. Computational Library Design: Development of an online server for 
sequence enrichment 
In Chapter 3, an algorithm to computationally output libraries of optimal amino 
acid choices for a set of sequence positions was presented.  Since the time of publication 
of the prediction of hGH-hGHR interface sequence tolerance profiles, the computational 
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library prediction code has been successfully used within the Kortemme Lab by Mariana 
Babor to predict antibody-HER2 interface sequence tolerances, and is now being 
modified by Colin Smith to examine PDZ-peptide interface specificities.  Also within the 
Kortemme lab, Florian Lauck is now incorporating the computational library design 
protocol into an online prediction server, which will be freely available to the academic 
community.   
This automated library design algorithm could be used to enhance protein design 
in a number of ways.  First, sequence positions predicted to be highly tolerant to 
substitution with a wide variety of differing amino acid types could be identified and 
subsets of amino acid types could be selected at such sites to “design in” new protein 
functionality without disrupting the original protein fold or function.  Alternatively, one 
could focus on sequence positions predicted to be more restricted with respect to 
tolerance to amino acid substitutions.  Amino acids substitutions at such sites would be 
expected to show strong effects on the original functionality, either by enhancing or 
completely disrupting the original protein functionality.   
While overall strong predictive performance of amino acid tolerances at the hGH-
hGHR interface was presented in Chapter 3, several extensions and modifications could 
be made to the library design algorithm that might improve performance even further.  
Section 5.2.2 discusses several modifications to the flexible backbone protocol that, if 
implemented, could be expected to improve library design predictions. Further, the 
protocol presented in Chapter 3 that examines amino acid tolerances at each interface site 
independently, can easily be extended to predict correlated mutational sequence changes 
expected to modify or enhance protein stability or functionality.   
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5.2.4. Future Directions for prediction of HIV-1 protease mutational tolerance  
Chapter 4 discusses a first step towards computationally integrating structural and 
functional constraints on protein sequence in order to predict amino acid sequence 
changes compatible with the given constraints.  Prediction of specific mutational changes 
tolerated by a protein fold and function might be particularly useful in anticipating drug 
resistance escape mutations, or those amino acid sequence changes able to destabilize or 
weaken protein-drug interaction without destroying original protein functionality.  
Knowledge of tolerance to specific resistance mutations within protein sequences is often 
obtained only empirically, after drugs have been developed and administered.  New 
rounds of drug design then seek primarily to avoid already discovered drug resistance 
mutations, without any a priori knowledge of what unobserved mutations may yet appear.  
The computational tolerance model outlined in Chapter 4, in combination with library 
design methodologies developed in Chapter 3, offers the ability to predict libraries of 
tolerated amino acid sequence variants, focused around a drug or ligand binding site.  If 
necessary, development of a library of variants containing possible resistance mutations 
could proceed in two stages, with an initial round of sequence variants designed to have 
enhanced fold or functional stability, followed by a second round of variants allowing 
slightly more destabilizing sequence changes near putative drug binding sites.  Novel 
drugs could then be screened against such libraries of sequence variants, in order to 
anticipate each drug’s suitability towards maintaining efficacy in the face of possible 
protein sequence changes.   
In addition to developing libraries containing putative drug resistance mutations, 
the tools outlined in Chapter 4 could be further developed in a number of ways.  First, the 
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model as presented considers only single, independent amino acid changes but could 
easily be expanded to consider correlated mutational changes by either (1) using a brute 
force approach to enumerate and score all possible double, and even triple combinations 
of amino acid changes or by (2) computationally evolving combinations of amino acid 
changes by ensuring that the sum total of the change in scores for each constraint for all 
incorporated sequence modifications is within some threshold value.  Such a two-pronged 
approach could allow one to make broad computational predictions about the most likely 
evolutionary order of accumulation of mutations, as well as specific predictions about the 
energetic and structural reasons for the appearance of double or triply correlated 
mutations.   
The tools of Chapter 4 could also be modified to examine two other interesting 
mutational patterns observed for HIV-1 protease. First, HIV-1 protease exists in several 
differing subtypes, each of which differs in what exact 99-residue amino acid sequence is 
considered to be “native”.  The computational model presented in Chapter 4 considers a 
protein’s mutational tolerance to be constrained not only by its amino acid sequence, but 
also by its underlying DNA sequence, by explicitly dis-favoring amino acid sequence 
changes that require more than one nucleotide mutation at the DNA level.  This opens the 
possibility that such a computational model might provide useful in predicting and 
understanding the specific mutational tolerance patterns observed among varying HIV-1 
protease subtypes.  Finally, it has been observed that the sequence of the peptide cleavage 
sites, 10 of which are known to be HIV-1 protease substrates, can co-evolve along with 
the appearance of mutations within the HIV-1 protease binding-site.  The computational 
protocol presented in Chapter 4 could easily be extended to predict tolerance to the co-
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evolution of sequence changes occurring in both the HIV-1 protease protein, as well as its 
substrate peptide.  
  144 
Bibliography 
 
 
 
1. Humphris, E.L. and T. Kortemme, Design of multi-specificity in protein interfaces. PLoS Comput 
Biol, 2007 Aug. 3(8): p. e164. 
2. Humphris, E.L. and T. Kortemme, Prediction of protein-protein interface sequence diversity using 
flexible backbone computational protein design. Structure, 2008 Dec 10. 16(12): p. 1777--1788. 
3. Desjarlais, J.R. and T.M. Handel, De novo design of the hydrophobic cores of proteins. Protein 
Sci, 1995. 4(10): p. 2006-18. 
4. Bolon, D.N., et al., Prudent modeling of core polar residues in computational protein design. J 
Mol Biol, 2003. 329(3): p. 611-22. 
5. Dahiyat, B.I. and S.L. Mayo, De novo protein design: fully automated sequence selection. 
Science, 1997. 278(5335): p. 82-7. 
6. Harbury, P.B., et al., High-resolution protein design with backbone freedom. Science, 1998. 
282(5393): p. 1462-7. 
7. Kuhlman, B., et al., Design of a novel globular protein fold with atomic-level accuracy. Science, 
2003. 302(5649): p. 1364-8. 
8. Shifman, J.M. and S.L. Mayo, Modulating calmodulin binding specificity through computational 
protein design. J Mol Biol, 2002. 323(3): p. 417-23. 
9. Chevalier, B.S., et al., Design, activity, and structure of a highly specific artificial endonuclease. 
Mol Cell, 2002. 10(4): p. 895-905. 
  145 
10. Havranek, J.J. and P.B. Harbury, Automated design of specificity in molecular recognition. Nat 
Struct Biol, 2003. 10(1): p. 45-52. 
11. Kortemme, T., et al., Computational redesign of protein-protein interaction specificity. Nat Struct 
Mol Biol, 2004. 11(4): p. 371-9. 
12. Kortemme, T. and D. Baker, Computational design of protein-protein interactions. Curr Opin 
Chem Biol, 2004. 8(1): p. 91--97. 
13. Bolon, D.N. and S.L. Mayo, Enzyme-like proteins by computational design. Proc Natl Acad Sci U 
S A, 2001. 98(25): p. 14274-9. 
14. Dwyer, M.A., L.L. Looger, and H.W. Hellinga, Computational design of a biologically active 
enzyme. Science, 2004. 304(5679): p. 1967-71. 
15. Havranek, J.J. and P.B. Harbury, Automated design of specificity in molecular recognition. Nat 
Struct Biol, 2003 Jan. 10(1): p. 45--52. 
16. Bolon, D.N., et al., Specificity versus stability in computational protein design. Proc Natl Acad Sci 
U S A, 2005. 102(36): p. 12724-9. 
17. Baldwin, E.P., et al., The role of backbone flexibility in the accommodation of variants that repack 
the core of T4 lysozyme. Science, 1993. 262(5140): p. 1715-8. 
18. Bordner, A.J. and R.A. Abagyan, Large-scale prediction of protein geometry and stability 
changes for arbitrary single point mutations. Proteins, 2004. 57(2): p. 400-13. 
19. Su, A. and S.L. Mayo, Coupling backbone flexibility and amino acid sequence selection in protein 
design. Protein Sci, 1997. 6(8): p. 1701-7. 
20. Harbury, P.B., et al., High-resolution protein design with backbone freedom. Science, 1998 Nov 
20. 282(5393): p. 1462--1467. 
21. Desjarlais, J.R. and T.M. Handel, Side-chain and backbone flexibility in protein core design. J 
Mol Biol, 1999. 290(1): p. 305-18. 
22. Simons, K.T., et al., Assembly of protein tertiary structures from fragments with similar local 
sequences using simulated annealing and Bayesian scoring functions. J Mol Biol, 1997. 268(1): p. 
209-25. 
  146 
23. Simons, K.T., et al., Ab initio protein structure prediction of CASP III targets using ROSETTA. 
Proteins, 1999. Suppl 3: p. 171-6. 
24. Kuhlman, B., et al., Design of a novel globular protein fold with atomic-level accuracy. Science, 
2003 Nov 21. 302(5649): p. 1364--1368. 
25. Saunders, C.T. and D. Baker, Recapitulation of protein family divergence using flexible backbone 
protein design. J Mol Biol, 2005. 346(2): p. 631-44. 
26. Wei, Y. and M.H. Hecht, Enzyme-like proteins from an unselected library of designed amino acid 
sequences. Protein Eng Des Sel, 2004 Jan. 17(1): p. 67--75. 
27. Treynor, T.P., et al., Computationally designed libraries of fluorescent proteins evaluated by 
preservation and diversity of function. Proc Natl Acad Sci U S A, 2007. 104(1): p. 48--53. 
28. Kortemme, T. and D. Baker, A simple physical model for binding energy hot spots in protein-
protein complexes. Proc Natl Acad Sci U S A, 2002. 99(22): p. 14116-21. 
29. Kortemme, T., A.V. Morozov, and D. Baker, An orientation-dependent hydrogen bonding 
potential improves prediction of specificity and structure for proteins and protein-protein 
complexes. J Mol Biol, 2003. 326(4): p. 1239-59. 
30. Lazaridis, T. and M. Karplus, Effective energy function for proteins in solution. Proteins, 1999. 
35(2): p. 133-52. 
31. Davis, I.W., et al., The backrub motion: how protein backbone shrugs when a sidechain dances. 
Structure, 2006 Feb. 14(2): p. 265--274. 
32. Davis, I.W., et al., The backrub motion: how protein backbone shrugs when a sidechain dances. 
Structure, 2006. 14(2): p. 265-74. 
33. Smith, C.A. and T. Kortemme, Backrub-like backbone simulation recapitulates natural protein 
conformational variability and improves mutant side-chain prediction. J Mol Biol, 2008. 380(4): 
p. 742-56. 
34. DePristo, M.A., D.M. Weinreich, and D.L. Hartl, Missense meanderings in sequence space: a 
biophysical view of protein evolution. Nat Rev Genet, 2005. 6(9): p. 678-87. 
35. Kim, P.M., et al., Relating three-dimensional structures to protein networks provides evolutionary 
insights. Science, 2006. 314(5807): p. 1938-41. 
  147 
36. Kortemme, T. and D. Baker, Computational design of protein-protein interactions. Curr Opin 
Chem Biol, 2004. 8(1): p. 91-7. 
37. Watters, A.L., et al., The highly cooperative folding of small naturally occurring proteins is likely 
the result of natural selection. Cell, 2007. 128(3): p. 613-24. 
38. Zarrinpar, A., S.H. Park, and W.A. Lim, Optimization of specificity in a cellular protein 
interaction network by negative selection. Nature, 2003. 426(6967): p. 676-80. 
39. Ambroggio, X.I. and B. Kuhlman, Computational design of a single amino acid sequence that can 
switch between two distinct protein folds. J Am Chem Soc, 2006. 128(4): p. 1154-61. 
40. Bogan, A.A. and K.S. Thorn, Anatomy of hot spots in protein interfaces. J Mol Biol, 1998. 280(1): 
p. 1-9. 
41. Clackson, T. and J.A. Wells, A hot spot of binding energy in a hormone-receptor interface. 
Science, 1995. 267(5196): p. 383-6. 
42. Lowman, H.B. and J.A. Wells, Affinity maturation of human growth hormone by monovalent 
phage display. J Mol Biol, 1993. 234(3): p. 564-78. 
43. Pal, G., et al., Comprehensive and quantitative mapping of energy landscapes for protein-protein 
interactions by rapid combinatorial scanning. J Biol Chem, 2006. 281(31): p. 22378-85. 
44. Andreeva, A., et al., SCOP database in 2004: refinements integrate structure and sequence family 
data. Nucleic Acids Res, 2004. 32(Database issue): p. D226-9. 
45. Xenarios, I., et al., DIP, the Database of Interacting Proteins: a research tool for studying cellular 
networks of protein interactions. Nucleic Acids Res, 2002. 30(1): p. 303-5. 
46. Davis, F.P. and A. Sali, PIBASE: a comprehensive database of structurally defined protein 
interfaces. Bioinformatics, 2005. 21(9): p. 1901-7. 
47. Glaser, F., et al., The ConSurf-HSSP database: the mapping of evolutionary conservation among 
homologs onto PDB structures. Proteins, 2005. 58(3): p. 610-7. 
48. DeLano, W.L., et al., Convergent solutions to binding at a protein-protein interface. Science, 
2000. 287(5456): p. 1279-83. 
49. Keskin, O. and R. Nussinov, Similar binding sites and different partners: implications to shared 
proteins in cellular pathways. Structure, 2007. 15(3): p. 341-54. 
  148 
50. Jackson, R.M., Comparison of protein-protein interactions in serine protease-inhibitor and 
antibody-antigen complexes: implications for the protein docking problem. Protein Sci, 1999. 
8(3): p. 603-13. 
51. Lu, W., et al., Binding of amino acid side-chains to S1 cavities of serine proteinases. J Mol Biol, 
1997. 266(2): p. 441-61. 
52. Lo Conte, L., C. Chothia, and J. Janin, The atomic structure of protein-protein recognition sites. J 
Mol Biol, 1999. 285(5): p. 2177-98. 
53. Ma, B., et al., Protein-protein interactions: structurally conserved residues distinguish between 
binding sites and exposed protein surfaces. Proc Natl Acad Sci U S A, 2003. 100(10): p. 5772-7. 
54. Villar, H.O. and L.M. Kauvar, Amino acid preferences at protein binding sites. FEBS Lett, 1994. 
349(1): p. 125-30. 
55. Mossessova, E., R.A. Corpina, and J. Goldberg, Crystal structure of ARF1*Sec7 complexed with 
Brefeldin A and its implications for the guanine nucleotide exchange mechanism. Mol Cell, 2003. 
12(6): p. 1403-11. 
56. Koehl, P. and M. Levitt, Protein topology and stability define the space of allowed sequences. 
Proc Natl Acad Sci U S A, 2002. 99(3): p. 1280-5. 
57. Taverna, D.M. and R.A. Goldstein, Why are proteins so robust to site mutations? J Mol Biol, 
2002. 315(3): p. 479-84. 
58. Wagner, A., Robustness, evolvability, and neutrality. FEBS Lett, 2005. 579(8): p. 1772-8. 
59. Aharoni, A., et al., The 'evolvability' of promiscuous protein functions. Nat Genet, 2005. 37(1): p. 
73-6. 
60. Pokala, N. and T.M. Handel, Review: protein design--where we were, where we are, where we're 
going. J Struct Biol, 2001. 134(2-3): p. 269-81. 
61. Xia, Y. and M. Levitt, Simulating protein evolution in sequence and structure space. Curr Opin 
Struct Biol, 2004. 14(2): p. 202-7. 
62. Butterfoss, G.L. and B. Kuhlman, Computer-based design of novel protein structures. Annu Rev 
Biophys Biomol Struct, 2006. 35: p. 49-65. 
  149 
63. Ponder, J.W. and F.M. Richards, Tertiary templates for proteins. Use of packing criteria in the 
enumeration of allowed sequences for different structural classes. J Mol Biol, 1987. 193(4): p. 
775-91. 
64. Larson, S.M., et al., Thoroughly sampling sequence space: large-scale protein design of structural 
ensembles. Protein Sci, 2002. 11(12): p. 2804-13. 
65. Dokholyan, N.V. and E.I. Shakhnovich, Understanding hierarchical protein evolution from first 
principles. J Mol Biol, 2001. 312(1): p. 289-307. 
66. Jaramillo, A., et al., Folding free energy function selects native-like protein sequences in the core 
but not on the surface. Proc Natl Acad Sci U S A, 2002. 99(21): p. 13554-9. 
67. Koehl, P. and M. Levitt, De novo protein design. II. Plasticity in sequence space. J Mol Biol, 
1999. 293(5): p. 1183-93. 
68. Kuhlman, B. and D. Baker, Native protein sequences are close to optimal for their structures. 
Proc Natl Acad Sci U S A, 2000. 97(19): p. 10383-8. 
69. Hayes, R.J., et al., Combining computational and experimental screening for rapid optimization of 
protein properties. Proc Natl Acad Sci U S A, 2002. 99(25): p. 15926-31. 
70. Treynor, T.P., et al., Computationally designed libraries of fluorescent proteins evaluated by 
preservation and diversity of function. Proc Natl Acad Sci U S A, 2007. 104(1): p. 48-53. 
71. Fu, X., J.R. Apgar, and A.E. Keating, Modeling Backbone Flexibility to Achieve Sequence 
Diversity: The Design of Novel alpha-Helical Ligands for Bcl-x(L). J Mol Biol, 2007. 
72. Ding, F. and N.V. Dokholyan, Emergence of protein fold families through rational design. PLoS 
Comput Biol, 2006. 2(7): p. e85. 
73. Humphris, E.L. and T. Kortemme, Design of multi-specificity in protein interfaces. PLoS Comput 
Biol, 2007. 3(8): p. e164. 
74. Dunbrack, R.L., Jr., Rotamer libraries in the 21st century. Curr Opin Struct Biol, 2002. 12(4): p. 
431-40. 
75. Cunningham, B.C. and J.A. Wells, Rational design of receptor-specific variants of human growth 
hormone. Proc Natl Acad Sci U S A, 1991. 88(8): p. 3407-11. 
  150 
76. Sidhu, S.S., et al., Phage display for selection of novel binding peptides. Methods Enzymol, 2000. 
328: p. 333-63. 
77. Schiffer, C., et al., Structure of a phage display-derived variant of human growth hormone 
complexed to two copies of the extracellular domain of its receptor: evidence for strong structural 
coupling between receptor binding sites. J Mol Biol, 2002. 316(2): p. 277-89. 
78. Friedland, G.D., et al., A correspondence between solution-state dynamics of an individual protein 
and the sequence and conformational diversity of its family. PLoS Comput Biol, 2009. 5(5): p. 
e1000393. 
79. Friedland, G.D., et al., A simple model of backbone flexibility improves modeling of side-chain 
conformational variability. J Mol Biol, 2008. 380(4): p. 757-74. 
80. Pal, G., et al., Intramolecular cooperativity in a protein binding site assessed by combinatorial 
shotgun scanning mutagenesis. J Mol Biol, 2005. 347(3): p. 489-94. 
81. Wollacott, A.M. and J.R. Desjarlais, Virtual interaction profiles of proteins. J Mol Biol, 2001. 
313(2): p. 317-42. 
82. Eyre-Walker, A. and P.D. Keightley, The distribution of fitness effects of new mutations. Nat Rev 
Genet, 2007. 8(8): p. 610--618. 
83. James, L.C. and D.S. Tawfik, Conformational diversity and protein evolution--a 60-year-old 
hypothesis revisited. Trends Biochem Sci, 2003. 28(7): p. 361-8. 
84. Copley, S.D., Enzymes with extra talents: moonlighting functions and catalytic promiscuity. Curr 
Opin Chem Biol, 2003. 7(2): p. 265-72. 
85. Gupta, R.D. and D.S. Tawfik, Directed enzyme evolution via small and effective neutral drift 
libraries. Nat Methods, 2008. 5(11): p. 939-42. 
86. Zhao, H., Directed evolution of novel protein functions. Biotechnol Bioeng, 2007 Oct 1. 98(2): p. 
313--317. 
87. Aharoni, A., et al., The 'evolvability' of promiscuous protein functions. Nat Genet, 2005. 37(1): p. 
73-6. 
88. Fernández, A., et al., Protein promiscuity: drug resistance and native functions--HIV-1 case. J 
Biomol Struct Dyn, 2005. 22(6): p. 615-24. 
  151 
89. Rhee, S.-Y., et al., Human immunodeficiency virus reverse transcriptase and protease sequence 
database. Nucleic Acids Res, 2003. 31(1): p. 298-303. 
90. Carrillo, A., et al., In vitro selection and characterization of human immunodeficiency virus type 1 
variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol, 1998. 72(9): p. 
7532-41. 
91. Seelmeier, S., et al., Human immunodeficiency virus has an aspartic-type protease that can be 
inhibited by pepstatin A. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6612-6. 
92. Hill, M., G. Tachedjian, and J. Mak, The packaging and maturation of the HIV-1 Pol proteins. 
Curr HIV Res, 2005 Jan. 3(1): p. 73--85. 
93. Debouck, C., et al., Human immunodeficiency virus protease expressed in Escherichia coli 
exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A, 
1987. 84(24): p. 8903-6. 
94. Ho, D.D., et al., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. 
Nature, 1995. 373(6510): p. 123-6. 
95. Wei, X., et al., Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 1995. 
373(6510): p. 117-22. 
96. Coffin, J.M., HIV population dynamics in vivo: implications for genetic variation, pathogenesis, 
and therapy. Science, 1995. 267(5197): p. 483-9. 
97. Wu, T.D., et al., Mutation patterns and structural correlates in human immunodeficiency virus 
type 1 protease following different protease inhibitor treatments. J Virol, 2003 Apr. 77(8): p. 
4836--4847. 
98. Condra, J.H., et al., In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. 
Nature, 1995 Apr 6. 374(6522): p. 569--571. 
99. Molla, A., et al., Ordered accumulation of mutations in HIV protease confers resistance to 
ritonavir. Nat Med, 1996 Jul. 2(7): p. 760--766. 
100. Ishikita, H. and A. Warshel, Predicting drug-resistant mutations of HIV protease. Angew Chem 
Int Ed Engl, 2008. 47(4): p. 697-700. 
  152 
101. Lin, Y., et al., Effect of point mutations on the kinetics and the inhibition of human 
immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry, 1995 Jan 
31. 34(4): p. 1143--1152. 
102. Muzammil, S., P. Ross, and E. Freire, A major role for a set of non-active site mutations in the 
development of HIV-1 protease drug resistance. Biochemistry, 2003. 42(3): p. 631--638. 
103. Olsen, D.B., et al., Non-active site changes elicit broad-based cross-resistance of the HIV-1 
protease to inhibitors. J Biol Chem, 1999. 274(34): p. 23699-701. 
104. Piana, S., P. Carloni, and U. Rothlisberger, Drug resistance in HIV-1 protease: Flexibility-assisted 
mechanism of compensatory mutations. Protein Sci, 2002 Oct. 11(10): p. 2393--2402. 
105. Baldwin, E.T., et al., Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. 
Nat Struct Biol, 1995 Mar. 2(3): p. 244--249. 
106. Loeb, D.D., et al., Complete mutagenesis of the HIV-1 protease. Nature, 1989. 340(6232): p. 397-
400. 
107. Sadiq, S.K., et al., Automated molecular simulation based binding affinity calculator for ligand-
bound HIV-1 proteases. J Chem Inf Model, 2008 Sep. 48(9): p. 1909--1919. 
108. Rhee, S.-Y., et al., HIV-1 Protease and reverse-transcriptase mutations: correlations with 
antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J 
Infect Dis, 2005. 192(3): p. 456-65. 
109. Bennett, D.E., et al., Drug resistance mutations for surveillance of transmitted HIV-1 drug-
resistance: 2009 update. PLoS One, 2009. 4(3): p. e4724. 
110. Johnson, V.A., et al., Update of the Drug Resistance Mutations in HIV-1. Top HIV Med, 2008. 
16(5): p. 138-45. 
111. Altman, M.D., et al., HIV-1 protease inhibitors from inverse design in the substrate envelope 
exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc, 2008 May 14. 130(19): 
p. 6099--6113. 
112. Chellappan, S., et al., Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 
protease. Proteins, 2007 Aug 1. 68(2): p. 561--567. 
  153 
113. Zennou, V., et al., Loss of viral fitness associated with multiple Gag and Gag-Pol processing 
defects in human immunodeficiency virus type 1 variants selected for resistance to protease 
inhibitors in vivo. J Virol, 1998 Apr. 72(4): p. 3300--3306. 
114. Prabu-Jeyabalan, M., et al., Structural basis for coevolution of a human immunodeficiency virus 
type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J 
Virol, 2004 Nov. 78(22): p. 12446--12454. 
115. Zhang, Y.M., et al., Drug resistance during indinavir therapy is caused by mutations in the 
protease gene and in its Gag substrate cleavage sites. J Virol, 1997. 71(9): p. 6662-70. 
116. Dauber, D.S., et al., Altered substrate specificity of drug-resistant human immunodeficiency virus 
type 1 protease. J Virol, 2002 Feb. 76(3): p. 1359--1368. 
117. Cote, H.C., Z.L. Brumme, and P.R. Harrigan, Human immunodeficiency virus type 1 protease 
cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, 
ritonavir, and/or saquinavir. J Virol, 2001 Jan. 75(2): p. 589--594. 
118. Bally, F., et al., Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical 
significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses, 
2000. 16(13): p. 1209-13. 
119. Nijhuis, M., et al., Increased fitness of drug resistant HIV-1 protease as a result of acquisition of 
compensatory mutations during suboptimal therapy. AIDS, 1999. 13(17): p. 2349--2359. 
120. Liu, Y., E. Eyal, and I. Bahar, Analysis of correlated mutations in HIV-1 protease using spectral 
clustering. Bioinformatics, 2008. 24(10): p. 1243-50. 
121. Garriga, C., et al., Mutational patterns and correlated amino acid substitutions in the HIV-1 
protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med 
Virol, 2007. 79(11): p. 1617--1628. 
122. Hong, L., et al., Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: 
insights into the mechanisms of drug resistance. Protein Sci, 2000. 9(10): p. 1898--1904. 
123. Jenwitheesuk, E. and R. Samudrala, Improved prediction of HIV-1 protease-inhibitor binding 
energies by molecular dynamics simulations. BMC Struct Biol, 2003. 3: p. 2. 
  154 
124. Jenwitheesuk, E. and R. Samudrala, Prediction of HIV-1 protease inhibitor resistance using a 
protein-inhibitor flexible docking approach. Antivir Ther, 2005. 10(1): p. 157--166. 
125. Best, R.B., et al., Relation between native ensembles and experimental structures of proteins. Proc 
Natl Acad Sci U S A, 2006. 103(29): p. 10901-6. 
126. Hornak, V., et al., HIV-1 protease flaps spontaneously open and reclose in molecular dynamics 
simulations. Proc Natl Acad Sci U S A, 2006 Jan 24. 103(4): p. 915--920. 
127. Erickson, J.W. and S.K. Burt, Structural mechanisms of HIV drug resistance. Annu Rev 
Pharmacol Toxicol, 1996. 36: p. 545-71. 
128. Rose, R.B., C.S. Craik, and R.M. Stroud, Domain flexibility in retroviral proteases: structural 
implications for drug resistant mutations. Biochemistry, 1998 Feb 24. 37(8): p. 2607--2621. 
129. Ho, D.D., et al., Characterization of human immunodeficiency virus type 1 variants with increased 
resistance to a C2-symmetric protease inhibitor. J Virol, 1994 Mar. 68(3): p. 2016--2020. 
130. Kaplan, A.H., et al., Selection of multiple human immunodeficiency virus type 1 variants that 
encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl 
Acad Sci U S A, 1994 Jun 7. 91(12): p. 5597--5601. 
131. Perryman, A.L., J.-H. Lin, and J.A. McCammon, HIV-1 protease molecular dynamics of a wild-
type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new 
target site for drugs. Protein Sci, 2004 Apr. 13(4): p. 1108--1123. 
132. Wang, W. and P.A. Kollman, Computational study of protein specificity: the molecular basis of 
HIV-1 protease drug resistance. Proc Natl Acad Sci U S A, 2001. 98(26): p. 14937-42. 
133. Chou, K.C., et al., Predicting human immunodeficiency virus protease cleavage sites in proteins 
by a discriminant function method. Proteins, 1996. 24(1): p. 51-72. 
134. Chou, K.C., C.T. Zhang, and F.J. Kezdy, A vector projection approach to predicting HIV protease 
cleavage sites in proteins. Proteins, 1993. 16(2): p. 195-204. 
135. Chellappan, S., et al., Design of mutation-resistant HIV protease inhibitors with the substrate 
envelope hypothesis. Chem Biol Drug Des, 2007. 69(5): p. 298-313. 
136. Ohtaka, H. and E. Freire, Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol, 2005. 
88(2): p. 193-208. 
  155 
137. Clemente, J.C., et al., Design, synthesis, evaluation, and crystallographic-based structural studies 
of HIV-1 protease inhibitors with reduced response to the V82A mutation. Journal of Medicinal 
Chemistry, 2008. 51(4): p. 852-860. 
138. Babor, M. and T. Kortemme, Multi-constraint computational design suggests that native 
sequences of germline antibody H3 loops are nearly optimal for conformational flexibility. 
Proteins, 2009. 75(4): p. 846-58. 
 
  
  156 
Appendix A. Chapter 2 Supplementary 
Materials 
 
A.1.1. Supplementary Figures 
 
 
Supplementary Figure A.1 Group I and Group II distributions of optimization in promiscuous 
interfaces.  
Predicted per-residue binding score improvements (relative to native) are shown for sequences selected in 
single- (A,C) and multi- (B,D) constraint simulations for group I (top, pink shading) and group II (bottom, 
blue shading). Colored bars indicate the magnitude of predicted per-residue improvement over native. 
Darker colored bars (compromise value >1, orange, red) indicate positions for which the simulation 
predicts a non-native residue to bind stronger than native. Lighter colored bars (compromise value <1, 
wheat, yellow) indicate simulations recovered the native (or near-native) residue type. Group I and group II 
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proteins show similar distributions of native residues predicted to be suboptimal when optimized for single 
binding interactions alone (A, C; compare red, orange, yellow bars). Optimization over multiple partners, 
however, differed between groups: a larger number of non-hotspot positions were still predicted to be 
suboptimal for group I when all partners were considered for optimization than seen in group II (“all other 
residues”, compare red, orange, yellow bars in B, D). This is consistent with our finding that native 
sequence recovery is lower overall for group I. 
 
 
Supplementary Figure A.2 Distribution of compromise for all 20 promiscuous proteins in the dataset.  
Constraint scores (see Section 2.4.4) are mapped onto each promiscuous protein in the dataset. Darker 
colors indicate stronger tradeoff in that some partners considered are predicted to “give up” potential gain 
so that other partners could fulfill their optimal interactions Overall, group I proteins (1-10,20) display 
lower levels of tradeoff than seen in group II (11-19).   
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Supplementary Figure A.3 Amino acid frequency distributions of sequences selected as optimal in 
the multi-constraint procedure.  
For each amino acid type, the number of times an amino acid type was correctly recovered as native is 
shown as black striped bars. Non-native substitutions of each amino acid type are shown as white bars. The 
native amino acid distribution is plotted for reference (solid black line). 
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Supplementary Figure A.4 Single- and Multi- Constraint Sequences Selected for 20 Multi-Specific 
Proteins  
The first row in each Table contains the interface residue PDB numbering, the second row lists the native 
sequence (red), and the following rows contain sequences predicted to be optimal in each simulation: multi-
constraint (2nd sequence), single constraint (3rd - last sequences). Plus signs in the Table denote that the 
native amino acid residue type was recovered as optimal. The number and percent of interface residues 
recovered to be identical to native is shown for each simulation in the rightmost column. Pink shading 
denotes that the original wild type amino acid type was calculated to be a hotspot for the given binding 
partner while grey shading signifies an interface positions not within 4Å of the shaded interaction partner 
(see Methods section in the main manuscript). 
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A.1.2. Supplementary Tables 
 
 
Supplementary Table A.1 Source of high-throughput interaction data for promiscuous proteins.  
Database of Interacting Proteins (DIP http://dip.doe-mbi.ucla.edu/) identification numbers, e-values and 
protein names for sequences identified as homologues to the 20 promiscuous proteins in our dataset. 
Interaction graphs (see Figure 2.2) are taken directly from each DIP protein listed. 
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Appendix B. Chapter 3, Supplementary 
Materials 
 
B.1.1. Supplementary Text 
 
Filtering of Backbones and Variation in Thresholds 
In order to estimate the influence of tunable parameters on the predicted tolerance  
profiles, we selected and scored sequences used a variety of conditions including: (i) 
design on up 500 “near-native” backbones, (ii) varying binding and folding thresholds to 
0%, 5% and 10% of the score of the wild-type sequence, (iii) use of a weakened Leonard 
Jones repulsive term (“soft” repulsive), (iv) pre-filtering the ensemble of near-native 
backbones and designing only on those with most favorable (negative) scores and (v) 
running the genetic algorithm optimization for varying numbers of generations. Overall 
varying the parameters listed above resulted in qualitatively similar profiles. The one 
exception to this general robustness of the methodology to parameters is the effect of 
varying the folding threshold: if this threshold was too lenient (accepting sequences with 
scores differing from native by 10% or more) profiles which should show strong signal 
for a small set of amino acid residues became flattened out. Similarly if this threshold 
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was too strong (0%) only a very small number of sequences were selected for inclusion in 
the tolerance profiles, which often resulted in biases in distributions due to taking a small 
sample. 
Variability of Fixed Backbone Tolerance Profiles at Four 
Interface Positions  
As described in methods, the score calculated for the optimized rotamer 
combinations for the native sequence on each backbone (“native score”) was used 
throughout the remainder of the simulation as a threshold by which other sequences are 
accepted or rejected (Figure 3.1). Due to the stochastic nature of the Monte-Carlo 
optimization protocol, two different sets of low- scoring rotamer combinations appeared 
to be selected for the fixed backbone simulations at four positions: 171D, 167R, 63N, and 
178R. In each case, this resulted in some fraction of the 100 independent runs on the 
fixed crystallographic backbone having a “native score” higher than that of the remainder 
of the runs, and thus accepting a different set of sequences. This caused a significant 
variation of the frequency of the most commonly observed residue type (for example 
variation for histidine in Figure 3.4F, and variation for arginine in Figure 3.4G, yellow 
bars). This problem seemed only to occur for polar residues and is hence likely to be 
linked to cases involving intricate alternative networks of polar interactions and 
complications in modeling these interactions accurately.  
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B.1.2. Supplementary Figures 
 
 
Supplementary Figure B.1: Structural Comparison of Crystallographic and Computational hGH-
hGHR B-Values  
(A) Color coded average per-residue B-values as taken from 1A22.pdb.  Chimera was used to divide the 
histogram of average experimental B-values into groups of sizes mimicking the distribution plotted in (B).  
These groups are as follows: 9.5<white<15.99; 15.99<blue<23.26; 23.26<green<30.52; 
30.52<yellow<37.79; 37.79<orange<45.05; red>45.05.  (B) Color coded average per-residue B-values as 
calculated by GROMACS for the backrub generated ensemble and were colored onto the 100-member 
ensemble as follows: 0!white<10; 10!blue<20; 20!green< 30; 30!yellow<40; 40!orange<50; red"50.  
Note the cartoon radius depicted for each ensemble member in (B) has been significantly reduced 
compared to the sizing shown for 1A22.pdb in (A).  All B-values calculated by GROMACS have been 
multiplied by a scaling factor of 10.  
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Supplementary Figure B.2 Comparison of Computationally Generated Tolerance Profiles to 
Tolerance  
Profiles of Experimentally Derived Sequences for all 35 hGH-hGHR Interface Positions Tolerance profiles 
generated by the flexible (blue box-plots) and fixed backbone (yellow box-plots) protocols are compared to 
the experimental tolerance profiles of folded sequences determined to bind hGHR (red lines) for all 35 
hGH-hGHR interface positions. Interface positions are ordered as in Figure 3.3. 
 
 
 
Supplementary Figure B.3 Structural Illustrations of the Possible Consequences of Backbone 
Flexibility  
(A) Comparison of side chain placement observed in the minimized crystallographic hGH-hGHR complex 
(1A22.pdb,brown) to side-chain placement seen in three ensemble members (yellow, hGHR; blue, hGH) 
around residue 67T. The hydrogen bonding interaction between 67T and a backbone nitrogen seen 
in1A22.pdb (red dotted lines) are absent for each ensemble member. This results in an overall favorable 
prediction of replacement of 67T for 67V when predictions are made on the flexible backbone ensemble.  
(B) Comparison of side chain placement observed in the minimized crystallographic hGH-hGHR complex 
(1A22.pdb,brown) to side-chain placement seen in four ensemble members (yellow, hGHR; blue, hGH) 
after mutation of residue 48P to 48F. For the crystallographic structure, mutation to 48Y and 48W are 
predicted to be highly favored over the native 48P. However, predictions made using the flexible backbone 
ensemble strongly reduce substitution by W and somewhat reduce substitution by Y. This could be due to 
side chain rearrangements of 49Q and 213Q resulting in a somewhat smaller pocket surrounding residue 
48, as suggested by the backbone shown in (B).  
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Appendix C. Chapter 4, Supplementary 
Materials 
 
C.1.1. Supplementary Figures  
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Supplementary Figure C.1 Model performance as parameters are varied.  
Variation of parameters for neutral (A) and selective pressure (B) computational models is shown. Fold 
(outermost labels, y-axis), dimer (middle labels, y-axis) and peptide (inner labels, y-axis) parameters 
weights (see Eq. 1, main text) were varied systematically along with score value added to native 
hydrophobic (outer labels, x-axis) or native polar (inner labels, x-axis). For each parameter combination the 
number of protein residue sties correctly predicted as having low (1-5%), medium (5-20%) or high (>20%) 
mutation rates under both a neutral (no protease inhibitors) and selective (1-9 protease inhibitor) models 
was recorded. The correct recovery (averaged over the three bins) of each parameter set is color-coded, 
with blue depicting strong discrimination among sites of low, medium and high mutation rate and red 
indicating poor discrimination. Parameter sets selected for model (see Supplementary Table C.3) are found 
within the black boxes on each plot. Variation of parameter adjusting for disfavoring polar to hydrophobic 
substitutions is not shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure C.2 Distribution of ERES values for tolerated amino acid types.  
A histogram showing the distribution of change in ERESFOLD (top row) ERESDIMER (2
nd row) and 
ERESPEPTIDE (3
rd row) relative to the native ERES scores is shown for mutations computationally predicted 
to be tolerated by the neutral (A) and selective (B) models. The distribution of WSUM values for tolerated 
mutations relative to the native WSUM value is also shown for each model (bottom row). Cumulative 
distribution functions calculated for the histograms shown for the neutral (black lines) and selective (red 
lines) models are given in (C). 
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Supplementary Figure C.3 Comparison of predicted frequencies with and without backbone 
flexibility for all crystallographic mutations.  
Bar plots depicting the frequency with which each mutation was observed in the Stanford database after 
protease treatment ((1), red bars), predicted by the full ensemble model ((2), black bars), predicted by 11 
fixed backbone structures crystallized in the absence of mutation (3), grey bars), or predicted by 11 
“backrub” ensembles generated from each fixed backbone structure in (3) ((4), striped bars) are shown. The 
67 mutations shown represent all the mutations contained within at least one crystallographic structure.  
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Supplementary Figure C.4 Comparison of ERESFOLD values with and without backbone flexibility 
for all crystallographic mutations.  
Bar plots depicting the distribution of ERESFOLD values calculated on all crystal structures containing each 
mutation at the time of crystallization (black bars), all crystal structures not containing each mutation at the 
time of crystallization (but possibly containing other mutations; black bars with white stripes), 11 crystal 
structures crystallized in the absence of any mutation (white bars with grey stripes), or 11 “backrub” 
ensembles generated from each fixed backbone structure (grey bars) are shown. The 67 mutations shown 
represent all the mutations contained within at least one crystallographic structure. The number of 
structures containing each mutation is shown in parenthesis under each black bar while the number of 
structures without each mutation is given in parenthesis under each black bar with white stripes. 
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Supplementary Figure C.5 Comparison of RMSF calculated for crystallographic and computational 
(“backrub”) structural ensembles  
C-alpha RMS fluctuations for the 263 crystallographic structures used to calculate ERESFOLD and 
ERESDIMER scores and the 16 crystallographic structures used to calculate ERESPEPTIDE scores are shown in 
black and red respectively.  For comparison, C-alpha RMS fluctuations for ensembles of structures 
independently generated by using the backrub protocol (as described in Section 4.3.4) starting from one of 
11 crystallographic structures with the native subtype-B consensus sequences are shown in grey.  RMS 
fluctuations are similar among all ensembles for most of the 99 residues in each HIV-protease chain.  Note, 
the crystallographic structures show large variation in the flap region (near residue 50) for both chains, as 
some crystallographic conformations have been solved in the "flap open" conformation.  The peptide bound 
structures show an asymmetric behavior between the two chains for this region while the backrub structures 
(all generated from a "flap-closed" starting conformation) show smaller fluctuations in the flap dynamics 
for both chains.  The positions of residue 1 and residue 99 are fixed during the entire backrub protocol, and 
thus show RMS fluctuations of zero.  
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C.1.2. Supplementary Tables  
 
1A30 1A8G 1A8K 1A94 1A9M 1AAQ 1AID 1AJV 1AJX 1AXA 
1BDL 1BDQ 1BDR 1BV7 1BV9 1BWA 1BWB 1C6X 1C6Y 1C6Z 
1C70 1D4H 1D4I 1D4J 1D4S 1D4Y 1DIF 1EBW 1EBZ 1EC0 
1EC1 1EC2 1EC3 1F7A 1FQX 1G2K 1G35 1G6L 1GNM 1GNN 
1GNO 1HBV 1HIH 1HIV 1HOS 1HPO 1HPS 1HPV 1HPX 1HSG 
1HTE 1HTF 1HTG 1HVH 1HVI 1HVJ 1HVK 1HVL 1HVR 1HVS 
1HWR 1HXB 1HXW 1IIQ 1IZH 1IZI 1K1T 1K1U 1K2B 1K2C 
1K6C 1K6P 1K6T 1K6V 1KJ4 1KJ7 1KJF 1KJG 1KJH 1KZK 
1LV1 1LZQ 1M0B 1MER 1MES 1MET 1MEU 1MRW 1MRX 1MSM 
1MSN 1MT7 1MT8 1MT9 1MTB 1MUI 1N49 1NH0 1NPA 1NPV 
1NPW 1ODW 1ODX 1ODY 1OHR 1PRO 1QBR 1QBT 1QBU 1RL8 
1RPI 1RQ9 1RV7 1SBG 1SDT 1SDU 1SDV 1SGU 1SH9 1SP5 
1T3R 1T7J 1T7K 1TCX 1TSQ 1TSU 1TW7 1U8G 1VIJ 1VIK 
1W5V 1W5W 1W5X 1W5Y 1WBK 1WBM 1XL2 1XL5 1YT9 1YTG 
1YTH 1ZLF 1ZTZ 2A1E 2A4F 2AID 2AOC 2AOD 2AOE 2AOF 
2AOG 2AOH 2AOI 2AOJ 2AQU 2AVM 2AVO 2AVQ 2AVS 2AVV 
2AZC 2B60 2B7Z 2BB9 2BBB 2BPV 2BPW 2BPX 2BPY 2BPZ 
2BQV 2CEJ 2CEM 2CEN 2F3K 2F80 2F81 2F8G 2FDD 2FDE 
2FGU 2FGV 2FLE 2FNS 2FNT 2FXD 2FXE 2HB3 2HC0 2HS1 
2HS2 2I0A 2I0D 2I4D 2I4U 2I4V 2I4W 2I4X 2IDW 2IEN 
2IEO 2NMW 2NMY 2NMZ 2NNK 2NNP 2NPH 2NXD 2NXL 2NXM 
2O4K 2O4L 2O4N 2O4P 2O4S 2PK5 2PK6 2PQZ 2PSU 2PSV 
2PWC 2PWR 2PYM 2PYN 2Q3K 2Q54 2Q55 2Q5K 2Q63 2Q64 
2QCI 2QD6 2QD7 2QD8 2QHY 2QHZ 2QI0 2QI1 2QI3 2QI4 
2QI5 2QI6 2QI7 2QNN 2QNP 2QNQ 2R5P 2R5Q 2UPJ 2UXZ 
2UY0 2Z4O 3AID 3B7V 3B80 3BVA 3BVB 4PHV 5HVP 7UPJ 
9HVP          
 
Supplementary Table C.1 Structural ensemble PDB codes for fold and dimer stability calculations.   
The table list each of the 263 pdb codes used for determining ERESFOLD and ERESDIMER scores.  
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Constraint Structure Substrate Sequence 
1MT7.pdb Matrix-Capsid VSQNY-PIVQN 
1 
1KJ4.pdb Matrix-Capsid  VSQNY-PIVQN 
1MT8.pdb Capsid-p2 KARVL-AEAMS 
2 
1F7A.pdb Capsid-p2 KARVL-AEAMS 
1MT9.pdb p1-p6 RPGNF-LQSRP 
3 
1KJF.pdb p1-p6 RPGNF-LQSRP 
1TSU.pdb Nucleocapsid-p1 ERQAN-FLGKI 
1TSQ.pdb Nucleocapsid-p1 RQVN-FLGKIN 
2FNS.pdb Nucleocapsid-p1 RQAN-FLGKIN 
4 
2FNT.pdb Nucleocapsid-p1 RQVN-FLGKIN 
5 1KJ7.pdb Nucleocapsid-p2 KATIM-MQRGN 
1KJG.pdb RT-RNAse H GAETF-YVDGA 
2NXD.pdb RT-RNAse H GADIF-YLDGA 
2NXL.pdb RT-RNAse H GAEVF-YVDGA 
6 
2NXM.pdb RT-RNAse H GAQTF-YVDGA 
7 1KJH.pdb RNAse H-IN  IRKIL-FLDGI 
8 Modeled TF-PR VSFNF-PQITL 
9 Modeled AutoP PQITL-WQRPL 
10 Modeled PR-RT CTLNF-PISPI 
 
Supplementary Table C.2 Structural ensemble of PDB codes and peptides used for substrate 
calculations.  
For each of the 10 endogenous peptides considered, the PDB codes of all crystal structures used, as well as 
their peptide sequence present in the crystallographic structure, are given. All peptides are denoted from 
P5-P5’ except for 1TSQ, 2FNS, and 2FNT which are given from P4-P6’. Amino acids not visible within 
the X-ray crystallographic density, and thus not present in computational simulations, are shown in grey. 
Amino acids colored red are peptide mutations observed in response to the HIV-1 protease drug resistance 
mutation V82A. Blue amino acids were computationally engineered for tighter protease binding affinity.  
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Weighted Term 
Neutral 
Model 
Selective 
Model  
Parameter 
Set  
WFOLD 0.4 0.6 
WDIMER 0.6 2.4 
WPEPTIDE 0.6 4.8 
0.2  0.4  0.6 
1.2    2.4     4.8 
FAVORNATIVE 1 1 
FAVORPOLAR_NATIVE 1.5 1 
PENALTYPOLAR!HP 1.5 1.5 
0    -0.5    -1        
-1.5       -2 
 
Supplementary Table C.3 Parameter values used in the computational model.  
All parameter values used in the neutral and selective models are as given. For parameter optimization, all 
possible combinations of parameter values listed in the parameter set were tested for their predictive ability 
in determining overall mutational frequencies at each of the 99 sequence sites in HIV-1 protease (see 
Supplementary Figure C.1).  
 
 
 
A D E F G H I K L M N P Q R S T V W Y 
A  1 1  1       1   1 1 1   
D 1  1  1 1     1      1  1 
E 1 1   1   1     1    1   
F       1  1      1  1  1 
G 1 1 1           1 1  1 1  
H  1       1  1 1 1 1     1 
I    1    1 1 1    1 1 1 1   
K   1    1   1 1  1 1  1    
L1    1  1 1   1  1 1 1   1   
L2    1   1   1     1  1 1  
M       1 1 1     1  1 1   
N  1    1 1 1       1 1   1 
P 1     1   1    1 1 1 1    
Q   1   1  1 1   1  1      
R1     1 1   1   1 1  1   1  
R2     1  1 1  1     1 1  1  
S1 1   1     1   1    1  1 1 
S2     1  1     1  1  1    
T 1      1 1  1 1 1  1 1     
V 1 1 1 1 1  1  1 1          
W     1    1     1 1     
Y  1  1  1     1    1     
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Supplementary Table C.4 MUTPROB values used in the computational model.  
The table shows MUTPROB values for every possible HIV-1 protease mutation. Starting from a given native 
amino acid type (horizontal rows) MUTPROB values to all other amino acid types (vertical columns) are 
shown.  White boxes denote MUTPROB values of zero. All boxes with a value of one were considered as 
tolerated for the naive single nucleotide mutational model, while all boxes colored blue were considered to 
be tolerated for a null model of chemically similar amino acid types. Leucines and arginines were assigned 
to one of two codons as follows: L1, residues (5,10,19,23,63,76,89) or L2, residues (24,33,38,90,97); R1, 
residue (8) or R2, residues (41,57,87). There were no serines in the HIV-1 protease sequence to assign to 
S1 or S2.  
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